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Abstract 
Colorectal cancer (CRC) is the third most common cancer worldwide Hypoxia plays a 
pivotal role in cancer, regulating cellular processes such as angiogenesis via the Hypoxia 
Inducible Factor (HIF) pathway. HIF-1α and HIF-2α, isoforms of the α-subunit, were previously 
thought to be functionally redundant, but mounting evidence supports their divergent roles in 
many cancers. In CRC their relative roles remain unclear. This study aimed to elucidate their 
relative contribution to hypoxic regulation of CRC using the Caco-2 cell-line. Ex vivo cultures of 
primary cells isolated from CRC tissue were used to validate the Caco-2 data. 
Caco-2 cells were stimulated with hypoxia (1% O2) or the hypoxia-mimetic 
dimethyloxaloylglycine (DMOG), with normoxia (21% O2) controls. Expression of known 
hypoxia-induced genes was quantified by polymerase chain reaction (PCR) and a PCR-based 
array was used to further characterise angiogenic genes. Protein expression was determined using 
Western Blotting and ELISA. The effect of selective HIF-isoform knockdown on gene expression 
was evaluated. Tumour-derived cultures (TDCs) were established using tissue obtained from 
surgically resected CRC specimens. mRNA expression of epithelial cell markers (Ep-CAM, VE-
Cadherin) was quantified by Q-PCR, and protein expression of the CRC tumour marker 
carcinoembryonic antigen (CEA) measured by ELISA. TDCs were exposed to hypoxia, and gene 
expression relative to normoxia was quantified by Q-PCR and PCR-based array. 
In Caco-2 cells, hypoxia upregulated both HIF isoform proteins, inducing genes involved 
in angiogenesis (VEGF, ANGPTL-4, EFNA-3, TGF-β1), metabolism (CA-IX, GLUT-1) and 
apoptosis (BNIP-3), with mRNA changes reflected at protein level. Three novel hypoxia-induced 
angiogenesis genes (ANGPTL-4, EFNA-3, TGF-β1) were identified. Hypoxia-induced ANGPTL-
4, BNIP-3 and TGF-β1 expression was reduced by siHIF-1α only, while EFNA-3 and VEGF 
expression was reduced by both siHIF-1α and siHIF-2α. TDCs expressed epithelial CRC cell 
markers, and showed similar hypoxia-induced angiogenesis gene expression to Caco-2 cells, 
although there was significant inter-donor variability. 
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1 INTRODUCTION 
 
The global importance of cancer has been apparent since the early part of the 20
th
 century. 
In 1939 the renowned American pathologist Professor James Ewing said: “public interest in the 
cancer problem is now at the highest point in history” (Newman 1939). Over 30 years later, 
President Richard Nixon declared what came to be known in the US as the “war on cancer” with 
the signing of the National Cancer Act in 1971, and US spending on cancer research rose from 
$15 billion in 1972 to $75 billion in 2005 (Cutler 2008). By 2008, the annual global spend on 
cancer research had reached almost $2 trillion (Eckhouse et al. 2008). In the same year, there were 
an estimated 12.7 million new cancer cases and 7.6 million cancer-related deaths worldwide, with 
the greatest disease burden falling on the developing world (56% of incidence and 63% of deaths) 
(American Cancer Society 2011). Cancer has the most devastating economic impact of any cause 
of death, with an estimated global cost of close to a trillion US dollars (approximately 1.5% of 
global GDP) (American Cancer Society 2010). Largely due to a growing and ageing global 
population, a continual rise in the global cancer burden is projected, and it has been estimated that 
annual figures will reach 30 million new cases and 13 million deaths by 2030 (Ferlay et al. 2010).  
In the USA, a decline in both cancer incidence and mortality has been reported since the 
1990s (Eheman et al. 2012). In the UK and Europe, although incidence continues to rise, 
mortality rates are declining (Coleman et al. 2008; Olsen et al. 2008; Mistry et al. 2011). These 
improving trends are the result of intense research activities that have led to significant advances 
in the prevention, detection and treatment of cancer. Our understanding of the molecular basis for 
the development and progression of cancer has increased profoundly over the past 50 years, but 
there remains significant scope for further progress.  
An important advance in the understanding of cancer has been the appreciation that rather 
than being simply the consequence of the disorganised, uncontrolled growth of randomly mutated 
cells, the development of a tumour requires the organised and rather sophisticated adaptation of 
normal physiological processes by cancer cells. This allows them to resist programmed cell death 
(apoptosis), evade the immune system, and survive unfavourable nutritional and metabolic 
conditions resulting from increased energy demands. Furthermore, cancer cells alter the structure 
and function of surrounding host cells and extracellular matrix components, furthering their 
survival, for example by stimulating the development of new blood vessels (angiogenesis). This 
manipulation of the tumour microenvironment results in an increase in tumour mass, allows 
invasion outside the cellular compartment of origin, and culminates in the spread to distant 
locations that is invariably fatal. 
Chapter 1 
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By the time a clinically significant tumour has developed, therefore, a highly complex 
series of alterations in normal cellular processes has occurred. This results in the acquisition of 
what have been described as the hallmarks of cancer: unlimited replicative potential, evasion of 
apoptosis, self-sufficiency in growth signals, insensitivity to growth inhibitors, stimulation of 
angiogenesis, tissue invasion and metastasis, reprogramming of energy metabolism and evasion 
of immune-mediated destruction (Hanahan and Weinberg 2011). A better understanding of the 
underlying molecular mechanisms has revolutionised approaches to cancer treatment. Where total 
surgical excision of the tumour is not possible, treatment has historically relied on the high 
turnover of cancer cells, aiming to cause fatal DNA damage using ionised radiation or cytotoxic 
drugs. Rapidly dividing cancer cells are disproportionately affected by this approach, but the 
inevitable collateral damage to normal cells results in significant side-effects. Elucidation of both 
normal and cancer cell biology at the molecular level has allowed the development of targeted 
therapies that have significantly greater specificity to cancer cells, resulting in improved efficacy 
and reduced toxicity. A notable success story has been the development of antiangiogenesis drugs 
such as bevacizumab (Avastin ™), which in the last decade has transformed the treatment of 
metastatic colorectal cancer (CRC). This monoclonal antibody targets Vascular Endothelial 
Growth Factor (VEGF), a highly potent stimulator of angiogenesis. 
All organisms that rely on aerobic metabolism have tightly regulated mechanisms by 
which cells respond to episodes of low oxygen tension (hypoxia) commonly encountered in the 
course of normal physiology. Angiogenesis is a critical mechanism by which organisms adapt to 
this, and hypoxia is one of the most potent stimuli for angiogenesis. Due to a high rate of 
relatively disorganised growth, most solid tumours are characterised by hypoxia, and it is now 
well established that this drives specific cellular pathways and mechanisms including 
angiogenesis (Harris 2002). Cancer cells that can adapt in this way not only survive but thrive in a 
hypoxic environment, leading to advanced disease and decreased survival.  
This work focuses on hypoxia-driven angiogenesis in CRC. The role of key regulatory 
proteins of the hypoxia pathway in the angiogenic response of a CRC cell-line is investigated, and 
the angiogenic response to hypoxia of primary cell cultures derived from individual patients’ 
tumours is examined. 
  
Chapter 1 
17 
1.1 Colorectal Cancer 
1.1.1 Epidemiology 
With an estimated 1.2 million new cases and 610,000 deaths globally in 2008, Colorectal 
Cancer (CRC) is the third most common cancer worldwide (American Cancer Society 2011). It is 
the second most common cause of cancer death in economically developed countries. In the UK, 
CRC accounts for 13% of all new cancer diagnoses (41,142 in 2009) and 10% of all cancer deaths 
(16,013 in 2010) (Cancer Research U. K. 2012). Geographical variation of both incidence and 
mortality is seen, age-standardised rates (ASR) for both being higher in more developed than in 
less developed countries (ASR per 100,000 in 2008 was 37.7 versus 12.1 for incidence, and 15.1 
versus 6.8 for mortality) (Ferlay et al. 2010). Both incidence and mortality are also related to 
ethnicity. In the US, both are highest in African-Americans and lowest in Asian/Pacific Islanders, 
with intermediate rates for Hispanics and Caucasians (Eheman et al. 2012). In Israel, CRC is the 
leading cause of cancer death in the ethnic Jewish community, and incidence is five times higher 
than Palestinians in the same country (Rozen et al. 1987). Furthermore, incidence is higher in 
Ashkenazy Jews than in Sephardic Jews (Chang and Morris 2006). Factors contributing to these 
geographic and ethnic variations include genetics, economics (e.g. access to medical care), 
lifestyle and environmental factors.   
CRC risk increases with age, with 72% of cases arising in people aged 65 or older in the 
UK. Incidence is similar for men and women up to the age of 50, after which it is more common 
in men, with the widest gap being between the ages of 65 and 74 (male:female ratio 17:10) 
(Garden 2006). 69% of cancers arise in the colon and 31% in the rectum and anus. A previous 
diagnosis of bowel cancer also increases the lifetime risk of developing a new metachronous 
tumour (Hayat 2007). First-degree relatives of patients with a history of colonic adenoma or 
carcinoma have a two- to threefold increased risk of CRC; the relative risk increases with the 
number of affected relatives, and with younger age at diagnosis in those relatives (Boland and 
Bresalier 2006). 
1.1.2 Aetiology 
Numerous observational studies have suggested an association between diet and 
incidence of CRC. That reduced fibre intake is associated with a higher CRC risk was first 
suggested in 1971 by Burkitt who noted reduced CRC incidence in West African populations who 
had high fibre intake (Burkitt 1971). Increased consumption of fruits and vegetables, and 
reduction in animal fat and red meat intake have subsequently been reported to reduce CRC risk 
(Willett 1989). In recent years, some of these findings have been called into question. A review by 
Willet reported that energy intake, or more precisely energy balance, had the most powerful and 
consistent dietary influence on CRC risk (Willett 2001). Six modifiable dietary/lifestyle risk 
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factors were identified: high body mass index (BMI), inadequate exercise, high alcohol 
consumption (combined with low folic acid intake), smoking and red meat consumption. 
The association between cancer and chronic inflammation was first noted in 1863 by 
Virchow, and tumours have been described as “wounds that do not heal” (Lujan et al. 2002; Jacob 
and Salky 2005). The tumour-associated inflammatory infiltrate described by Virchow, composed 
of leucocytes, macrophages and lymphocytes, provides a rich source of cytokines, growth factors 
and angiogenic factors which enhance the malignant potential of tumours (Garden 2006). Chronic 
infections are implicated in the aetiology of approximately 15% of cancer deaths worldwide 
(American Cancer Society 2011). In addition, anti-inflammatory drug use reduces the risk of CRC 
and other tumours (Giacchetti et al. 2000; Kabbinavar et al. 2005b), and the therapeutic targeting 
of inflammatory cells and mediators in cancer is a promising area of research (Yan et al. 2006; 
Balkwill and Mantovani 2010). CRC is associated with the inflammatory bowel diseases (IBDs) 
Ulcerative Colitis (UC) and Crohn’s Disease, which are characterised by episodic and often 
progressive bowel inflammation. The risk is proportional to the severity, duration, and extent of 
colonic involvement. Overall prevalence of CRC is higher in UC than in Crohn’s (3.7% versus 
1%) (Kabbinavar et al. 2005d; Goldberg 2006). The risk increases significantly with time, with 
the cumulative probability of developing CRC in UC being 2% by 10 years, 8% by 20 years and 
18% by 30 years (Venook et al. 2005). While UC is confined to the large bowel, Crohn’s can 
affect any part of the alimentary tract, and is associated with an increased risk of small bowel 
cancer (Hurwitz 2004). Epithelial dysplasia is an important marker of risk of malignancy in IBD, 
and is found in 90% of IBD-related CRC (Fearon and Vogelstein 1990).  
Colorectal polyps commonly occur sporadically in small numbers, but may also be part of 
hereditary syndromes associated with large numbers of polyps throughout the colon. Polyps may 
be neoplastic or non-neoplastic, with only the former (also known as adenomas) having malignant 
potential. Traditionally, three histological types of adenomas were described: tubular adenomas, 
the most common (75%) but with the lowest malignant potential (5%); villous, the least common 
(10%), but with the greatest malignant potential (40%); and intermediate tubulovillous adenomas 
(Umetani et al. 2000). Malignant potential is also directly related to polyp size (Church 2004; 
Conlin et al. 2005). Traditional adenomas develop via the canonical adenoma-carcinoma sequence 
(Figure 1.1 and section 1.1.3). A further group of neoplastic polyps, known as serrated adenomas, 
has been identified in recent years. Before their malignant potential was recognised they were 
classed as (non-neoplastic) hyperplastic polyps (Levine 1997; Russo et al. 2005). They were then 
thought of as a variant of “traditional” villous or tubulovillous adenomas, but are now considered 
a distinct histological entity. They arise via the serrated pathway, a molecular pathway distinct 
from the classical adenoma-carcinoma sequence. They are subdivided into sessile-serrated 
adenomas/polyps (SSA/Ps), which have a flat morphology and are more commonly found in the 
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proximal colon, and traditional serrated adenomas (TSAs), which are pedunculated and found 
predominantly in the distal colon.  
Adenomas and carcinomas show similar anatomical distribution, with adenomas 
occurring earlier. Foci of CRC are often present in otherwise benign polyps, and the risk of CRC 
is proportional to degree of cellular atypia or dysplasia, and to the number of adenomas present. 
Perhaps the strongest evidence that carcinomas arise from adenomas is that systematically 
removing adenomatous polyps as part of an endoscopic screening programme decreases the 
incidence and mortality of CRC (Boland and Bresalier 2006). 
Although over 70% of CRC occurs sporadically (Kaz and Brentnall 2006; Lakatos and 
Lakatos 2006) our understanding of the genetic basis of CRC is largely derived from the study of 
hereditary conditions which predispose individuals to CRC. The best-described are Familial 
Adenomatous Polyposis (FAP) and Hereditary Non-Polyposis Colorectal Cancer (HNPCC) which 
account for 3-5% of all CRC. FAP is an autosomal dominant condition characterised by the 
development of multiple (typically 500-2500) benign colonic and rectal adenomas. Colonic 
polyps usually first occur in adolescence, increasing in number and size with age. Virtually all 
individuals with FAP develop cancer by the age of 55, and the average age of diagnosis is 42 (20 
years earlier than in sporadic cases). FAP is caused by mutations in the adenomatous polyposis 
coli (APC) gene. This is an initial step in the adenoma-carcinoma sequence, also known as the 
chromosomal instability (CIN) Pathway. The most severe mutations lead to the development of 
over 5000 polyps and a mean age at cancer diagnosis of 35 years; the least severe develop less 
than 100 polyps and are diagnosed at a mean age of 50 or 60 years. HNPCC (Lynch Syndrome), 
is also inherited in an autosomal dominant fashion. There are two types – type I is associated with 
an 80% lifetime risk of developing CRC; type II is associated with reproductive tract and extra-
colonic tumours. In contrast to FAP, the development of HNPCC is characterised by defects in 
DNA repair which leads to Microsatellite Instability (MSI) (discussed in next section).  
1.1.3 Molecular Genetics 
The CIN pathway, first proposed by Fearon and Vogelstein (Fearon and Vogelstein 
1990), describes the sequential transition from healthy colonic epithelium, to increasingly 
dysplastic adenoma and finally to CRC, by progressive accumulation of sporadic chromosomal 
mutations. The initial mutation is in the adenomatous polyposis coli (APC) gene, a tumour 
suppressor gene found on chromosome 5q. This is followed during the adenoma phase by 
mutations in the K-ras oncogene (chromosome 12p). p53 mutations (chromosome 17p), and 
deletions in DCC (“deleted in colorectal cancer”) and SMAD (chromosome 18q) occur latest, 
during the transition to carcinoma.  
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Figure 1.1 Adenoma-Carcinoma Sequence 
The canonical adenoma-carcinoma (CIN) pathway describes a series of stepwise mutations in the 
development of CRC from normal epithelium (modified from Walther et al. 2009). 
It has been suggested that functional loss of APC is a prerequisite for progression towards 
malignancy, and APC mutations are seen in up to 80% of sporadic carcinomas (Kinzler and 
Vogelstein 1996; Lüchtenborg et al. 2004). The APC protein inhibits the Wnt signalling pathway 
which is involved in embryogenesis and normal physiological processes as well as cancer. APC 
mutation leads to increased transcription of genes implicated in CRC carcinogenesis such as 
VEGF and matrix metalloproteinases (MMPs) (Zhang et al. 2001; Schneikert and Behrens 2007; 
Wu et al. 2007).  
p53 is a transcription factor that has been described as the “cellular gatekeeper for growth 
and division” (Levine 1997). p53 mutations are associated with a variety of cancers and are seen 
in 40-60% of sporadic CRC (Webley et al. 2000; Conlin et al. 2005; Russo et al. 2005). The 
normal p53 protein mediates repair of damaged DNA, and causes apoptosis where such damage 
cannot be repaired. It has also been implicated in angiogenesis. In CRC tissue, mutant p53 
expression is associated with increased markers of angiogenesis such as VEGF expression and 
microvascular density (MVD) (Kondo et al. 2000), and gene-transfer of wild-type p53 can 
suppress VEGF expression and angiogenesis in CRC cell-lines (Bouvet et al. 1998). There is 
some controversy in the literature as to whether p53 mutations in CRC are associated with a better 
or poorer prognosis (Remvikos et al. 1992; Adrover et al. 1999), and outcomes may be dependent 
on the cellular location of mutated p53 (Sun et al. 1992), and on the type of mutation (Webley et 
al. 2000; Russo et al. 2005). 
Mutations in the K-ras oncogene are found in a number of cancers, primarily those of 
gastro-intestinal (GI) origin, and have been reported in up to 50% of CRC (Umetani et al. 2000; 
Kikuchi et al. 2009). The RAS proteins (K-ras, H-ras and N-Ras) are part of a large superfamily 
of low molecular weight GTP-binding proteins. They are self-inactivating signal transducers for 
several pathways controlling cell growth. In its inactive state RAS is bound to GDP. Transient 
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activation occurs when signalling from cell-surface receptors promotes substitution of GDP with 
GTP, which in turn leads to activation of downstream pathways (e.g. PI3K/Akt and 
Raf/MEK/ERK pathways) (Lowy and Willumsen 1993; Downward 2003). Self-inactivation can 
occur through the intrinsic ability of RAS to hydrolyse GTP back to GDP, a process accelerated 
by GTPase activating proteins (GAPs) (Bourne et al. 1990). RAS mutations inhibit this self-
regulation both by reducing its intrinsic hydroxylase activity and by inhibiting GAPs (Lin et al. 
2000; Brand and Wheeler 2012) so that mutant RAS proteins remain in the activated GTP-bound 
state. In CRC, K-ras mutations result in enhanced proliferation (van Houdt et al. 2010), reduced 
apoptosis (Ward et al. 1997), enhanced proteolysis and binding of tumour cells to extracellular 
matrix (Pollock et al. 2005), and promotion of tumour angiogenesis via VEGF upregulation 
(Zhang et al. 2001). K-ras mutations are associated with poor prognosis in stage II (Belly et al. 
2001) and stage III disease (Ahnen et al. 1998), and are predictive of poor response to 
chemotherapy (Karapetis et al. 2008b; Van Cutsem et al. 2009). K-ras has a central role in the 
epidermal growth factor (EGF) receptor signalling pathway which is important in CRC 
pathogenesis (Lockhart and Berlin 2005). K-ras mutations activate EGF receptor (EGFR) 
signalling independently of ligand stimulation. Chemotherapeutic agents that inhibit EGFR, e.g. 
cetuximab and panitumumab, can improve outcomes in advanced CRC (Cunningham et al. 2004; 
Jonker et al. 2007), but response is poor in the presence of K-ras mutation (Amado et al. 2008; 
Karapetis et al. 2008a). 
Chromosome 18q, which is mutated in 70% of primary CRC, is the locus of the tumour 
suppressor genes DCC and SMAD4 (Fearon and Vogelstein 1990). DCC is a cell surface receptor 
which is markedly reduced or absent in advanced CRC (Fearon et al. 1990), and induces 
apoptosis when not bound to its ligand netrin-1 (Mehlen and Fearon 2004). It was recently shown 
that DCC mutation leads to reduced apoptosis, and the development of an invasive and metastatic 
phenotype in CRC and breast cancer (Castets et al. 2012; Krimpenfort et al. 2012). SMADs act as 
signal transducers for the TGF-β superfamily (Miyazono 2000). SMAD4 deficiency in CRC cell-
lines enhances VEGF expression, apoptosis resistance and cell migration (Papageorgis et al. 
2011).  
While the CIN pathway is a feature of FAP, the micro-satellite instability (MSI) pathway 
is associated with HNPCC. Microsatellites are normal simple sequence repeats (SSRs) of 1 to 4 
DNA base pairs which are of a set length in every individual. Defective DNA-repair due to failure 
of mismatch repair enzymes causes shortening or lengthening of these repeats. MSI is a feature of 
15% of CRC, with 3% being associated with HNPCC (Boland and Goel 2010). In sporadic 
cancers MSI results from hypermethylation of the MLH1 gene promoter (Kane et al. 1997), which 
leads to the rapid development of additional mutations. Colorectal tumours with MSI have 
distinctive features, including a tendency to arise in the proximal colon, lymphocytic infiltrate, 
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and poor differentiation. They have a slightly better prognosis than colorectal tumours without 
MSI and do not have the same response to chemotherapeutics. 
While it was previously assumed that almost all colorectal carcinomas arose via the CIN 
pathway, it is now clear that this pathway accounts for only approximately 60% of colon 
carcinoma (Jass 2007). Most of the remaining 40% develop via the more recently described 
serrated pathway which leads to CpG island methylated phenotype (CIMP) carcinoma 
(approximately 35%), with the remaining 5% arising via the MSI pathway. The serrated pathway 
is initiated by mutation of BRAF which leads to inhibition of normal apoptosis and the 
development of serrated lesions (Snover 2011). Such lesions are prone to methylation of the CpG 
island promoter regions resulting in the epigenetic silencing of a number of genes. The best 
characterized of these is the MLH1 gene, which is the gene silenced in sporadic MSI carcinomas. 
Following silencing of MLH1, serrated lesions become MSI positive and are prone to the rapid 
development of additional mutations.  
 
Figure 1.2 Genetic Pathways of CRC Tumorigenesis 
Schematic representation of genetic pathways leading from normal epithelium to CRC. 
Thus CRC can develop via multiple pathways (Figure 1.2). In a recent review by Jass, a 
classification of 5 molecular types of CRC as defined by MSI and CIMP status (high, low or 
negative) is described, which corresponds to clinical and morphological features (Jass 2007). This 
underlines the importance of recognising the heterogeneity of CRC, which has important 
implications for the management of this disease. 
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Figure 1.3 CRC classification based on CIMP and MSI status. 
Schematic representation of 5 molecular subtypes of CRC based on CpG island methylator phenotype 
(CIMP) status (H, high; L, low; Neg, negative) and DNA microsatellite instability (MSI) status (H, high; L, 
low; S, stable). The size of each segment of the black circle approximates to the frequency of each group. 
The groups (and their frequencies) are as follows: 1, CIMP-H, MSI-H (12%); group 2, CIMP-H, MSS/MSI-
L (8%);  3, CIMP-L, MSS/MSI-L (20%); 4, CIMP-Neg, MSS/MSI-L (57%); 5, CIMP-Neg, MSI-H (3%). 
Groups 1-3 arise via the serrated pathway, group 4 via the CIN pathway, and group 5 corresponds to 
HNPCC. Figure from (Jass 2007). 
1.1.4 Clinical Presentation and Diagnosis 
Although diagnosis in asymptomatic patients is increasing since the National Bowel 
Cancer Screening Programme was introduced in 2006, the majority of CRC is still diagnosed in 
symptomatic patients. Symptoms include abdominal pain, a palpable mass, vomiting, change of 
bowel habit, rectal bleeding and tenesmus, and they vary according to the site of the tumour 
(Majumdar et al. 1999). Other non-CRC-specific symptoms include weight loss and iron-
deficiency anaemia due to occult blood loss. Up to 20% of patients present as emergencies with 
perforation causing peritonitis or with obstruction (Koehne et al. 1999). Metastatic disease is 
present at first diagnosis in as few as 10% of patients (Cancer Research U. K. 2011), but 
ultimately develops in up to 60% of patients, with the liver (approximately 50%) and lung (10%) 
being the most common sites (Geoghegan and Scheele 1999).  
Following an initial clinical examination, a broad range of diagnostic studies can be 
employed in the evaluation of suspected CRC. 40-80% of patients with rectal cancers present with 
masses palpable by digital rectal examination (DRE) (Shallow et al. 1955; McSherry et al. 1969), 
© John Wiley & Sons 2006
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Rectosigmoid cancers which account for 36% of all CRC can be detected by DRE and/or rigid 
sigmoidoscopy. Cancers sited within 60cm of the anal verge are amenable to examination by 
flexible sigmoidoscopy. These constitute the majority of cancers causing rectal bleeding and/or a 
change in bowel habit. Patients presenting with ‘red flag’ symptoms consistent with proximal 
cancers, such as otherwise unexplained iron-deficiency or change of bowel habit, should be 
assessed by colonoscopy. In patients diagnosed with potentially curable CRC, the incidence of 
synchronous lesions is in the order of 4-5%, and therefore completion colonoscopy is important to 
visualise the entire length of colon (Finan et al. 1987; Barillari et al. 1990). 
Crucial to the management of CRC is accurate clinical, radiological and histopathological 
staging, since this is the most accurate predictor of outcome, and forms the basis of decisions 
about the most appropriate treatment for the patient. Pre-operative staging in the form of 
computed tomography (CT) of the thorax, abdomen and pelvis allows accurate determination of 
local and distant extent of disease. In rectal cancers, pelvic magnetic resonance imaging (MRI) 
and endoanal ultrasound allow assessment of local tumour infiltration, which helps to determine 
whether curative excision with tumour-free margins is feasible.  
98% of cancers within the large bowel are adenocarcinomas, with rarer tumours 
comprising of carcinoid, primary and secondary lymphoma and leiomyosarcoma. 
Macroscopically, the tumours can appear as papilliferous, ulcerating, annular circumferential 
lesions, diffusely infiltrating and colloid tumours producing excess mucus. The Dukes’ 
classification of tumours was introduced in 1932, and categorises CRC lesions by depth of 
invasion and local metastasis into stages A, B and C (Dukes 1932), with a fourth stage D 
subsequently introduced to describe distant metastasis (Whittaker and Goligher 1976). The 
modified Astler-Coller classification  further subdivided stages B and C (Astler and Coller 1954). 
While the Dukes’ stage remains in common use clinically, these two classification systems have 
been superseded by the more precise TNM (Tumour, Node, Metastasis) classification, which was 
first introduced in 1977 and is currently in its 7th Edition (Figure 1.4) (American Joint Committee 
on Cancer 2010). Table 1.1 illustrates the importance of staging as a predictor of survival. Patients 
presenting with Dukes’ A CRC are almost twice as likely to survive for 5 years after diagnosis 
compared to those presenting with Dukes’ C, and only 1 in 15 patients with distant metastasis 
(Dukes’ D) survive this long. 
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Figure 1.4 Staging of CRC   
Figure shows definition of TNM Classification (TNM 7), and comparison of TNM, Dukes’ and Modified 
Astler-Coller (MAC) Staging of CRC. * Dukes’ B is a composite of better (T3 N0 M0) and worse (T4 N0 
M0) prognostic groups, as is Dukes’ C (any TN1 M0 and any T N2 M0). ** The original Dukes 
classification did not include Dukes’ D. Modified from AJCC Cancer Staging manual 7th Edition (American 
Joint Committee on Cancer 2010).  
 
A number of molecular biomarkers that are predictive of response to chemotherapy have 
been identified in recent years, and are the subject of continued research (Tejpar et al. 2010). The 
evaluation of these is increasingly a part of routine pathological evaluation of resected tumours 
(Engstrom et al. 2009b; Engstrom et al. 2009a). K-ras status is the best established, as mutations 
are associated with resistance to EGFR blockade (Amado et al. 2008; Karapetis et al. 2008a). An 
association with BRAF mutations and poor anti-EGFR response has also been reported (Tol et al. 
2009). Reliable biomarkers that are predictive of response bevacizumab therapy are yet to be 
identified (Jubb and Harris 2010). 
 
 
(D)**
(D)**
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Table 1.1 Dukes’ Staging and CRC Survival 
Percentage of cases and 5-year relative survival rates by Dukes' stage at diagnosis for CRC patients 
diagnosed in England (1996-2002) (Cancer Research U. K. 2011). (* Dukes’ D incidence of up to 25% has 
been reported (Fong et al. 1996; Rees et al. 2008)). 
Dukes' Stage at diagnosis Percentage of cases 5-year relative survival 
A 8.7% 93.2% 
B 24.2% 77.0% 
C 23.6% 47.7% 
D 9.2% * 6.6% 
Unknown 34.3% 35.4% 
 
1.1.5 Treatment 
1.1.5.1 Surgery 
Decisions regarding patient management should be discussed by a multidisciplinary team 
comprised of a panel of specialists with clinically relevant skills and expertise, in order for all 
patients to benefit from suitably informed oncological and surgical opinions. The mainstay of 
treatment is surgical resection. The goals of surgery are en-bloc resection with adequate margins 
of normal colon proximal and distal to the tumour, removal of regional lymph nodes, and 
restoration of bowel continuity. Accomplishment of these goals optimises the chance of 
preventing locoregional recurrence of the disease, and provides better quality of life for patients. 
For colonic lesions, segmental resection of the bowel with its regional lymph nodes is the 
accepted practice, but there has been a recent trend towards extended right hemicolectomy for 
tumours of the transverse colon and splenic flexure. In rectal cancers, careful removal of the 
tumour by total mesorectal excision (TME) ensures removal of all locoregional lymph nodes 
while preserving autonomic nerves and limiting blood loss. Although the technique can increase 
operating time and surgical complications, it significantly reduces local recurrence rates, and as 
part of an anterior resection or abdomino-perineal excision of rectum (APER), TME is considered 
the gold standard (MacFarlane et al. 1993; Quirke et al. 2009). Intersphincteric resection is an 
alternative to APER for low rectal tumours, and is significantly preferable in terms of patients’ 
quality of life. It allows primary coloanal anastomosis avoiding a permanent colostomy, preserves 
sphincter function, and reduces the risk of urinary and sexual dysfunction (Schiessel et al. 1994; 
Martin et al. 2012b). 
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For small rectal cancers and polyps with small areas of invasive cancer, local excision is 
safe providing that clear resection margins are demonstrated at histological examination 
(Whiteway et al. 1985). Excision by transanal endoscopic microsurgery (TEM) has gained 
popularity, with data suggesting that this is at least as good as traditional transanal resection 
(Middleton et al. 2005; Zacharakis et al. 2007). Preoperative assessment of depth of invasion and 
nodal disease by MRI and endoanal ultrasound is paramount in these patients, and 
histopathological examination of some of these locally excised lesions may identify a proportion 
of patients who will require more radical surgery.  
The presence of distant metastasis predicts significantly poorer prognosis. In recent years, 
resection of liver metastases has gained significant ground, and is offered to patients with up to 
four lesions providing they are confined to one lobe of an otherwise healthy liver, the volume to 
be resected is less than 70% of total liver volume, and there is no unresectable extra-hepatic 
disease (Zdenkowski et al. 2012). Up to 23% of patients with liver metastases have resectable 
lesions, and neoadjuvant chemotherapy (oxaliplatin, irinotecan) can increase this by a further 12% 
(Adam et al. 2004). Survival rates of 30% at 5 years and 25% at 10 years can be achieved with 
this strategy (Gallagher and Kemeny 2010). Where logistics allow, simultaneous resection of the 
primary and secondary lesions may be performed by colorectal and hepato-biliary surgeons. 
Resection of lung metastases can also be undertaken in patients with controlled primary disease 
who are fit for thoracotomy. 5-year survival rates of 50% have been reported in patients with 
solitary lesions, although outcomes are less favourable where there are multiple unilateral lesions 
(40%) and worse still with bilateral metastases (12.5%) (Inoue et al. 2004). 
1.1.5.2 Chemo-radiotherapy 
Significant improvements in survival rates for late-stage CRC (Dukes’ C and D) have 
been achieved in recent years largely due to the use of (neo-)adjuvant chemo- and radiotherapy, 
which can be used in combination (chemoradiotherapy (CRT)). Traditional chemotherapeutic 
agents consist of cytotoxic drugs such as topoisomerase-inhibitors (e.g. irinotecan) and anti-
metabolites (5-fluorouracil (5-FU), which is usually used in combination with leucovorin (LV)). 
More recently, platinum-based drugs (oxaliplatin) and the FU pro-drug capecitabine have shown 
promise (Arkenau et al. 2008). These drugs are generally used in combinations designed to 
minimise toxicity while maintaining efficacy. 
While the use of pre-operative (neo-adjuvant) CRT might be thought to introduce the risk 
of progression by delaying surgery, it can in fact improve outcomes, as first demonstrated by the 
Swedish Rectal Cancer Trial (1997). Patients with resectable rectal cancers who received short-
course radiotherapy (SCRT; 1 week of treatment) before “traditional” (non-TME) anterior 
resection or APER were found to have a significant reduction in local recurrence compared to 
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surgery alone (11% versus 27%). Improvement in survival rates was also seen (overall survival 
(OS) 58% versus 48% at 5 years; cancer-specific survival 74% versus 65% at 9 years). The 
benefits in both local recurrence and OS persisted at a median follow-up of 13 years (Folkesson et 
al. 2005). Results from the Dutch TME Trial showed that SCRT also improves local recurrence 
rates when this technique (which in itself reduces local recurrence compared to traditional 
surgery) is used, although significant survival benefits were not seen (Kapiteijn et al. 2001; 
Peeters et al. 2007).  
For patients with advanced locoregional (T3 or T4) rectal disease, long course (4-5 
weeks) pre-operative radiotherapy given in combination with 5-FU has been shown to be effective 
in down-staging tumours, improving resectability and allowing sphincter-preserving surgery 
(Sauer et al. 2004; Bosset et al. 2005). Indeed 15-20% of patients receiving long-course 
chemoradiotherapy (LCCR) show a pathological complete response (pCR), i.e histological 
examination of the resected specimen shows no viable tumour cells (Chan et al. 2005; Quah et al. 
2008). There is some controversy as to whether pCR confers a survival advantage (Onaitis et al. 
2001; Pucciarelli et al. 2004; Chan et al. 2005). However in a systematic review and meta-
analysis which included 16 studies and 3363 patients, Martin et al. reported that compared to 
partial and non-responders, complete responders had lower local and distant recurrence rates 
(odds ratio (OR) 0.25 and 0.23 respectively), and better disease-free (OR 4.33) and overall 
survival (OR 3.28) (Martin et al. 2012a). The study reported a mean local recurrence rate of 0.7% 
(range 0 – 2.6%) in patients with pCR, suggesting that the risk of local recurrence is all but 
eradicated. This raises the possibility of such patients having less radical surgery such as local 
excision (Callender et al. 2010), or even being managed with an expectant (“watch and wait”) 
approach, by which surgery is offered once a recurrence has been detected (Habr-Gama et al. 
2004; Habr-Gama et al. 2006). However, although complete responders have a four-fold reduction 
in distant metastases, a significant risk remains (8.7%) despite the apparent disappearance of the 
primary. It may be that some patients showing pCR would benefit from adjuvant chemotherapy to 
reduce this risk, but identifying which these would be remains a challenge.  
CRT therefore offers hope to the large subgroup of patients (up to 55% of all CRC) who 
present late with advanced disease (Campbell et al. 2001), with potential curative resection 
following adequate downstaging of the tumour (Adam et al. 2008; Fleming et al. 2011). 
Furthermore, post-operative chemotherapy in the form of 5-FU as a single agent, or combined 
with oxaliplatin, improves disease-free survival and OS for patients with lymph node positive 
disease (Wolmark et al. 2000; Andre et al. 2004; NICE 2005).  
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1.1.5.3 Novel Biological Agents 
The management of patients with inoperable or recurrent disease, or who are resistant to 
CRT, remains challenging. Much work is focussed on the development of new treatments aimed 
at retarding tumour growth and/or causing tumour regression. The last decade has seen the 
development of novel therapeutic agents that target specific cellular pathways. This is exemplified 
by the monoclonal antibody bevacizumab (Avastin®), which inhibits VEGF. VEGF is the key 
effector of angiogenesis, a process that is critical in the pathogenesis of cancer, as discussed in 
detail below (section 1.2). Endothelial cells are central to angiogenesis, and are co-opted by 
tumours in order to develop the new blood vessels required to sustain rapid growth (Folkman 
1971; Folkman and Shing 1992) (section 1.2.2). VEGF is a potent promoter of endothelial cell 
survival, mitogenesis, migration, differentiation, as well as regulating the function of other cell-
types such as smooth muscle and haematopoietic cells. It plays a central role in both physiological 
and pathological angiogenesis. In CRC, expression of VEGF increases with progression along the 
adenoma-carcinoma pathway (Wong et al. 1999; Kondo et al. 2000). Increased expression of 
VEGF and its receptor KDR (Kinase Dependent Receptor) is associated with metastasis and poor 
prognosis (Ishigami et al. 1998; Lee et al. 2000; Harada et al. 2001). VEGF expression and MVD, 
a measure of angiogenesis, is strongly associated with depth of invasion, lymph node metastasis 
and liver metastasis (Nakasaki et al. 2002). 
These observations, which are paralleled in several other cancers, were first made in the 
1990s, and provided strong evidence that VEGF may be a therapeutic target. The first clinical 
confirmation of this came in clinical trials of bevacizumab, which was shown to improve overall 
survival in metastatic CRC (mCRC) when used in combination with traditional chemotherapy 
(Kabbinavar et al. 2003; Hurwitz et al. 2004). Bevacizumab was subsequently licensed for use in 
non-squamous non-small cell lung cancer (NSCLC), glioblastoma, metastatic renal cell carcinoma 
(RCC) and breast cancer (Scott 2007; Planchard 2011; Melichar et al. 2012; Patel et al. 2012). 
While bevacizumab is specific to VEGF-A (the most dominant VEGF isomer in CRC), the newer 
aflibercept binds VEGF-A and VEGF-B, as well as placental growth factor (PlGF). Aflibercept 
improves survival in mCRC even in patients who have previously failed bevacizumab treatment 
(Van Cutsem et al. 2012). In the wake of promising results with bevacizumab therapy, the 
development of several VEGF-inhibiting drugs with different modes of action has followed 
(Figure 1.5). These include the receptor tyrosine kinase inhibitors (RTKIs), such as sunitinib, a 
VEGF-receptor RTKI (used in RCC and gastro-intestinal stromal tumours (GIST)) (Gan et al. 
2009). Other drugs inhibit downstream VEGF-activated pathways: the Raf/MEK/ERK pathway is 
inhibited by sorafenib (which also inhibits VEGFR), used in RCC and hepatocellular carcinoma 
(Escudier et al. 2007; Llovet et al. 2008); and the PI3K/AKT/mTOR pathway is inhibited by 
temsirolimus (a rapamycin analog), used in RCC (Amato 2011; Ibrahim et al. 2012). Regorafenib, 
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a new inhibitor that targets several RTKs (VEGFR, PDGFR, FGFR) as well as downstream 
pathways (e.g. Raf), has shown efficacy when used as monotherapy in refractory mCRC (Grothey 
et al. 2012), and received FDA approval in September 2012. Bevacizumab is discussed in detail in 
Section 0. 
Another newly developed class of agents inhibits the ErbB signalling pathway (Hynes 
and MacDonald 2009). EGFR is a member of the ErbB receptor tyrosine kinase family, and EGF 
binding promotes clonal expansion of transformed cells, and modulates cellular adhesion, 
differentiation and apoptosis, enhancing tumourigenicity and malignant progression (Yarom and 
Jonker 2011). Human cancers can overactivate the ErbB signalling pathway by overproduction of 
ligands and/or corresponding receptors, or expression of constitutively activated receptors. 
Overexpression of both EGF and EGFR is seen in CRC (Salomon et al. 1995; Messa et al. 1998), 
and is associated with poorer prognosis (Karameris et al. 1993; Spano et al. 2005; Zlobec et al. 
2007). Cetuximab is a chimeric monoclonal anti-EGFR antibody, whereas the newer 
panitumumab is the first fully human anti-EGFR monoclonal antibody. Both have been shown to 
improve outcomes in mCRC in phase III trials (Cunningham et al. 2004) (Jonker et al. 2007; 
Peeters et al. 2010). 
 
Figure 1.5 Inhibitors of VEGF signalling 
VEGF binding to VEGFR, a receptor tyrosine kinase, leads to receptor dimerization and subsequent auto-
phosphorylation of the receptor complex. Interaction with cytoplasmic signalling molecules activates 
pathways leading to a variety of tumourigenic processes including angiogenesis. Examples of clinical 
inhibitory compounds are shown (see text). Aflibercept is used in age-related macular degeneration (PI3K 
indicates phosphoinositide 3‐kinase; mTOR, mammalian target of rapamycin; MEK, mitogen‐activated 
protein kinase kinase; ERK, extracellular signal‐regulated kinases.) (modified from Cook and Figg 2010) 
CA: A Cancer Journal for Clinicians
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1.2 Angiogenesis 
Angiogenesis is the formation of new blood vessels from existing vasculature (as distinct 
from vasculogenesis, the formation of new blood vessels de novo). Angiogenesis plays an 
important role in normal adult human physiology. It is normally quiescent, only coming into play 
in specific circumstances, such as in wound healing, and in the female reproductive cycle. It is 
tightly regulated by angiogenic and antiangiogenic (angiostatic) factors, the latter being dominant 
in the “normal” state. VEGF is a key regulator of angiogenesis, and its role in both physiological 
and pathological angiogenesis discussed in a detailed review by Chung and Ferrara (Chung and 
Ferrara 2011). Loss of intrinsic control of angiogenesis tips the balance in favour of angiogenic 
factors (the so-called “angiogenic switch”), leading to pathological chronic inflammatory 
conditions and fibroproliferative disorders (for example in ophthalmic and rheumatic diseases). In 
cancer cells this allows exploitation of the various control mechanisms which regulate 
angiogenesis resulting in improved survival, increased proliferation and growth, and enhanced 
tumour spread. In order to appreciate the mechanisms by which cancers transform these 
regulatory pathways to promote angiogenesis, an understanding of the regulatory systems 
underlying physiological angiogenesis is necessary.  
1.2.1 Physiological Angiogenesis  
Sprouting angiogenesis occurs in several well-characterised stages, with each stage 
requiring coordinated signals between various growth factors and receptors (summarised in 
Figure 1.6). The first step of angiogenic remodelling of mature vasculature requires 
disengagement of endothelial cells from surrounding supporting cells. This destabilisation process 
is driven by a progressive shift in angiopoietin (ANGPT) expression from ANGPT-1, which 
maintains vessels in a quiescent state, to ANGPT-2 which encourages pericyte detachment 
(Maisonpierre et al. 1997). This detachment renders endothelial cells accessible to angiogenic 
stimuli, such as VEGF and FGF-2, which activate endothelial cells, resulting in  release of 
proteases such as MMP, plasminogen activators (uPA and tPA) (Millauer et al. 1993; Pepper 
1997), and interstitial collagenase (Unemori et al. 1992). These proteases degrade and remodel the 
endothelial cell basement membrane and surrounding extracellular matrix (Moses 1997), and new 
matrix synthesized by stromal cells is then laid down. This, in combination with the proliferative 
(Gospodarowicz et al. 1987; Connolly et al. 1989; Gospodarowicz et al. 1989) and pro-migratory 
effects (Terranova et al. 1985; Dimmeler et al. 2000) of VEGF and FGF-2, allows migration of 
endothelial cells which create finger-like projections into the region to be vascularised. Invasion 
and migration of endothelial cells through extracellular matrix (ECM) comprising of Type I 
collagen, vitronectin, fibronectin, and fibrin requires cell-matrix interactions, which are mediated 
by integrins such as v 3 (Cheresh 1987). Integrin v 3 mediates endothelial cell attachment, 
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spreading, and migration (Leavesley et al. 1993), and its importance for endothelial cell function 
is reflected by its transient expression on tips of sprouting endothelial cells, and on newly formed 
blood vessels in granulation tissue (Clark et al. 1996; Li et al. 2003b). As the endothelial cells 
coalesce together to form tube-like structures, mesenchymal cells proliferate and migrate along 
the abluminal surface of the endothelium under the influence of platelet derived growth factor-B 
(PDGF-B), maturing to form pericytes and smooth muscle cells (Conway et al. 2001). Presence of 
an enveloping layer of pericytes inhibits further endothelial cell proliferation and migration, 
signalling the end of new blood vessel formation (Beck and D'Amore 1997). Finally, ECM is 
deposited around the new vessel under the control of TGF- , secretion of which is regulated by 
interactions between endothelial cells and the vascular smooth muscle cell-pericyte complex. This 
signals the final stages of vessel stabilisation and maturation (Beck and D'Amore 1997). 
 
Figure 1.6 Sprouting Angiogenesis 
Sprouting angiogenesis: formation of blood vessels is a multi-step process, which includes (i) reception of 
angiogenic signals (yellow circles) by endothelial cells (EC); (ii) retraction of pericytes from the abluminal 
surface of capillary and secretion of protease from activated endothelial cells (aEC) and proteolytic 
degradation of basement membrane (blue dashed line) and extracellular matrix; (iii) chemotactic migration 
of EC under the induction of angiogenic stimulation; (iv) proliferation of EC and formation of 
lumen/canalisation by fusion of formed vessels with formation of tight junctions; (v) recruitment of 
pericytes and deposition of new basement membrane and initiation of blood flow (modified from Yue et al. 
2007). 
1.2.2 Angiogenesis in Cancer 
The fine balance between pro- and anti-angiogenic factors is disrupted in pathological 
conditions such as psoriasis, ophthalmic and rheumatic diseases where inflammation recruits 
inflammatory cells causing release of pro-angiogenic factors and proteases. The pivotal role of 
angiogenesis in the development of tumours was demonstrated by Folkman in the early 1970s 
who showed that for continued growth, a tumour which exceeds 1-2mm
3 
in volume requires its 
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own blood supply (Folkman 1971). Signals that trigger the angiogenic switch include metabolic 
stress, genetic mutations that activate certain oncogenes or inactivate tumour suppressor genes, 
and the presence of an immune or inflammatory response (Carmeliet and Jain 2000). For most of 
these causative factors, VEGF is the common effector inducing angiogenesis, especially in the 
presence of other angiogenic allies such as nitric oxide synthase (NOS), PDGF-B and ANGPT-2 
(Carmeliet and Jain 2000). Hypoxia, a feature of most solid tumours, also potently and 
consistently induces VEGF expression by recruiting hypoxia inducible factor (HIF)-dependent or 
HIF-independent mechanisms (see below). 
Once the balance is tipped in favour of angiogenesis, the process of sprouting 
angiogenesis described previously ensues. Unlike normal blood vessels, tumour vessels are 
structurally and functionally abnormal Figure 1.7 (Jain 1994; Jain 2001). 
 
Figure 1.7 Normal versus abnormal (cancer) vessel architecture 
Normal vasculature (left) is composed of mature vessels arranged in an ordered manner. Abnormal tumour 
vasculature (right), is composed largely of immature vessels with increased permeability, vessel diameter, 
vessel length, vessel density, tortuosity and interstitial fluid pressure. (Modified from Jain 2001) 
Abnormal perivascular cells, and an excess of endothelial cells with weak inter-
endothelial junctions, contribute to formation of tortuous irregular networks of dilated and 
hyperpermeable blood vessels (Gazit et al. 1997; Baish and Jain 2000; Hashizume et al. 2000; 
Dejana et al. 2009).Further, the mechanical stress from the solid mass of proliferating cancer cells 
leads to compression of the vessel lumen (Padera et al. 2004). The combination of raised IFP and 
areas of vascular collapse leads to regional hypoxia and acidosis within tumours (Goethals et al. 
2006; Goel et al. 2011).  
In the face of increased oxygen demand by the growing tumour therefore, oxygen 
© 2001 Nature Publishing Group
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delivery is in fact reduced, creating a positive feedback loop in which the resultant hypoxia 
encourages development of more dysfunctional vessels. Other sequelae of tumour angiogenesis 
include increased risk of metastasis, and resistance to therapeutic agents. Impaired integrity of the 
vascular endothelium increases access of tumour cells in the primary site to the circulation, and 
hence transport to distant sites (Tien et al. 2001; Galaup et al. 2006), while increased IFP and 
vascular collapse reduces intratumoural blood flow, compromising delivery of cytotoxic agents 
(Jain 1994; Jain 1998).  
1.2.3 Angiogenesis Genes 
Given the intricate coordination of numerous processes required to establish a new blood 
supply, it is no surprise that a multiplicity of genes have been implicated in angiogenesis. In this 
study, a PCR Array consisting of 84 angiogenesis-related genes was used (see Table 2.5 for full 
list of genes). A description of all the genes is beyond the scope of this work. However, genes 
encountered in subsequent chapters are discussed below. They fall into 5 broad functional 
categories: transcription factors, cytokines, growth factors, vascular remodelling factors and 
matrix remodelling factors. Several of the genes are pleiotropic to varying degrees, falling into 
more than one functional group. 
Transcription Factors 
HIF (hypoxia inducible factor) and HAND2 (Heart- and neural crest derivatives-
expressed protein 2) are both members of the basic loop-helix-loop (bHLH) family of 
transcription factors. HIF is the focus of Chapters 3 and 4, and is described in detail below (1.3.1). 
HAND2 plays an important role in cardiovascular and sympathetic nervous system development 
(Yamagishi et al. 2000; Voth et al. 2009), and has been reported to regulate ECM remodelling 
(Yin et al. 2010). Embryonic HAND2 mutations lead to a similar angiogenic phenotype to 
mutations in VEGF and its receptors, suggesting that HAND2’s angiogenic function may be 
mediated via the VEGF signalling pathway (Yamagishi et al. 2000). It has been reported to be 
overexpressed in squamous cell carcinoma of the lung (Metodieva et al. 2011).  
Cytokines 
Chemokines (chemo-attractant cytokines) direct movement of target cells along a 
concentration gradient, and play an important role in numerous processes including inflammation 
and angiogenesis. CCL11 (eotaxin), a member of the CC chemokine group (β-chemokines), 
induces chemotaxis in eosinophils. It stimulates endothelial cell migration, implicating it in 
angiogenesis (Salcedo et al. 2001). Upregulation of CXCL-3 (GRO3), CXCL-9 and interleukin 8 
(IL-8/CXCL-8), all members of the CXC chemokine group, has been reported in CRC tissue 
(Erreni et al. 2009; Doll et al. 2010). CXCL-3 and IL-8 belong to the angiogenic ELR-positive 
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subgroup of CXC-chemokines, which as well as attracting and activating neutrophils, can 
stimulate endothelial cell migration (Vandercappellen et al. 2008). CXCL-9 is a member of the 
angiostatic ELR-negative subgroup of CXC-chemokines which can be induced by IFN-γ.  
The interferons are primarily involved in immune responses to pathogens, and they also 
play an important role in mediating the immune response to tumour cells (Dunn et al. 2006). They 
also have angiostatic properties, both by inhibiting angiogenic factors such as VEGF, IL-8, basic 
fibroblast factor (bFGF) and MMP-9 (von Marschall et al. 2003), and by direct inhibition of 
endothelial cell function (Indraccolo 2010). IFN-γ is associated with increased CRC risk, and is 
upregulated in CRC tissue compared to adjacent normal tissue (Slattery et al. 2011; Nam and Park 
2012). In a CRC cell-line xenograft model, IFN-γ-stimulated mesenchymal stem cells (MSCs) 
promote angiogenesis and tumour growth in a VEGF-mediated mechanism (Liu et al. 2011). 
Interferons have shown significant anti-tumour activity in pre-clinical models of CRC (Ozawa et 
al. 2001; Choi et al. 2004), and have been used therapeutically in several cancers including 
Kaposi’s sarcoma and malignant melanoma (Dunn et al. 2006). However, while IFN-γ has been 
shown to improve survival when used as an adjunct in ovarian cancer (Windbichler et al. 2000), a 
study in CRC showed no benefit (Wiesenfeld et al. 1995). 
TNF-α plays a critical role in systemic inflammation, and its role in autoimmune diseases 
is underlined by the success of anti-TNF therapies such as infliximab in rheumatoid arthritis 
(Brennan et al. 1989a; Feldmann and Maini 2003). The link between inflammation and cancer is 
well-established (Karin et al. 2002). Indeed TNF was first identified for its ability to induce 
haemorrhagic necrosis in cancer cell-lines (Carswell et al. 1975). TNF signalling results in 
induction of apoptosis and the destruction of tumour-associated blood vessels (Kashii et al. 1999; 
Prévost-Blondel et al. 2000; Lejeune 2002). However, TNF also promotes the development and 
progression of cancer (Moore et al. 1999; Balkwill 2006; Egberts et al. 2008; Balkwill 2009). 
Elevated TNF-α levels have been demonstrated in many cancers including CRC, and are 
associated with poor prognosis (Naylor et al. 1990; Szlosarek and Balkwill 2003). TNF-α can 
induce cancer cell production of other angiogenic genes such as VEGF, MMP-9, TGF-β1 and IL-
8 (Nabors et al. 2003; Balkwill 2004; Kulbe et al. 2005; Stuelten et al. 2005). TNF-α has been 
reported to upregulate VEGF production by mesenchymal stem cells, promoting angiogenesis and 
tumour growth in CRC cell xenografts (Liu et al. 2011). TGF- 1 is discussed in the subsequent 
section, due to its function as both a cytokine and growth factor. 
Growth Factors 
Growth factors stimulate cellular growth, proliferation and cellular differentiation. 
Transforming growth factor-β1 (TGF-β1) is the founding member of the TGF-β superfamily of 
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multifunctional cytokines which have a modulatory role on virtually all cell types. It controls 
processes such as differentiation, proliferation, migration and apoptosis as well as regulating 
immune responses and the extracellular environment. It has a tumour suppressive effect in early 
cancer, but paradoxically as tumours progress they can develop the ability to exploit TGF-β 
signalling pathways to promote tumourigenicity (Massagué 2008). Elevated TGF-β1 levels have 
been reported in serum from CRC patients as well as in tumour tissue, and expression correlates 
with markers of angiogenesis such as VEGF expression, MVD, as well as with metastasis and 
prognosis (Tsushima et al. 1996; Xiong et al. 2002a; Xiong et al. 2002b; Gulubova et al. 2010).  
Ephrin-A3 is a member of the largest family of receptor tyrosine kinase (RTK) systems. 
The receptors (of which there are 13, designated “Eph”) and the ligands (9, designated “ephrins”) 
are classified into two groups based on sequence homology and binding preferences. Ephrin A 
ligands (including ephrin-A3, encoded by the EFNA-3 gene) generally bind EphA receptors, 
while ephrin B ligands generally bind EphB receptors, but interactions across the classes can 
occur (Himanen et al. 2004). A large number of receptor-ligand combinations is possible, and 
Eph-ephrin interactions have pleiotropic functions including axonal guidance, cell migration and 
angiogenesis (Wilkinson 2000; Adams 2002; Himanen et al. 2004). A unique property of Eph-
ephrin interactions is bidirectionality, with signalling being triggered both in the ligand-
expressing and the receptor-expressing cell (Mellitzer et al. 1999; Kullander and Klein 2002). 
Both forward and reverse signalling regulate cell motility, and Eph-ephrin interaction can lead to 
both cellular attraction and repulsion, depending on the receptor-ligand combination and cell type 
involved (Davy and Soriano 2005). By modulating changes in attraction/repulsion, migrating cells 
can be guided along precise paths. Ephrin-A3 is one of the least investigated ephrin ligands.  
PDGF (platelet-derived growth factor) is a member of the same growth factor family as 
VEGF with diverse functions (Yu et al. 2003). It is a potent mitogen for cells of mesenchymal 
origin, and induces cellular processes including angiogenesis, proliferation, migration and 
apoptosis (Yu et al. 2003). It is critical in embryonic development, and plays an important role in 
inflammation and wound healing. Its tumourigenicity was first discovered almost 30 years ago 
(Deuel et al. 1983), and it has been implicated in several cancers such as gliomas, sarcomas and 
leukaemias, as well as CRC (Heldin 2012; Peterson et al. 2012).  
Vascular Remodelling Factors 
The angiopoietin (ANGPT) family of proteins play a central role in angiogenesis. Their 
functions are mediated through Tie-1 and Tie-2 receptors which are expressed on vascular and 
lymphatic endothelial cells. Angiopoietin-1 and -2 (ANGPT-1, ANGPT-2) are functionally 
antagonistic and both signal via the Tie-2 (TEK) receptor. Primarily expressed by mesenchymal 
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cells, ANGPT-1 recruits mural cells, and promotes assembly and maturation of blood vessels 
leading to vessel stabilisation and normalisation; conversely, ANGPT-2 is stored by endothelial 
cells and destabilises vessels, inducing vascular sprouting and branching (Brindle et al. 2006; 
Fagiani et al. 2011). Overexpression of ANGPT-1 has been reported to suppress angiogenesis and 
tumour growth in CRC, while ANGPT-2 has the opposite effect (Ahmad et al. 2001b; Stoeltzing 
et al. 2003). However, in other cancers ANGPT-1 can enhance angiogenesis (Machein et al. 
2004), and the aberrant vessels resulting from ANGPT-2 overexpression can lead to reduced 
tumour growth (Yu and Stamenkovic 2001).  
The angiopoietin-like (ANGPTL) proteins, of which there are seven, are structurally 
similar to the ANGPT family, but do not bind to the Tie receptors, indicating that they may have 
different functions to the ANGPT proteins (Morisada et al. 2006). Indeed, as well as being 
involved in angiogenesis, ANGPTL-4 has remarkably diverse functions, and is involved in lipid 
metabolism, cell-differentiation, vascular permeability and wound healing (Zhu et al. 2012). The 
ANGPTL-4 protein undergoes cleavage into two fragments which can oligomerize in a number of 
ways, and can also be subject to further post-translational modification. This structural complexity 
underlies its multifunctionality (Zhu et al. 2012). The role of ANGPTL-4 in cancer has emerged 
in recent years, and is summarised in an excellent review by Tan et al. (Tan et al. 2012). Of the 
seven ANGPTLs, ANGPTL-3 is the most closely related to ANGPTL-4 but is much less well 
understood.  
Matrix Remodelling Factors 
The matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases 
which have an important role in the degradation of ECM proteins. As well as removing physical 
barriers to cell motility and exposing ECM-bound receptor binding sites and regulatory 
molecules, MMPs can also interact directly with growth factor binding proteins and precursors, 
cell-adhesion molecules and other proteinases (Egeblad and Werb 2002; Rupp et al. 2008). Their 
function is critical in normal physiology, for example in embryological development and 
angiogenesis. They also play a central role in cancer invasion and metastasis. They are 
upregulated in most types of cancer including CRC, and their expression is associated with poor 
prognosis (Egeblad and Werb 2002). MMPs are synthesised as inactive zymogens (pro-MMPs) 
which require proteolytic cleavage either by other activated MMPs or by serine proteases. MMP 
activity is also tightly regulated by endogenous inhibitors such as α-2-microglobulin and tissue 
inhibitors of metalloproteinases (TIMPs). MMP-2 (gelatinase A) and MMP-9 (gelatinase B) are 
both upregulated in CRC and associated with angiogenesis (Kim and Kim 1999).  
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ANPEP (alanine aminopeptidase) is a zinc-dependent ectopeptidase that is involved in 
both in normal and malignant development (Wickström et al. 2011). As with the MMPs, its 
enzymatic activity can both disrupt the ECM structure and modulate function of specific such 
peptide substrates (Bhagwat et al. 2001; Tsujimoto et al. 2007). It promotes human umbilical vein 
endothelial cell (HUVEC) proliferation, migration and capillary tube formation in vitro 
(Fukasawa et al. 2006). Urokinase-type plasminogen activator (uPA/PLAU) is a component of the 
urokinase plasminogen activating system (uPAS), which also has both proteolytic and non-
proteolytic activity and has been implicated in angiogenesis (Blasi and Carmeliet 2002; Choong 
and Nadesapillai 2003; Ulisse et al. 2009).  
Collagen type IV alpha 3 (α-3(IV)), encoded by the COL4A3 gene, is an isoform of Type 
IV collagen which is the major structural component of the mammalian basement membrane 
(BM) (Lemmink et al. 1997). BM disruption is a necessary step in the initiation of invasion of 
epithelial tumours (Tanjore and Kalluri 2006). α-3(IV) has been shown to inhibit angiogenesis 
and tumour growth in an in vivo melanoma model (Petitclerc et al. 2000). This may be through 
the action of the angiostatic peptide tumstatin, a product of α-3(IV) cleavage by MMP-9 (Hamano 
et al. 2003). Another possible mechanism by which α-3(IV) inhibits angiogenesis is through 
suppression of MMP-2 activation (Martinella-Catusse et al. 2001).  
 
1.2.4 Angiogenesis Inhibition in CRC 
There is a multiplicity of angiogenesis inhibiting drugs in current use, and new molecules 
continue to be developed. In 2009 there were 44 VEGFR inhibitors in development (Ivy et al. 
2009), and in 2012 there were 8 novel antiangiogenics in phase III trials (Troiani et al. 2012). 
Inhibitors are general either anti-VEGF antibodies or inhibitors of receptor tyrosine kinases, but 
new inhibitors are emerging that have multiple targets, such as regorafenib. They are most 
commonly used in combination with cytotoxic drugs. This is in part due to a general issue with 
clinical trials. As ethical considerations preclude the enrolment of patients into a trial where they 
may be deprived of the best existing therapy (in the “control” arm), the majority of randomised 
clinical trials (RCTs) have investigated the addition of novel antiangiogenics (and/or placebo) to a 
standard cytotoxic drug regimen. In some cases, trials have compared antiangiogenic 
monotherapy with “best supportive therapy” (i.e. no active treatment), but this is generally in 
patients with advanced disease who have failed treatment with established regimens. 
While novel antiangiogenics have shown a great deal of promise in the treatment of 
advanced disease, their use is hampered by limited response rates, potentially serious side-effects 
(see below) and by often prohibitive costs. A detailed discussion of all antiangiogenesis therapies 
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is beyond the scope of this work, and the reader is directed to excellent reviews by Gasparini and 
by Harrison (Gasparini et al. 2005; Harrison 2012). In this section I outline some general 
principles of their use in cancer, and then discuss bevacizumab in greater detail (section 1.2.4.1). 
An important goal for anti-angiogenic therapy is to reverse the abnormalities in 
permeability and network structure (Jain 2001). By pruning immature and inefficient blood 
vessels and eliminating excess endothelial cells, the vasculature is “normalised”, leading to  
increased vascular patency, improved tumour perfusion and drug delivery, and decreased tumour 
hypoxia (Dickson et al. 2007; Zhou et al. 2008). In rectal cancer patients treated with 
bevacizumab for example, a reduction in interstitial hypertension and an increase in pericyte 
coverage (suggesting normalisation) has been reported (Willett et al. 2004). More direct evidence 
of normalisation comes from a study in glioblastoma patients, in which angiogenic blockade 
resulted in a reduction in tumour vessel size and permeability, and a resultant reduction in tissue 
oedema (Batchelor et al. 2007). However, vessel normalisation is usually transient, and prolonged 
treatment with neutralising antibodies to VEGF or anti-VEGFR eventually leads to reduced 
tumour perfusion, impairing oxygenation and drug delivery (Figure 1.8), which suggests that 
uninterrupted treatment with such drugs may not be optimal for combination chemotherapy with 
cytotoxic drugs (Ma and Waxman 2008). Intermittent treatment regimes may allow for the 
recovery of tumour vessels in between periods of anti-angiogenic drug administration, although 
this introduces the risk of tumour cell recovery from the effects of the cytotoxic drugs. 
Interestingly, a rapid decrease in tumour perfusion and drug delivery is seen with receptor 
tyrosine kinase (RTK) inhibitors (Kim et al. 2005). This may be due to vasoconstriction caused by 
inhibition of autocrine VEGF-mediated responses which are not seen with neutralising VEGF 
antibodies (Ma and Waxman 2008). Despite increasing hypoxia and reducing drug delivery, 
RTKIs can still improve the anti-tumour response when used in combination with cytotoxics 
(Troiani et al. 2007; Ma and Waxman 2009), particularly when RTKI administration follows a 
period of cytotoxic monotherapy. This is partly due an increase in drug retention within the 
tumour, enhancing drug efficacy, which opens up the possibility of treatment modalities such as 
intratumoural injection of cytotoxics following angiogenesis treatment (Ma et al. 2011; Wang et 
al. 2011b).  
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Figure 1.8 Normalisation of tumour vasculature by angiogenesis inhibition 
A: Antiangiogenic drugs can induce functional normalization of tumour vasculature, transiently increasing 
uptake of co-administered cytotoxic drugs. However, continuous treatment ultimately decreases tumour 
blood flow and uptake of cytotoxics. B: intermittent antiangiogenesis treatment schedules may allow 
tumour vasculature recovery between drug administration cycles, improving delivery of cytotoxics. From 
(Ma and Waxman 2008) 
 
1.2.4.1 Bevacizumab 
As the first targeted antiangiogenesis therapy to be licensed in cancer, bevacizumab is 
also the best understood. Its efficacy in clinical trials provided confirmation of the pivotal role of 
VEGF in cancers in general and CRC in particular. There is a close correlation between VEGF 
expression and indices of CRC progression. Increased VEGF expression in tumour versus normal 
tissue was reported almost 20 years ago (Brown et al. 1993). Upregulation is seen in colonic 
adenomas, with a progressive increase that follows the adenoma-carcinoma sequence (Wong et al. 
1999; Kondo et al. 2000). Expression correlates with MVD, a measure of angiogenesis strongly 
associated with depth of invasion, and lymph node and liver metastasis (Nakasaki et al. 2002). 
Expression of VEGF and its receptor KDR correlates with tumour proliferation, metastasis and 
poor prognosis (Takahashi et al. 1995; Ishigami et al. 1998; Lee et al. 2000; Harada et al. 2001). 
These observations were supported by evidence from preclinical studies which 
demonstrated attenuation of tumour growth and metastasis in vitro following administration of 
neutralising VEGF antibodies (Kim et al. 1993; Warren et al. 1995), and the first clinical trials of 
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bevacizumab began in 1996. In combination with traditional chemotherapy, it was shown to 
improve survival in late-stage disease (Hurwitz et al. 2004; Kabbinavar et al. 2008). A number of 
subsequent trials have consistently reported increased response rate (RR), and prolonged 
progression free survival (PFS) and overall survival (OS). This is seen when used as first-line 
therapy in addition to the “Saltz Regimen” (irinotecan, FU and LV) (Hurwitz et al. 2004) 
(Kabbinavar et al. 2005a), or as second-line therapy in combination with newer cytotoxic agents 
such as in the FOLFOX4 regimen (oxaliplatin, FU and LV) (Giantonio et al. 2007) (Saltz et al. 
2008). Two meta-analyses reported consistent improvements in RR (Welch et al. 2010), PFS and 
OS (Galfrascoli et al. 2010; Welch et al. 2010). 
More recent trials have investigated the role of bevacizumab in less advanced disease 
(Stage II and III CRC), with somewhat unexpected results (Kerr and Young 2011). The NSABP 
C-08 trial found no benefit of bevacizumab plus FOLFOX over FOLFOX alone (Allegra et al. 
2011). In the AVANT trial, the addition of bevacizumab to FOLFOX in fact resulted in a small 
reduction in overall survival (De Gramont et al. 2011). Interestingly, withdrawal of bevacizumab 
at the end of the trial period appeared to be associated with an increased rate of relapse (Kerr and 
Young 2011). 
In the context of mCRC where median OS prior to the advent of anti-angiogenic therapy 
was of the order of 12 months, an improvement of several weeks to months is clinically 
significant, and there is evidence of improved quality of life during this period (Kabbinavar et al. 
2008). Nevertheless, there are significant limitations with regard to response rates, side effects 
and cost. Although response rates as high as 50% have been reported (Saltz et al. 2008), there 
remains a significant population of patients who do not benefit from bevacizumab. It has been 
reported that the development of hypertension or a skin rash after initiation of bevacizumab 
therapy correlates with better response (Saif et al. 2008; Scartozzi et al. 2009). Similarly, an 
increase in levels of several circulating biomarkers has been detected in patients after treatment 
begins, but only one (intercellular adhesion molecule 1, ICAM-1) was found to have any 
predictive value (Dowlati et al. 2008). However, to date no factors have been identified that can 
reliably predict response to bevacizumab prior to commencement of therapy (Galfrascoli et al. 
2010; Jubb and Harris 2010), and this is currently under investigation in the FOCUS-3 trial in the 
UK. Even in those patients who do respond to bevacizumab, the demonstrable tumour shrinkage 
and delayed progression seem to be transient, and are followed by tumour regrowth. It appears 
that as with most systemic cancer therapies, anti-angiogenic drugs are subject to the development 
of resistance. Of greater potential concern is the phenomenon of rebound, whereby tumours 
relapsing after cessation of anti-angiogenic therapy exhibit a more aggressive phenotype, with 
increased invasiveness and metastasis (Loges et al. 2009). This has been reported in glioblastoma 
and CRC (Cacheux et al. 2008; Zuniga et al. 2010). Both these clinical studies involved small 
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numbers, and are contradicted by a pooled analysis of phase III RCTs of bevacizumab in CRC 
which found no evidence of rebound (Miles et al. 2010). However, rebound has been suggested as 
a possible explanation for the results from the AVANT trial (see above) (Kerr and Young 2011). 
A more detailed understanding of the mechanisms underlying treatment failure is clearly 
necessary, and this is an area of much research and debate (Kerbel et al. 2001; Bergers and 
Hanahan 2008). 
Bevacizumab therapy is associated with adverse events including hypertension, 
thromboembolic events, bleeding, GI perforation and proteinuria (Ferrara et al. 2005). Two 
studies have reported a bevacizumab-induced five-fold increase in the incidence of severe 
hypertension (Hurwitz et al. 2004) (Kabbinavar et al. 2005c). A meta-analysis which included 20 
studies and over 12,000 patients with several cancer types found the incidence of all grades of 
hypertension to be 24% (Ranpura et al. 2010). Hypertension is an expected class effect of anti-
angiogenic therapy, since VEGFR activation results in production of the potent vasodilator nitric 
oxide leading to hypotension, and VEGF infusion has been shown to reduce systolic blood 
pressure in angina patients (Horowitz et al. 1997; Henry et al. 2003). Bevacizumab has been 
reported to disrupt the microcirculation in non-tumour tissue in vivo, reducing capillary density 
and endothelial cell vasodilator-response, effects which are reversed after cessation of treatment 
(Mourad et al. 2008; Steeghs et al. 2010). Patients receiving bevacizumab should have their blood 
pressure monitored and hypertension treated with oral anti-hypertensives. As there is some 
evidence that development of severe hypertension is associated with improved response to anti-
VEGF therapy, discontinuation of bevacizumab in these cases is controversial (Rixe et al. 2007; 
Scartozzi et al. 2009). 
Mild, asymptomatic proteinuria has further been reported in all studies of bevacizumab 
(Chen and Cleck 2009). In a meta-analysis, the risk of significant proteinuria was increased by 
2.52, although it remains relatively rare, with an incidence of 1.4% (Ranpura et al. 2010). Patients 
on bevacizumab require monitoring for proteinuria, and cessation of treatment has been 
recommended if urinary protein excretion exceeds 2g per 24 hours (Chen and Cleck 2009). 
VEGF plays an important role in endothelial cell-platelet homeostasis, and bevacizumab 
has been shown to be internalised by platelets, leading to a profound reduction in platelet-derived 
VEGF and platelet function (Verheul et al. 2007). Disruption of the VEGF pathway may thus be 
expected to affect coagulation. Treatment with bevacizumab is associated with a risk of serious 
arterial thromboembolic events (ATE) (Scappaticci et al. 2007; Schutz et al. 2010). Previous ATE 
and age over 65 years are significant risk factors (Scappaticci et al. 2007), and aspirin use has a 
protective effect in these patients. The association between venous thromboembolism (VTE), 
cancer and cytotoxic chemotherapy is well documented, contributing factors being the pro-
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thrombotic state associated both with surgery and with carcinomatosis itself. The evidence for 
VTE in the context of bevacizumab therapy is less clear cut. Scappaticci et al reported no effect 
on VTE incidence in CRC (Scappaticci et al. 2007). However, a meta-analysis has subsequently 
reported a 33% increase in high-grade (life-threatening) VTE (Nalluri et al. 2008). This study 
analysed 13 trials of bevacizumab in all cancers, and reported an overall 33% increase in all-
grades of VTE (relative risk 1.33, 95% CI 1.13-1.56, p<0.001). 
Mucocutaneous bleeding and epistaxis are common adverse effects, reported in up to 24% 
of bevacizumab treated CRC patients (Chen and Cleck 2009), and an increased incidence of 
severe bleeding requiring transfusion, primarily of the GI tract, has been reported (Giantonio et al. 
2007). There have also been reports of GI perforation (Hapani et al. 2009), and surgical 
complications including delayed wound healing (Hochster et al. 2008), wound failure (dehiscence 
or incisional hernias) (Allegra et al. 2009), and anastomotic leak or breakdown (August et al. 
2008; Bège et al. 2009). Even where these complications are not life-threatening, they can have a 
major impact on patients’ quality of life. The physiological response to injury that is necessary for 
healing following surgery is dependent on functional platelets and an adequate blood supply. 
Antiangiogenic therapy, which disrupts both, might therefore be anticipated to adversely affect 
surgical outcomes. It has been recommended that major surgery be avoided within six weeks of 
cessation of bevacizumab therapy where possible (Bose et al. 2010). 
Thus, the efficacy of bevacizumab for mCRC first seen in clinical trials over 10 years ago 
is balanced by clinical data that has accumulated since, demonstrating limited response rates and 
significant side-effects. Its failure to increase overall survival in non-metastatic CRC was 
unexpected. Two recent developments are of significant note. In the US, the FDA announced its 
withdrawal of approval for bevacizumab in metastatic breast cancer, citing the lack of evidence of 
sufficient efficacy in the light of significant side-effects (FDA 2010). In the UK, the National 
Institute for Health and Clinical Excellence announced that bevacizumab is not recommended for 
metastatic CRC, stating that its efficacy does not justify the high costs (NICE 2010).  
The development of bevacizumab was taken to herald a new era in anticancer therapy 
(Grothey 2005). Some of the initial promise has been fulfilled. Certainly, the concept of 
angiogenesis blockade as an effective strategy in the management of cancer is proven. As new 
antiangiogenic agents continue to be developed, the experience from bevacizumab illustrates the 
need for a deeper understanding of angiogenesis regulation and therapeutic inhibition, particularly 
with respect to understanding mechanisms of resistance, and the development of predictive 
biomarkers. 
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1.3 Hypoxia 
Hypoxia plays a pivotal role in cancer, as well as in other diseases such as atherosclerosis 
and rheumatoid arthritis. The exponential rate of tumour growth typically outstrips the capacity of 
new blood vessels to develop and infiltrate the expanding tumour mass. The resulting inadequate 
supply of oxygenated blood leads to hypoxia, which has been demonstrated in cancers of the head 
and neck, breast, cervix, prostate, skin (melanoma) as well as the colon and rectum (Wouters et al. 
2002; Goethals et al. 2006). As discussed in Section 1.2.2, tumours are restricted to 2-3mm
3
 in 
size without neo-vascularisation (Folkman and Shing 1992). However, angiogenesis in cancer 
results in structurally and functionally inept blood vessels (Denekamp 1990; Konerding et al. 
1999). The vessel network has a haphazard architecture, and immature vessel walls are “leaky”, 
resulting in the accumulation of extravascular fluid. This increases interstitial pressure which 
impedes oxygen diffusion within the tumour microenvironment. Thus, despite the expansion in 
the tumour vascular network, solid tumours continue to harbour hypoxic regions. Tumour hypoxia 
has been confirmed indirectly using immunohistochemistry (IHC) to identify exogenously infused  
imidazole-based markers, or endogenous hypoxia markers such as carbonic anhydrase and other 
hypoxia-inducible proteins (Wouters et al. 2002; Goethals et al. 2006). Direct measurement using 
oxygen electrodes shows that intratumoural oxygen tensions are typically below 30 mmHg 
(approximately 4% O2) in many solid tumours including CRC (Harris 2002; Goethals et al. 
2006). 
Tumour hypoxia is an indicator of poor prognosis. It is associated with more advanced 
stage at time of diagnosis in cervical cancer (Sundfør et al. 1998). In rectal cancer, Mattern et al. 
showed that intratumoural hypoxia correlates with MVD and VEGF expression (Mattern et al. 
1996). Prospective studies in several cancers have shown that tumour hypoxia at time of diagnosis 
predicts increased likelihood of development of metastasis and poorer survival (Brizel et al. 1996; 
Hockel and Vaupel 2001; Wouters et al. 2002). It is also associated with increased resistance to 
both chemo- and radiotherapy (Gray et al. 1953; Hockel et al. 1996).  
Numerous cellular processes are regulated by hypoxia in tumour cells, and the reader is 
directed to a comprehensive review by Harris (Harris 2002). These include cell metabolism, 
proliferation, migration and apoptosis, as well as angiogenesis. Cellular detection of, and 
adaptation to, decreased oxygen tension is primarily through the action of Hypoxia Inducible 
Factor (HIF) (see section 1.3.1)  
Hypoxia is a highly effective stimulus to angiogenesis through potent HIF-mediated 
induction of VEGF and other angiogenic factors such as ANGPT-2. Angiogenic responses, albeit 
markedly attenuated, can also be induced by hypoxia in the absence of HIF, through induction of 
factors such as IL-8 as well as VEGF (Levy et al. 1996; Ryan et al. 1998; Mizukami et al. 2004; 
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Mizukami et al. 2005). Hypoxia upregulates VEGF gene transcription through a 
PI3K/Rho/ROCK-dependent pathway (Mizukami et al. 2006b). In addition to increasing VEGF 
transcription, hypoxia stabilises VEGF mRNA (Ikeda et al. 1995; Levy et al. 1996).  
Hypoxia interferes with normal mechanisms of DNA repair leading to increased genetic 
instability (Bristow and Hill 2008). It stimulates secretion of MMPs and modulates expression of 
adhesion molecules, promoting metastasis (Esteban et al. 2006; Wu et al. 2008). In addition, it 
exerts a strong selection pressure on the heterogeneous population of cancer cells, promoting 
survival of cells demonstrating more malignant phenotypes (Hockel and Vaupel 2001; Sullivan 
and Graham 2007). For example, normal responses to hypoxia can lead to apoptosis, which is 
promoted by the activation of signalling via p53. In a heterogeneous cell population, cells with a 
wild-type p53 succumb to hypoxia-induced apoptosis, while those with a p53 mutation (common 
in cancers) are resistant (Graeber et al. 1996).  
 
1.3.1 The HIF Pathway 
Hypoxia Inducible Factors (HIFs) are a family of three transcription factors (HIF-1, 2 and 
3) which are central to the complex homeostatic mechanisms involved in the cellular response to 
hypoxic stress. HIF-1  is the best understood, and has been described as the “Master Regulator” 
of oxygen homeostasis (Semenza 1998). It has been shown to regulate 70 genes involved in 
angiogenesis, nutritional stress, tumour metabolism, invasion and cell death (Semenza 2002a; Lee 
et al. 2004; Wenger et al. 2005). HIF-2  is less well characterised and very little is known about 
the role of HIF-3 . HIF proteins are continuously degraded in normoxia, but become stabilised in 
hypoxic conditions (generally at below 5% O2), with increasing activity as oxygen tension 
decreases (Figure 1.9) (Bracken et al. 2006). This is a consequence of regulation by four enzymes, 
the three prolyl hydroxylases (PHD-1, -2 and -3) and Factor Inhibiting HIF (FIH-1), all of which 
require oxygen as well as the cofactors 2-oxoglutarate (2-OG) and iron. 
The HIFs are composed of a common constitutively-expressed β-subunit, and three 
distinct -subunits (Figure 1.10). Both and subunits contain a DNA-binding basic helix-loop-
helix motif that, in combination with the adjacent Per-ARNT-Sim (PAS) domain, cause the α- and 
β-subunits to dimerise. In the -subunit, an oxygen-dependent degradation (ODD) domain 
contains proline residues that in normoxia are rapidly hydroxylated by PHDs, leading to 
proteasomal degradation mediated by binding to the von Hippel–Lindau (vHL) protein (Ivan et al. 
2001; Jaakkola et al. 2001; Yu et al. 2001). 
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Figure 1.9 Structure and enzyme regulation of HIF-1  
In the presence of oxygen, hydroxylases are active. Hydroxylation of proline residues P402 and P564 in 
HIF-1α (P405 and P530 in HIF-2α) by PHDs allows interaction with the von Hippel–Lindau protein 
(pvHL). Complexed with the ubiquitin-activating enzyme (E1), pvHL mediates the ubiquitination (Ub) of 
HIF1α, marking it for proteasome degradation before dimerisation with the β-subunit can occur. FIH-1 
hydroxylates the asparigine residue N803 (N815 in HIF-2α) which inhibits binding of the transcription 
coactivators p300 and CREB-binding protein (CBP). In hypoxia, therefore, HIF-1α is stabilised by 
dimerisation with HIF-β, and the heterodimer translocates to the nucleus where transcription of target genes 
progresses unhindered (Courtesy T. Khong). 
vHL is a tumour suppressor gene, a germline mutation of which causes von Hippel-
Lindau disease, a heritable cancer syndrome characterised by the formation of multiple, highly 
angiogenic tumours (Kaelin and Maher 1998). Hydroxylation of specific proline residues in the 
HIF-α subunit allows binding of the functional vHL gene product pvHL which initiates 
polyubiquitination (tagging of lysine residues with multiple copies of ubiquitin, a 76 amino-acid 
basic polypeptide), followed by the recruitment of the E3 ubiquitin ligase complex. This destines 
-subunits to proteasomal degradation by 26S proteasome (Salceda and Caro 1997; Maxwell et 
al. 1999). (In vHL-defective cells such as the renal carcinoma cell-lines RCC and 786-O, HIF-α is 
constitutively stabilised.) FIH-1 appears to have a role secondary to that of the PHDs, exerting an 
additional level of negative control on HIF-  protein that has escaped degradation (Stolze et al. 
2004). FIH hydroxylates an asparagine residue in the C-terminal activation domain (CTAD) of 
the  subunit, preventing binding to this region of two co-activators, p300 and CBP, and thus 
inhibiting HIF transcriptional activity (Lando et al. 2002; McNeill et al. 2002). 
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Figure 1.10 Comparative protein structure of HIF-α and  subunits 
Both α and  subunits contain a basic helix-loop-helix motif (bHLH) and a Per-ARNT-Sim (PAS) domain, 
interaction of which allows dimerisation. The α subunits contain an oxygen-dependent degradation (ODD) 
domain and an N-terminal activation domain (N-TAD). In addition, HIF-1α and HIF-2α (but not HIF-3α) 
possess a C-terminal activation domain (C-TAD). Oxygen-dependent PHD and FIH enzymes regulate HIF 
by hydroxylating proline (Pro) and asparagine residues (Asn) respectively (see text for details). Arrows 
indicate the isoform-specific position of these residues. (Adapted from Smirnova et al. 2012) 
The positions of the proline residues that are modified by the PHDs differ for each HIF-
isoform (Figure 1.9 . For HIF-1 the residues are Pro402 and Pro564 (Bruick and McKnight 
2001; Epstein et al. 2001; Ivan et al. 2001; Yu et al. 2001); Pro405 and Pro531 for HIF-2  (Chan 
et al. 2002); and only one, Pro490, in HIF-3  (Maynard et al. 2003). Isoform specificity is also 
seen for FIH, which hydroxylates asparagine residue Asn803 in HIF-1  and Asn851 in HIF-2  
(Lando et al. 2002). (HIF-3  lacks a CTAD, and is therefore not regulated by FIH (Maynard et al. 
2003).) 
The oxygen dependence kinetics of the PHDs and FIH are such that small changes in 
oxygen tension cause significant changes in enzymatic activity, and are therefore rapidly 
transduced to changes in HIF-  protein levels (Epstein et al. 2001; Hirsila et al. 2003). Their 
catalytic activity falls with oxygen tension, leading to accumulation of the HIF-  subunit, which 
enters the nucleus to dimerise with HIF-1  and the transcriptional co-activators CBP/p300. The 
co-activators remodel the chromatin structure by virtue of their histone acetyltransferase activity, 
and facilitate recognition by the transcriptional complex of a hypoxia response element (HRE) in 
the target gene promoter. This directs the expression of HIF-target genes that are central to 
hypoxia-responses. While this oxygen-dependent post-translational regulation of HIF is the 
predominant and best understood mechanism of HIF stabilisation, other enzymatic modifications 
9Pro
Pro Pro
Pro Pro Asn
Asn
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contribute to HIF regulation, such as acetylation, S-nitrosylation and phosphorylation, all of 
which determine HIF half-life and/or transcriptional activity (Brahimi-Horn et al. 2005). 
The PHDs and FIH-1 are regulated by the availability of co-substrates, including molecular 
oxygen, HIF and 2-OG, and by the presence of co-factors, such as Fe
2+ 
and ascorbate (Ivan et al. 
2001; Hewitson et al. 2002). Hydroxylation efficiency is influenced by oxygen availability and 
affinity of the enzymes for oxygen. The PHDs are more sensitive to hypoxia, and have minimal 
activity at 1% O2, whereas FIH-1 is remains active at oxygen tensions as low as 0.2% (Mahon et 
al. 2001; Lando et al. 2002; Koivunen et al. 2004; Stolze et al. 2004). The hydroxylases bind Fe
2+
, 
which keeps the catalytic centre of the enzyme ready for substrate binding. Therefore Fe
2+
-
chelating molecules (iron antagonists), such as desferrioxamine (DFO), CoCl2, and Ni
2+
 ions, or 
reactive oxygen species (ROS) that oxidise Fe
2+
 to Fe
3+
, act as PHDs inhibitors. 2-OG antagonists 
also inhibit PHDs and FIH. Dimethyloxalylglycine (DMOG) is one such (exogenous) antagonist, 
which is a commonly used experimental hypoxia-mimetic. Examples of endogenous antagonists 
are intermediates of the Krebs cycle (e.g. succinate, fumarate), and by-products of glycolysis (e.g. 
pyruvate). 
Interestingly, while hypoxia decreases the enzymatic activity of PHDs, it induces their 
transcription and translation (Epstein et al. 2001; Berra et al. 2003; Cioffi et al. 2003; Del Peso et 
al. 2003; Metzen et al. 2003; Marxsen et al. 2004). Both PHD-2 (Metzen et al. 2005) and PHD-3 
(Pescador et al. 2005) gene promoters possess a HRE, and in many cell types an increase in 
oxygen-mediated HIF-  degradation is seen in chronic hypoxia. The presence of an HRE points 
to PHD-2 and PHD-3 being HIF targets, and this has been shown demonstrated in a number of 
cells in vitro. PHD-2 is solely regulated by HIF-1α in hypoxia (Berra et al. 2003; Appelhoff et al. 
2004; Aprelikova et al. 2004; Marxsen et al. 2004), whereas PHD-3 is dependent on both HIF-1α 
(Aprelikova et al. 2004; Marxsen et al. 2004) and HIF-2α (Huang et al. 2002; Appelhoff et al. 
2004; Aprelikova et al. 2004; Marxsen et al. 2004). 
HIF Target Genes 
A consensus HRE has been identified in the oxygen-dependent regions of over 70 
validated HIF target genes, and microarray experiments suggest that there may be up to 200 HIF 
targets (Wenger et al. 2005). Four such genes are VEGF, BNIP-3, GLUT-1 and CA-IX. The 
importance of VEGF in angiogenesis and cancer is described elsewhere (sections 1.1.5.3, 1.3.2.1). 
BNIP-3 (Bcl2/adenovirus E1B 19d-interacting protein) is a pro-apoptotic gene and is described 
below (section 1.3.2.2). GLUT-1 (glucose transporter 1) and CA-IX (carbonic anhydrase 9) are 
both involved in energy metabolism, and have been used as endogenous markers of hypoxia 
(Airley et al. 2003; Hoskin et al. 2003).  
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The phenomenon of increased glucose uptake by tumour tissue was first described by 
Warburg in 1927 (Warburg et al. 1927). The discovery of the glucose transporter GLUT-1 in the 
hepatoma cell-line HepG2 provided a structural and functional basis of this increased uptake 
(Mueckler et al. 1985; Airley et al. 2010). GLUT-1 is induced by hypoxia, and indeed is used as 
an experimental marker of hypoxia (Zhang et al. 1999; Albertella et al. 2008; Chung et al. 2009). 
It is overexpressed in many cancers including CRC, particularly in peri-necrotic regions (Chung 
et al. 2009; Airley et al. 2010), and is associated with poor prognosis (Cooper et al. 2003).  
The carbonic anhydrases are a family of metalloenzymes that catalyse carbon dioxide 
hydration. Due to its induction by hypoxia, carbonic anhydrase IX (CA-IX) is commonly used as 
a marker of cellular hypoxia. CA-IX is overexpressed in many cancers including CRC, and is 
associated with poor prognosis (Saarnio et al. 1998; Korkeila et al. 2009; McDonald et al. 2012). 
Tumour cell metabolism is characterised by a high rate of glucose metabolism, the deleterious 
effects of which are counteracted by CA-IX. It maintains a favourable intracellular pH for tumour 
growth and survival, as well as facilitating invasiveness by acidifying the extracellular space 
(Swietach et al. 2010; Parks et al. 2011). It also influences proliferation, migration and apoptosis 
(Svastová et al. 2003; Cianchi et al. 2010; Shin et al. 2011). 
 
1.3.2 Role Of HIF In Cancer 
Due to similarities in structure, regulation and mode of action of the two main HIF-α 
isoforms they were initially thought to have the same effects. There are, however, significant 
differences. For example, HIF-1  is evolutionarily older and is ubiquitously expressed in 
organisms from C. elegans to humans, while HIF-2  is only expressed in higher vertebrates and 
in specific tissues (Muz et al. 2009). There is increasing evidence that they play different, even 
opposing, roles (Seton-Rogers 2007; Loboda et al. 2012). Generally, HIF-1  is thought to 
regulate genes involved in metabolism, regulating glycolysis and glucose uptake, as well as 
angiogenesis, while HIF-2  has been reported to regulate genes involved in cell-proliferation and 
tumourigenesis (Franovic et al. 2009). It may be that in vivo predominance of HIF-2  would 
allow uncontrolled cellular proliferation, with serious consequences in diseases associated with 
hypoxia, such as cancer. In addition, there is evidence that the relative roles of the two isoforms is 
tissue-dependent (see below) (Carroll and Ashcroft 2006). 
1.3.2.1 Angiogenesis 
Tissue hypoxia is a highly potent pro-angiogenic stimulus, acting predominantly through 
the up-regulation of VEGF, the importance of which has been discussed in Section 1.2. Hypoxia 
induces transcriptional activation of VEGF mRNA and stabilises VEGF mRNA (Levy et al. 
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1996). These effects are mediated through both HIF-dependent and HIF-independent pathways 
(Levy et al. 1996; Mizukami et al. 2006a). Evidence suggests that the relative roles of the HIF-α 
isoforms in the regulation of VEGF are tissue-specific ( 
Table 1.2). Interestingly, the cancers in which HIF-2  is the predominant VEGF regulator 
are vHL-deficient, suggesting that loss of vHL may lead to a change of predominant isoforms. 
HIF induces expression of other genes known to exert angiogenic effects, such as TGF-
3, nitric oxide synthase 2, haemoxygenase-1, plasminogen activator inhibitor-1 and endothelin-1 
(Semenza 2001). It also promotes transformation of the ECM for sprouting and in-growth of new 
tumour vessels in CRC by upregulating production of ECM proteases, such as MMP-2, cathepsin 
D and urokinase plasminogen activator receptor (uPAR) (Krishnamachary et al. 2003). The 
remodelling of the ECM is also a prerequisite for tumour cell invasion and metastasis. HIF-1  
further enhances the invasive potential of malignant CRC cells by altering expression of integrins 
on the surface of cancer cells and production of ECM proteins (Krishnamachary et al. 2003). 
 
Table 1.2 VEGF Regulation by HIF-α isoforms in solid tumours 
In the studies listed, the relative contribution of HIF-1α and HIF-2α to VEGF regulation was investigated. 
Studies were in human tissue or cell-lines except where specified. All studies compared HIF-1α to HIF-2α.  
 
1.3.2.2 Apoptosis 
The term “apoptosis” describes a coordinated program of cell “suicide” by which 
multicellular organisms can eliminate damaged, infected or redundant cells (Kerr et al. 1972). It is 
essential for normal development, tissue homeostasis, and defence against pathogens. Evasion of 
apoptosis is one of the hallmarks of cancer (Hanahan and Weinberg 2011), and hypoxia drives 
metastasis in part by selection of apoptosis-resistant cells (Graeber et al. 1996; Hockel and Vaupel 
Predominant Isoform Methodology Reference 
HIF-1α HIF-2α   
Breast  Gene silencing (siRNA) (Carroll and Ashcroft 2006) 
 Renal 
Gene silencing (siRNA) 
(Raval et al. 2005; Carroll and 
Ashcroft 2006) 
Gastric  
immunohistochemistry, Gene 
silencing (siRNA) (Song et al. 2009) 
Colon  immunohistochemistry (Imamura et al. 2009) 
 Liver (mouse) Gene knockout  (Rankin et al. 2008) 
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2001; Sullivan and Graham 2007). HIF-1  has been shown to both induce and to prevent 
hypoxia-induced apoptosis (Carmeliet et al. 1998; Akakura et al. 2001). It stabilises the tumour 
suppressor p53, and upregulates BNIP-3 in a p53-dependent manner (Fei et al. 2004; Greijer and 
van der Wall 2004). HIF-2  is reportedly not involved in hypoxia-induced apoptosis, although it 
is involved in hypoglycaemia-induced apoptosis (Brusselmans et al. 2001). 
The first mammalian regulator of apoptosis to be identified was the anti-apoptotic Bcl-2 
(Tsujimoto et al. 1984), and 15 members of the Bcl-2 family have subsequently been identified. 
Those most closely related to Bcl-2 promote survival by the inhibiting ability of proteases 
(caspases) to dismantle the cell. Those more distantly related (e.g. BNIP-3, BAX) promote 
apoptosis through mechanisms which include interference with the activity of anti-apoptotic 
(Adams and Cory 1998). Opposing members can heterodimerise (e.g. Bcl-2 and BAX) (Oltvai et 
al. 1993), and appear to titrate each other’s function, so that whether activation of apoptosis is 
dependent on their relative concentrations. HIF-1α-dependent upregulation of bcl-2 has been 
reported in embryonic stem-cells (Carmeliet et al. 1998). Interestingly, in breast cancer and 
melanoma bcl-2 has also been shown to synergise with hypoxia in upregulating VEGF via a HIF-
1α-mediated pathway (Trisciuoglio et al. 2010). 
BNIP-3 is upregulated in tumour tissue of several cancers including CRC, and is 
associated with more aggressive disease (Koukourakis et al. 2006; Burton and Gibson 2009). 
Interestingly, in CRC tumour samples, it has been reported that BNIP-3 expression may be either 
up- or downregulated (Bacon et al. 2006). HIF-1α dependent upregulation of BNIP-3 by hypoxia 
is well-established (Sowter et al. 2001; Greijer and van der Wall 2004), and has been reported in 
several cancer cell-lines including CRC (Sowter et al. 2001; Bacon et al. 2006). However, not all 
CRC cell-lines upregulate BNIP-3 in response to hypoxia, and Bacon et al. reported that those 
which did not were resistant to hypoxia-induced cell death. Preventing hypoxia-induction of 
BNIP-3 may therefore be a mechanism by which tumours can evade apoptosis. In addition, a 
direct pro-survival role in the context of hypoxia has been postulated for BNIP-3, through the 
promotion of autophagy which can prolong survival in the context of defective apoptosis 
(Degenhardt et al. 2006; Mathew et al. 2007; Bellot et al. 2009). 
Survivin, a member of the Inhibitor of Apoptosis Protein (IAP) family, negatively 
regulates apoptosis. It has been shown to be upregulated in most tumours and in CRC is 
associated with poorer prognosis (Abd El-Hameed 2005; Sah et al. 2006). In the CRC cell-lines 
LS174T and SW480, HIF-1α has been reported to upregulate survivin expression at both mRNA 
and protein level (Fan et al. 2008; Wu et al. 2010). XIAP (X-linked inhibitor of apoptosis 
protein), another member of the IAP family, is overexpressed in CRC tissue (Krajewska et al. 
2005). It has been shown to protect against hypoxia-induced apoptosis in cholangiocarcinoma 
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which is particularly resistant to hypoxia, but little is known about its role in CRC (Marienfeld et 
al. 2004). 
1.3.2.3 Cell Adhesion 
A critical process in the progression of cancer from in-situ through invasive to metastatic 
disease is the loss of cancer cell adhesion to neighbouring cells and surrounding extracellular 
matrix, migration from primary to distant sites, and re-establishment of new cell-cell and cell-
matrix adhesion at the target organ (Paschos et al. 2009). There is some evidence that hypoxia 
influences these events, although the mechanisms are poorly understood. It may be expected that 
hypoxia, which promotes metastasis, would downregulate tumour cell expression of cell-adhesion 
molecules (CAMs), and this has indeed been reported. For example, E-cadherin, a major 
component of epithelial cell-cell junctions, has been shown to be downregulated by hypoxia in 
ovarian and renal cancer (Imai et al. 2003; Esteban et al. 2006), but there is no clear evidence of 
this in CRC. However, CD151, a transmembrane protein involved in cell-adhesion and migration, 
is reduced in primary CRC tumour compared to adjacent normal tissue (Chien et al. 2008). The 
same study reported CD151 downregulation by hypoxia in three CRC cell-lines (SW480, SW620 
and HCT116), leading to a reduction in the strength of cell-cell and cell-matrix adhesions.  
Vascular-endothelial cadherin (VE-Cadherin; Cadherin 5 (CDH5)) is normally expressed 
by endothelial rather than epithelial cells. However, epithelial expression of VE-Cadherin is seen 
in cancers exhibiting “vasculogenic mimicry” (VM), in which tumour cells form capillary-like 
structures and matrix-rich patterned networks in three-dimensional cultures, imitating the 
embryonic vasculogenic network (Maniotis et al. 1999). VM has been described in CRC and 
found to correlate with poor prognosis (Baeten et al. 2009). In a preliminary PCR Array 
experiment performed in our laboratory prior to the commencement of my study, VE-Cadherin 
was found to be downregulated by DMOG in Caco-2 cells (T. Khong, unpublished data). 
In the same PCR Array experiment, downregulation of Stabilin-1 (STAB-1) was also seen 
following DMOG stimulation. STAB-1 is a large transmembrane protein that was first described 
in endothelial cells of hepatic sinusoids. Its multifunctionality is reflected in its numerous aliases 
which include CLEVER-1 (common lymphatic endothelial and vascular endothelial receptor-1) 
and FEEL-1 (Fasciclin, EGF-like, laminin-type EGF-like and link domain-containing scavenger 
receptor 1). It has been implicated in a number of roles related to scavenging, lymphocyte 
migration, cell-adhesion and angiogenesis (Salmi et al. 2004; Karikoski et al. 2009). Given the 
versatility of STAB-1 function it is likely that its role is context- and/or cell-specific, and its role 
in cancer is poorly understood.  
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1.3.2.4 Inflammation 
Virchow first described a tumour-associated inflammatory infiltrate 150 years ago. 
Macrophages, which can represent up to 50% of tumour mass (Solinas et al. 2009), constitute a 
highly heterogeneous population, originating from blood monocytes and differentiating into M1 
(classically activated) or M2 (alternatively activated) phenotypes. Tumour-associated 
macrophages (TAMs) which have an M2 phenotype, have been implicated in connecting the 
innate immune system, chronic inflammation and tumourigenesis (Solinas et al. 2009). Other 
myeloid-related cells associated with tumours are Tie-2 macrophages and myeloid-derived 
suppressor cells (MDSCs). 
TAMs predominantly infiltrate poorly vascularised, hypoxic regions within solid tumours 
(Leek and Harris 2002), and enhance angiogenesis, invasion and metastasis through secretion of 
growth factors and cytokines including VEGF (Condeelis and Pollard 2006; Jedinak et al. 2010). 
High HIF-2α expression in TAMs correlates with high tumour grade and poor prognosis in a 
variety of cancers (Talks et al. 2000). Hypoxia has been reported to induce both HIF-1α and HIF-
2α in TAMs (Imtiyaz et al. 2010). In mice lacking HIF-2α in myeloid cells, experimentally-
induced hepatic and colonic tumours showed reduced TAM migration and infiltration into tumour 
tissue, resulting in reduced tumour cell proliferation and progression. 
1.3.3 HIFs In CRC 
Strong evidence for the critical role played by HIF in CRC is provided by 
immunohistochemical examination of tumour tissue, and in vitro studies. CRC tissue samples 
consistently coexpress elevated levels of HIF-1  and VEGF, and these correlate with MVD, local 
and lymphovascular invasion, and liver metastasis (Kuwai et al. 2003; Simiantonaki et al. 2008). 
In addition, HIF-1α activity is induced by genetic mutations that commonly occur in CRC, such 
as the K-ras oncogene, and the tumour suppressor genes p53, vHL, and PTEN (Ravi et al. 2000; 
Kuwai et al. 2004; Giles et al. 2006; Greijer et al. 2008; Pencreach et al. 2009). Furthermore, HIF-
1α overexpression promotes tumour growth and angiogenesis in CRC xenograft models (Ravi et 
al. 2000; Dang et al. 2006).  
The relative roles of HIF-α isoforms in CRC have not been extensively studied, and there 
is controversy in the few published studies in the literature (Table 1.3). Based on 
immunohistochemical staining in primary rectal carcinoma, Rasheed et al have reported that 
increased expression of both isoforms, but that only HIF-1  is related to increased vascular 
invasion, more advanced tumour stage and poorer prognosis (Rasheed et al. 2009). Imamura et al 
report stronger VEGF upregulation and increased MVD with overexpression of HIF-1  than with 
HIF-2  (Imamura et al. 2009). Conversely, both Yoshimura et al and Cleven et al. found poor 
prognosis to correlate with increased HIF-2  staining, but not HIF-1  (Yoshimura et al. 2004; 
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Cleven et al. 2007). Yoshimura et al also reported HIF-2  but not HIF-1  expression to correlate 
closely with increased MVD. 
Table 1.3 Relative Roles of HIF-α isoforms in CRC 
Different authors report contradictory roles for HIF-1α and HIF-2α in CRC in both in vivo and in vitro 
studies. (NB: * Dang et al. investigated HIF-1α only.) 
 
The picture remains unclear with in vitro studies. Using gene-silencing in the CRC cell-
line SW480 (primary adenocarcinoma, Dukes’ B; (Leibovitz et al. 1976)), Imamura et al report 
that HIF-1  promotes tumour growth whereas HIF-2  suppresses it. Data from Dang et al. 
supports the pro-proliferative role of HIF-1  using a different CRC cell-line (HCT116, primary 
adenocarcinoma; (Brattain et al. 1981)), although in their study no comparison was made with 
HIF-2  (Dang et al. 2006). In contrast, Franovic et al report that in HCT116 cells (and a variety 
of other cancers), HIF-2  promotes growth. HIF-2  knockdown significantly impaired cell 
proliferation and tumourigenesis, whereas HIF-1  knockdown had no effect (Franovic et al. 
2009). 
While CRC is generally considered to include rectal as well as colon tumours, there are 
significant differences between proximal and distal tumours. For example, distant metastases are 
more common with proximal tumours, and local invasion with distal tumours; prognosis is poorer 
with proximal tumours (Meguid et al. 2008; Benedix et al. 2010). While anatomical location in 
itself contributes to these differences (e.g. distal rectal tumours growing in the relatively confined 
pelvic space become symptomatic earlier than proximal intra-abdominal tumours), there is 
evidence that the cellular biology also differs (Fusunyan et al. 1998; Bleeker et al. 2000). The 
published literature is often unclear with regard to the anatomical site of the cancers included in 
the study. For example, while Rasheed et al. included only rectal cancers, Imamura et al. do not 
specify the tumour site. Yoshimura et al. distinguish between right (proximal) and left (distal) 
 Predominant Isoform Methodology 
 HIF-1α HIF-2α  Cell-line 
Advanced stage,  
poor prognosis 
Rasheed et al. Yoshimura et al. immunohistochemistry  
Angiogenesis 
Imamura et al. 
(VEGF) 
Yoshimura et al. 
(MVD) 
immunohistochemistry  
Cell Proliferation 
Imamura et al.  gene silencing (siRNA) SW480 
(Dang et al.)* Franovic et al. gene silencing (siRNA) HCT116 
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tumours, noting that the latter stain more strongly for HIF-2 , but do not state whether rectal 
cancers are included, or if MVD and prognosis varies independently with anatomical site. (The 
anatomical site of origin of CRC cell-lines is more difficult to ascertain, many of them having 
been derived in the 1970s.) This lack of clarity may contribute to the lack of consistency in the 
data. 
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1.4 Study Rationale 
The potential for HIF inhibition as a therapeutic strategy in CRC has been recognised for 
some time (Semenza 2002b). There is evidence that HIF-induction enhances resistance to 
chemotherapy (including novel biologicals) (Rohwer et al. 2010; Zhao et al. 2010) and 
radiotherapy (Moeller et al. 2007). HIF induction is likely to be a feature of response to 
antiangiogenic therapy, since effective disruption of tumour blood supply would result in hypoxia, 
and HIF inhibition may improve the efficacy of antiangiogenic drugs, particularly in tumours 
overexpressing HIF (Semenza 2012). HIF inhibition is an “off-target” effect of several anti-cancer 
drugs (e.g. mTOR inhibitors such as temsirolimus; topoisomerase inhibitors such as topotecan) 
(Semenza 2007). In some cases the inhibition is known to be HIF-1α specific (Semenza 2012), 
while for others (including some used in CRC) the effect on HIF-2α is unknown. Interestingly, a 
reciprocal relationship between the isoforms, in which inhibition of one leads to induction of the 
other, has been reported in breast and renal cancer (Raval et al. 2005; Carroll and Ashcroft 2006). 
If both isoforms have independently deleterious effects, this raises the possibility that selective of 
inhibition of one isoform may in fact be undesirable. Certainly there is evidence that simultaneous 
inhibition of both isoforms can be beneficial (Burkitt et al. 2009), and drugs that inhibit both 
isoforms are under development (Bohonowych et al. 2011; Chen and Sang 2011). Despite the 
evidence that the two isoforms have distinct functions, some publications discussing HIF 
inhibition continue to consider anti-HIF-1α activity alone (Wang et al. 2011a; Xia et al. 2012). 
Evidently, a deeper understanding of the relative roles of the isoforms (which the 
evidence suggests are tissue- and disease specific) is required in order to understand the potential 
consequences of selective HIF-isoform inhibition. This, in addition to the controversy with 
respect to isoform roles in CRC, points to an unmet need that this study seeks to address.  
The main aim of the study was to elucidate the relative roles of HIF-1α and HIF-2α in the 
hypoxia-regulation of genes relevant to CRC pathogenesis in the CRC cell-line Caco-2. Prior to 
investigation of the role of the HIF isoforms, characterisation of the hypoxia responses of Caco-2 
was necessary (Chapter 3). Several genes were selected on the basis of relevance to cancer 
pathogenesis, and existing evidence of hypoxia-regulation in cancer. In addition to well-described 
HIF-target genes (VEGF, BNIP-3, GLUT-1 and CA-IX), genes involved in apoptosis (Bcl-2, 
Survivin, XIAP) and cell adhesion (VE-Cadherin, CD151, STAB-1) were investigated. Given the 
importance of angiogenesis in the hypoxia-driven pathogenesis of cancer, the study focussed on 
genes involved in angiogenesis. A PCR Angiogenesis Array was used to identify hypoxia-
regulated genes, which were validated by Q-PCR. Following characterisation of Caco-2 responses 
to hypoxia, the role of the HIF isoforms was investigated by selective knockdown using short 
interfering RNA (siRNA) (Chapter 4).  
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The use of an immortalised cell-line such as Caco-2 has several advantages, including the 
ability to conduct carefully controlled experiments repeatedly, obtaining consistent results, at 
relatively low cost. However CRC is a highly heterogeneous disease, in which even within a 
single tumour, a high degree of genotypic and phenotypic diversity is seen (Morel et al. 2008). 
This in stark contrast to the clonogenic homogeneity of cell-lines which in itself confers the 
advantages described above. Cell-lines are therefore far from representative of tumours in vivo, 
and there are significant limitations in translating cell-line-derived data to the clinic or bedside. 
The use of more than one cell-line in a study can partially address this issue. An alternative that 
more effectively closes the gap between in vitro and in vivo milieus is to use cell-lines derived de 
novo, directly from primary tumours. However, this introduces significant technical challenges. 
Our lab has experience with techniques in which ex vivo cultures of cells are derived from fresh 
tissue (atherosclerotic plaques, rheumatoid joints) (Brennan et al. 1989b; Monaco et al. 2004). 
Indeed a previous study has succeeded in establishing short-term cultures from CRC tissue which 
were successfully used in cytokine-stimulation experiments (T. Khong, unpublished data). 
Therefore, rather than study several CRC cell-lines, this study attempted to develop this technique 
in order to establish a tumour-derived culture (TDC) model, and to investigate hypoxia-responses 
in terms of angiogenesis genes, comparing them to Caco-2 responses (Chapter 5).  
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1.4.1 Objectives 
1. To characterise the hypoxia response of Caco-2 cells, in terms of known HIF targets, 
genes involved in apoptosis and cell-adhesion, and with a particular focus on 
angiogenesis genes. 
(Chapter 3) 
 
2. To investigate the relative contribution of HIF-1α and HIF-2α isoforms in this 
hypoxia response.  
(Chapter 4)  
 
3. To establish primary cultures of cells derived directly from CRC tissue and 
investigate their hypoxia-induced angiogenesis responses, comparing them to those of 
Caco-2 cells. 
(Chapter 5) 
 
1.4.2 Null Hypotheses 
1. HIF-1α and HIF-2α have identical roles in the hypoxia-regulation of Caco-2 cells. 
2. There is no similarity between hypoxia-induced angiogenesis gene expression in 
TDCs compared to Caco-2 cells.
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2 MATERIALS AND METHODS 
2.1 Caco-2 Cells 
The Caco-2 cell-line used in the study was purchased from the American Type Culture 
Collection (ATCC, Rockville, MD, USA). It is an adherent cell-line (Figure 2.1) that was 
originally isolated from a primary colonic tumour in a 72-year-old Caucasian male, and expresses 
characteristics of enterocyte differentiation upon reaching confluence in vitro (Fogh et al. 1977). 
It is widely used to assess intestinal transport of drugs through a cell monolayer absorption model. 
Tumourigenicity of the cell-line is demonstrated by the development of moderately-well 
differentiated adenocarcinoma following inoculation into nude mice, although low “take” rates 
have been are reported, limiting its use in xenograft models (de Bruïne et al. 1993; Liu et al. 
2007). 
 
Figure 2.1 Photomicrograph of Caco-2 cells  
Figure shows adherent Caco-2 cells at low (left) and high (right) density (confluence).  
2.1.1 Cell Culture 
The cells were thawed on receipt according to supplier’s instructions in the 
Microbiological Safety Cabinet (Napflow 1200, Napco, Thermo Scientific, Waltham, MA, USA). 
The thawed cells were resuspended in 10mL of culture medium and plated in a 75cm
2
 flask 
(Falcon™ T75, Becton Dickinson Labware, Bedford, MA, USA). With the lid loosened to allow 
free exchange of gases, the cells were incubated in a humidified atmosphere at 37°C in 21% O2 
and 5% CO2 (Napco 6500 Incubator, Napco, Thermo Scientific, Waltham, MA, USA). The base 
medium used was Eagle's Minimum Essential Medium (EMEM) (Biowhittaker, Lonza, 
Low density High densityScale bar = 100µm Scale bar = 100µm
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Switzerland) containing non-essential amino acids (NEAA) and sodium pyruvate. The culture 
medium was completed by supplementation with 10% Foetal Bovine Serum (FBS; Biowest, 
Nuaille, France), 2mM Glutamine, and 1.1 U/mL of streptomycin (100 U/mL) and 1.1 μg/mL 
penicillin (PAA Laboratories GmbH, Pasching). This is referred to as “complete culture medium” 
hereafter. Medium was changed every 2 days.  
Caco-2 cells undergo enterocytic differentiation upon reaching full confluence, therefore 
cells were passaged at 80% confluence. Cells were trypsinised with 4 mL of 0.25% 
Trypsin/EDTA to release the cells into suspension, with the duration of trypsinisation varying 
from 3 to 10 minutes depending on the passage number and confluence of the cell culture. The 
proteloytic activity of trypsin was neutralised by the addition of 10 mL of complete culture 
medium (with 10% FBS). An 80% confluent cell culture within a T75 flask yielded 1 x 10
7
 cells. 
Cells were generally passaged every 5 days to a subcultivation ratio of 1:3.  
In order to maintain the stock of Caco-2 cells, at the first passage after thawing frozen 
cells, one third of the cells yielded was re-frozen in liquid nitrogen (freezing medium was 10% 
DMSO in FBS). Passage number can influence protein expression and functional characteristics 
of cell-lines (Wenger et al. 2004; Hughes et al. 2007). This has been reported in several studies of 
Caco-2 (Briske-Anderson et al. 1997; Yu et al. 1997; Sambuy et al. 2005). During early 
experiments I observed that with each passage it took longer for cells to detach when trypsinised. 
Significantly greater time was required by passage 6 or 7, although further passages remained 
possible. Indeed studies investigating the effect of passage number on cell-line function generally 
compared passage numbers below 30 (“low”) and above 80 (“high”). Given these relatively high 
numbers, it was felt that potential variability in my results would adequately minimised by 
discarding cells after 5 passages. To ensure this, flasks were routinely labelled with passage 
number, but passage numbers were not recorded for data analysis purposes. 
Loss of adhesion in adherent epithelial cells can occur in response to infection or 
exposure to toxins (Zodl et al. 2003; Minnaard et al. 2004). It is a feature of epithelial cell 
apoptosis (Frisch and Francis 1994), and detachment has been shown to precede and induce 
apoptosis in Caco-2 cells (Giovannini et al. 1999; Kozlova et al. 2001). Cells were therefore 
discarded if significant detachment was seen. 
2.1.2 Stimulation 
Caco-2 cells were seeded in 960mm
2
 trays with a seeding cell population of 
approximately 2 x 10
5
 per well (density approximately 2 x 10
4
 cells per cm
2
). The cell cultures 
were then allowed to settle for 48 hours in complete culture medium prior to commencement of 
experiments. The medium was changed prior to stimulation with DMOG or hypoxia. Cells were 
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incubated for 24 hours before removal of supernatants and, following cell lysis in the appropriate 
buffer, cells were harvested and extraction of protein and/or RNA was performed (see below). 
The Galaxy ‘R’ carbon dioxide incubator (Wolf, York, England) allows levels of oxygen, 
carbon dioxide and nitrogen to be varied independently. In these experiments, carbon dioxide 
saturation was kept constant at 5%, while the oxygen saturation was initially varied between 1% 
and 10%. Care was taken to minimise re-oxygenation of cells during harvesting of cells. Since the 
unstable HIF-1  protein has a half-life of 5 minutes, the time interval between transferring cells 
out of the incubator to time of cell lysis was kept to a minimum. As well as being oxygen-
dependent, the HIF regulating enzymes (PHDs and FIH-1) also require 2-OG as substrate. 
Dimethyloxalylglycine (DMOG) is a competitive 2-OG analogue, and is therefore commonly 
used as a hypoxia-mimetic. DMOG (Biomol, Plymouth Meeting, PA, USA) was initially used at 
concentrations of 0.5 and 1 mM. 
2.1.3 Transfection 
Gene-silencing using RNA interference is an invaluable method of studying the role of a 
specific gene. One available technique is the use of short interfering RNAs (siRNAs). These are 
short (21-23nt) anti-sense RNA sequences which, on binding the target mRNA, lead to its 
cleavage. They are highly specific, with a single nucleotide mis-match often being sufficient to 
prevent cleavage of the target mRNA (Tuschl 2001). Knockdown of the target genes is achieved 
by lipid-mediated transfection. A lipophilic transfection agent (Lipofectamine or Oligofectamine) 
is mixed with siRNA in aqueous medium Opti-MEM Reduced Serum Medium (all three reagents 
from Invitrogen). After a brief period of incubation, the lipids form liposomes containing siRNA. 
When these are added to the cells, they merge with phospholipid bilayer of the cell membrane, 
releasing the siRNA into the cell. 
Caco-2 cells were seeded in 48cm
2
 plates at a density of 1.5 x 10
5 
cells/cm
2
.
 
50% 
confluence was achieved after 48 hours, at which time transfection was performed. Since serum 
and antibiotics reduce the efficiency of transfection, the medium was changed to serum- and 
antibiotic-free medium at the start of transfection. Prior to formation of the liposome complexes, 
the transfection agent was diluted in Opti-MEM (1:50 dilution for lipofectamine, 1:7.5 for 
oligofectamine). The siRNA was diluted in Opti-MEM separately. After 5 minutes the two were 
mixed and incubated for 20 minutes at room temperature to allow complex formation. This was 
then added to the cells gently to ensure that the complexes were not disrupted. Cells were then 
incubated for 6 hours at 37°C, after which antibiotics and FBS were added to the final 
concentrations of complete culture medium.  This protocol was developed following optimisation 
experiments in which variations of transfection agent dilution, siRNA concentration, cell 
confluence and serum starvation were used (see Chapter 4 Results). Hypoxia and/or DMOG 
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stimulation experiments were commenced 24 hours after the transfection period was complete. 
siRNA sequences were purchased from MWG (Heidelberg, Germany) and details are shown in 
Table 2.1. siLuc from Dharmacon (Thermo Fisher Scientific, Cramlington, UK) was used as an 
irrelevant control. 
 
Table 2.1 siRNA Sequences 
A list of siRNA sense sequences. siRNA were purchased from MWG (Heidelberg, Germany), apart from 
siLuc purchased from Dharmacon (Thermo Fisher Scientific, Cramlington, UK) 
siRNA Sense Sequence 
siHIF-1α 5’ – [agcaguaggaauuggaacauu]RNA [tt]DNA 3’ 
siHIF-2α 5’ – [gcgacagcuggaguaugaauu]RNA[tt]DNA-3’ 
siFIH-1 5’ [caguugcgcaguuauagcuuc]RNA [tt]DNA 3’ 
siLuc 5’ – [cguacgcggaauacuucga]RNA [tt]DNA 3’ 
 
2.2 Primary Colorectal Cancer Cells 
Ethical approval was granted for the project (Local Ethics Research Committee Ref: 
07/Q0407/6). All patients included were attending Charing Cross Hospital for bowel resection as 
part of their treatment for CRC. The tissue used for this study was obtained from the resection 
specimen at the time of operation, with no additional procedure required for the patient, with 
written, informed consent obtained pre-operatively. Demographic and pathological data were 
obtained from medical records and histopathology reports. 
Immediately after surgical resection of the specimen comprising of tumour with adequate 
margins of normal tissue, a small piece of tissue (approximately 1cm
3
) was taken from the edge of 
the tumour. This was placed in a sample pot containing 20mL of transport medium (RPMI 1640 
containing amphotericin 2.5µg/mL, gentamicin 100µg/mL. Penicillin 200U/mL and streptomycin 
200µg/mL (PAA Laboratories GmbH, Pasching, Germany)) and transferred to the laboratory (or 
stored at 4°C where this was not possible immediately). Tissue was washed by repeatedly 
agitating in 10mL of fresh transport medium 5 times, and then mechanically digested using 
surgical forceps, a disposable scalpel and scissors, taking care to discard first any necrotic areas, 
connective tissue or blood clots. The tissue was then subjected to enzymatic digestion in 
Collagenase A (Roche, Mannheim, Germany; 1mg/mL in RPMI) for 1 hour at 37°C. The 
resulting cell suspension was diluted with Hank’s Buffered Salt Solution (HBSS; Biowhittaker) 
and sieved through a nylon filter (70µm pore size; BD Biosciences, Franklin Lakes, USA) to 
remove debris and disaggregate the cells. The resulting cell suspension was then subjected to a 
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differential density-gradient separation. It was carefully layered onto an equal volume of 
Histopaque®-1077 (Sigma-Aldrich, St Louis, MO, US) in a 15mL conical tube (Falcon), and 
centrifuged at 400G for 30 minutes. Cells at the interface between Histopaque and HBSS were 
extracted and washed by further centrifugation (150G, 10 minutes) in HBSS. The resulting pellet 
was resuspended in 1mL primary cell culture medium (transport medium supplemented with 20% 
FBS) and the cells counted by the trypan-blue exclusion method. Cells were plated on duplicate 
600mm
2
 tissue culture plates at a density of 5 x 10
4
 cells/cm
2
 (in duplicate or triplicate wells 
where cell yield allowed), and incubated at 37
o
C. They were allowed to settle for 1 hour before 
commencing hypoxia experiments, with one plate being transferred to the hypoxia incubator (1% 
O2). After 24 hours supernatants were removed for protein analysis by ELISA, and RNA 
extracted as for Caco-2 cells. These cultures are referred to as tumour-derived cultures (TDCs) 
hereafter.  
There was considerable morphological heterogeneity seen in the TDCs (Figure 5.1, 
Figure 5.2). Since the only “purifying” step (density gradient separation) was designed to reduce 
red cell numbers, it was anticipated that the methodology would yield populations of mixed cells. 
In addition to CRC tumour cells, these might include fibroblasts, tumour-associated macrophages 
and other immune cells (Franks 1976; Park et al. 2004). In order to confirm the presence of 
colonic epithelial cells, expression of epithelial cell markers Ep-CAM and VE-Cadherin was 
evaluated by Q-PCR (section 2.3.3), and the CRC tumour marker carcinoembryonic antigen 
(CEA) protein by ELISA (section 2.4.1). Due to technical and time restraints, more detailed 
characterisation (or further purification) of the TDCs was not performed in this study (see Future 
Work, section 6.2.2). 
 
2.3 Analysis of gene expression by Polymerase Chain Reaction (PCR) 
2.3.1 RNA Extraction 
Caco-2 cells remained firmly adherent throughout the experiment, while TDCs were 
partly in suspension. Initial steps for cell harvest were different for each cell-type. For Caco-2 
cells the supernatant was removed and stored at -20°C for protein analysis. Each well was washed 
with 1mL of cold (4°C) phosphate buffered saline (PBS (Merck)) before the addition of 250µL 
RNA-Bee
TM
 (AMS Biotechnology, Abingdon, U.K). (As RNABee contains phenol which is toxic 
and volatile, the rest of the extraction was performed in a fume cupboard.) Cells were scraped 
from the bottom of the well with a cell scraper, and the cell/RNABee mixture was transferred to 
separate 1.5mL Eppendorf tubes.  
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For the TDCs, from each well the medium containing suspended cells was transferred to 
separate 2mL Eppendorfs. 250µL of RNABee was added to the adherent cells in each well. The 
suspended cells were centrifuged for 3 minutes at 1500rpm, at the end of which the pellet was 
preserved, and the supernatant was removed and stored at -20°C for protein analysis. The 
adherent cells were scraped from the bottom of each well, and the resulting cell/RNABee mixture 
from each well was used to dissolve the corresponding pellet from the centrifuged cells that had 
been in suspension, before transfer to a clean 1.5mL Eppendorf. Particular care was taken to 
ensure that adherent and suspended cells from the same well were mixed together. Therefore, the 
sample for each well contained RNA from both the adherent and the suspended cells. Extraction 
then proceeded in the same way for both Caco-2 cells and TDCs.  
50µL of chloroform was added and the sample vortexed for 30-60 seconds, and kept on 
ice for 5 minutes. The samples were then centrifuged at 12,000G at 4°C for 15mins, resulting in a 
biphasic mixture. The top, clear aqueous layer containing RNA (approximately 100µL) was 
transferred to a fresh Eppendorf, and 125µL isopropan-2-ol added to precipitate the RNA. After 
gentle agitation of the tubes to ensure thorough mixing, the sample was left at room temp for 10 
minutes, after which centrifugation (12,000G, 4°C, 5 minutes) revealed a cream/yellow-coloured 
pellet of RNA. (Where RNA concentration is low, samples require longer to precipitate, and in 
practice samples were usually stored in isopropan-2-ol at -80°C overnight before proceeding to 
centrifugation). The isopropan-2-ol was discarded taking care not to lose the pellet which was 
then washed with 500µL of 70% ethanol. After further centrifugation (7,500G, 4°C, 5 minutes) 
the ethanol was discarded leaving the RNA pellet which was then allowed to air-dry (the ethanol 
is more volatile than isopropan-2-ol, speeding up the air-drying process) before being dissolved in 
30µL of RNAse-free water (treated with diethylpyrocarbonate (DEPC)).  
In order to remove DNA contamination, RNA was treated with DNAse (TurboDNAse™, 
Ambion, Applied Biosystems, Warrington, UK). For each 30µL RNA sample, a reaction mix of 
RNAsin (1µL), TurboDNAse (2µL) and buffer (4µL) was added. After 30 minutes incubation at 
37°C, a further 1µL TurboDNAse was added. Following incubation for another 30 minutes, 
DNAse inactivation agent (8µL) was added, before centrifugation for 2 minutes at 10,000g. The 
aqueous phase was then transferred to a fresh Eppendorf, and the pellet containing DNA 
contaminant was discarded. 
RNA concentration and purity was then measured by spectrophotometry (Nanodrop ND 
1000, Thermo Fisher Scientific, Cramlington, UK). Absorbance (Abs) was measured at 260nm 
and 280nm wavelengths, and RNA concentration and purity were calculated using the following 
formulae: 
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RNA concentration (µg/mL)  =  Abs260 x 40 x dilution factor * 
RNA purity  =  Abs260/Abs280 
(*40 is a conversion factor for RNA.)  
The ratio of absorbance at 260nm and 280nm provides an estimation of contaminants that 
absorb the ultraviolet light, such as protein. The RNA sample was considered pure when the ratio 
was between 1.8 and 2.  
 
2.3.2 cDNA Synthesis 
Direct amplification of RNA is limited due to the inability of the Taq polymerase to 
recognise RNA as a template. To overcome this limitation the retroviral reverse transcriptase 
enzyme M-MLV reverse transcriptase from the Moloney murine leukaemia virus (Roth et al. 
1985) was used to produce a complementary strand of DNA (cDNA) from a RNA template. The 
reaction mixture comprises of an RNA template, an oligoDT primer, triphosphate 
deoxynucleotides, reverse transcriptase enzyme and a reaction medium. 
Following RNA quantitation by spectrophotometry, the volume of RNA to be included in 
the reaction was determined in order to achieve a total quantity of 500ng of RNA. DEPC water 
was then added to the RNA sample to achieve a total volume of 11 L and 1 L of OligoDT 
primer was added. The specimen was incubated in the PCR machine at 70
o
C for 10 minutes to 
unravel any secondary structures within the template and then rapidly cooled for 5 minutes to 
prevent these secondary structures from reforming. A prepared reaction mix comprising of the 
reagents listed in Table 2.2 was then added to each specimen. The M-MLV reverse transcriptase, 
RNase H Minus, Point Mutant (M-MLV RT (H-)) was obtained from Promega (Promega, 
Madison, USA). The specimen was then returned to the PCR machine and incubated at 21
o
C for 
10 minutes to allow annealing between primer and RNA template. The temperature was 
subsequently raised to 42
o
C and maintained for an hour to provide optimal conditions for the 
reverse transcriptase enzyme to catalyse cDNA synthesis. At the end of the reaction, the enzyme 
was inactivated by heating the specimen for 15 minutes at 70
o
C. The final product was diluted in 
double distilled water and stored at -20
o
C. 
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Table 2.2 Reverse Transcription Reagents and Volumes 
Components of RT-PCR master mix. 8µL was added to each sample. RNasin (Ribonuclease Inhibitor to 
preserve RNA integrity); dNTPs (deoxyribonucleotide triphosphates) including a mixture of dATP, dGTP, 
dCTP, dTTP; M-MLV Reverse Transcriptase (all purchased from Promega, Southampton, UK). DEPC 
(diethylpyrocarbonate).  
Reagents Volume ( L) 
DEPC water 1.5 
dNTP 1.0 
M-MLV enzyme 0.5 
RNAsin 1.0 
Buffer 4.0 
 
2.3.3 Quantitative PCR (Q-PCR) 
PCR allows amplification of a short, well defined part of a DNA strand which acts as a 
template. In order to amplify a specific gene of interest, primers consisting of short artificial 
strands of DNA designed to complement the beginning and end of the DNA fragment is used. 
Sequences for the primers used are listed in Table 2.3. 
Table 2.3 Sequences of primers used in gene expression experiments and expected 
product sizes. 
Primer 
Primer sequence Gene 
Product 
Size  
(bp) Forward Reverse 
HIF-1α cacctctggacttgcctttc ggctgcatctcgagactttt 194 
HIF-2α ccttcaagacaaggtctgca ttcatccgtttccacatcaa 443 
VEGF cttgccttgctgctctacct ctgcatggtgatgttggact 282 
BNIP-3 ctgctgctctctcatttgct accccaggatctaacagctc 168 
GLUT-1 tggcatggcgggttgt ccagggtagctgctccagc 63 
ANGPTL-4 ccacttgggaccaggatcac cggaagtactggccgttgag 115 
CA-IX gctgtcaccagggtggggt ccagtctcggctacctctgct 100 
Survivin agccagatgacgaccccata caagggttaattcttcaaactgctt 92 
BAX ctgacggcaacttcaactgg tcttggatccagcccaacag 159 
XIAP caatatggagactcagcagttgga gcactattttcaagataaaagccgtt 85 
Bcl-2 tcgccctgtggatgactga cagagacagccaggagaaatca 133 
PHD-2 gcacgacaccgggaagtt ccagcttcccgttacagt 178 
PHD-3 ttgggatgccaagctaca cgtgtgggttcctacgatct 125 
FIH-1 caatgtactggtggcatcacatag ggccactttctgatgagctt 131 
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Ep-CAM cgcagctcaggaagaatgtg tgaagtacactggcattgacg 87 
CD151 gctggagatcatcgctggtatc ggtggtagcgcctggtcat 100 
VE-Cadherin gccaggtatgagatcgtggt gtgtcttcaggcacgacaaa 151 
STAB-1 actcttcgtccctgtcaatg tcactgatgatgaggctgag 155 
18S gtaacccgttgaaccccat ccatccaatcggtagtagcg 152 
β-actin cccagagcaagagagg gtccagacgcaggatg 364 
TBP tgcctccagaatatgcctct caatggttttcaagctttcca 203 
 
The PCR reaction requires a mixture of specific concentrations of deoxynucleotide 
triphosphates (dNTPs), PCR buffer and polymerase enzyme (all of which are contained in SYBR 
Green Jumpstart
TM
 Taq ReadyMix
TM
 (Sigma, St Louis, MO, USA) in appropriate proportions), in 
addition to forward and reverse primers, purified water, and the cDNA template (Table 2.4). 
Table 2.4 Constituents of Q-PCR reaction mix 
 
Reagent 
Concentration 
( M) 
Volume 
( L) 
SYBR Green Jumpstart
TM
 Taq ReadyMix
TM
  2× 7.5 
Primer (Forward & Reverse) 6.25 0.6 
Template DNA 
1:5 dilution with 
H2O 
6.0 
Purified water  0.9 
 
The Rotor-Gene 6000, a 72 closed-tube centrifugal thermal cycler (Corbett Research, 
Mortlake, Sydney, Australia) was used to amplify, detect and quantify the gene products. Each 
sample was analysed in triplicate. The Rotor-Gene was programmed to perform 40 amplification 
cycles, each comprising of 95
o
C for 10 seconds (DNA denaturation), followed by 60
o
C for 15 
seconds (annealing) and finally 72
o
C for 20 seconds (extension). 
SYBR Green, used as the detection agent, emits minimal fluorescence in its unbound 
state. During the PCR reaction, increasing amounts are bound within the newly-synthesised 
double-stranded DNA causing an increase in fluorescence emission which is detected and 
recorded in real-time. The number of amplification cycles required to reach an arbitrarily chosen 
level (threshold) of fluorescence emission (termed the Ct value) is directly proportional to the 
starting amount of the target cDNA. Relative quantification, or the comparative C t method, was 
used to determine changes in the steady-state transcription of a gene following stimulation. To 
minimise errors, for example due to inefficiencies in reverse transcription, Ct values for the target 
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gene in each sample were normalised to the ubiquitously expressed “housekeeping gene” 18S (the 
small sub-unit of ribosomal RNA) in the same sample, using the equation: 
∆Ct TARGET = ∆Ct TARGET - ∆Ct 18S 
The Ct value for the target gene in the stimulated sample is then compared to that in the 
control or calibrator sample. The relative expression (fold-change) is given by 2
-∆∆Ct
 where: 
∆∆Ct = ∆Ct TARGET - ∆Ct CALIBRATOR 
Down-regulation of gene expression may be expressed in terms of fold-change, in which 
case it is a number between zero and 1, or fold-regulation which allows downregulation to be 
expressed as (the negative of) a number greater than one, simplifying comparisons of up- and 
downregulation. Fold-regulation is calculated as follows: 
 Fold regulation = -1/(fold-change) 
†
 
†
 (where fold-change is less than 1) 
For example, a fold-change of 0.5 equals a fold-regulation of -2, or a 2-fold 
downregulation. (Where genes are upregulated, fold-regulation is taken to mean the same as fold-
change, and the above calculation is not performed.) 
 
2.3.4 PCR Array 
The PCR array system enables analysis of the expression of a focused panel of genes. 
Each PCR array profiles simultaneously a collection of disease- or pathway-specific genes, 
generating single, gene-specific amplicons and preventing the co-amplification of non-specific 
products. 
To profile the expression of 84 genes involved in angiogenesis, the Human Angiogenesis 
RT
2
 Profiler™ PCR Array (SABiosciences, West Sussex, UK) was used. A list of the genes in the 
array is shown in Table 2.5. The genes include growth factors and their receptors, chemokines and 
cytokines, matrix molecules (proteases and their inhibitors), adhesion molecules and transcription 
factors. cDNA prepared as described in 2.3.2 was mixed with nuclease-free water and RT
2
 PCR 
SYBR® Green Master Mix (SABiosciences), and aliquoted to duplicate 96-well plates coated 
with a set of optimised primers. The reaction was performed using the ABI Prism 7700 Sequence 
Detector and the real-time PCR cycling programme (Software Detection System 1.9.1) from 
Applied Biosystems (Foster City, CA, USA). The arrays were initially heated to 95
o
C for 10 
minutes to activate the polymerase, and this was followed by 40 repeated cycles comprising of 15 
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seconds at 95
o
C for melting, 40 seconds for annealing at 55
o
C and 20 seconds for extension at 
78
o
C. Ct values were obtained using the pre-installed ABI Prism ® 7700 Sequence Detection 
System software by setting the threshold at the exponential phase of gene amplification. Relative 
gene expression was calculated by 2
-∆∆Ct
 comparative method using PCR array data analysis 
software provided by the manufacturer. Since one of the five 5 housekeeping genes on the Array, 
GAPDH (glyceraldehyde-3-phosphate dehydrogenase) is known to be hypoxia regulated, gene 
expression was normalised to the other four (B2M: Beta-2-microglobulin, HPRT1: Hypoxanthine 
phosphoribosyltransferase 1, RPL13A: Ribosomal protein L13a, ACTB: Actin beta). The relative 
levels of genomic DNA contamination were evaluated by the built-in RNA quality controls. 
 
Table 2.5 Genes in the Human Angiogenesis RT² Profiler™ PCR Array 
A list of the 84 Genes included in the Angiogenesis RT² Profiler™ PCR Array (Catalogue PAHS-024A). 
Refseq Symbol Gname Description Function 
NM_005163 AKT1 
AKT/MGC99656/P
KB/PKB-
ALPHA/PRKBA/R
AC/RAC-ALPHA 
V-akt murine thymoma viral 
oncogene homolog 1 
Transcription factor 
NM_001146 ANGPT1 AGP1/AGPT/ANG1 Angiopoietin 1 Vascular remodelling 
NM_001147 ANGPT2 AGPT2/ANG2 Angiopoietin 2 Vascular remodelling 
NM_014495 ANGPTL3 ANGPT5/FHBL2 Angiopoietin-like 3 Adhesion molecule 
NM_0010396
67 
ANGPTL4 
ANGPTL2/ARP4/FI
AF/HFARP/NL2/PG
AR/pp1158 
Angiopoietin-like 4 
Cellular metabolism 
& vascular 
remodelling 
NM_001150 ANPEP 
APN/CD13/GP150/
LAP1/P150/PEPN 
Alanyl (membrane) 
aminopeptidase 
Extracellular matrix 
remodelling 
NM_001702 BAI1 FLJ41988/GDAIF 
Brain-specific angiogenesis 
inhibitor 1 
Adhesion molecule 
NM_002986 CCL11 
MGC22554/SCYA1
1 
Chemokine (C-C motif) 
ligand 11 
Chemokine 
NM_002982 CCL2 
GDCF-
2/HC11/HSMCR30/
MCAF/MCP-
1/MCP1/MGC9434/
SCYA2/SMC-CF 
Chemokine (C-C motif) 
ligand 2 
Chemokine 
NM_001795 CDH5 
7B4/CD144/FLJ173
76 
Cadherin 5, type 2 (vascular 
endothelium), VE-Cadherin 
Adhesion molecule 
NM_030582 COL18A1 
FLJ27325/FLJ34914
/KNO/KNO1/KS/M
GC74745 
Collagen, type XVIII, alpha 
1 
Adhesion molecule 
NM_000091 COL4A3 - 
Collagen, type IV, alpha 3 
(Goodpasture antigen) 
Adhesion molecule 
NM_001511 CXCL1 
FSP/GRO1/GROa/
MGSA/MGSA-
a/NAP-3/SCYB1 
Chemokine (C-X-C motif) 
ligand 1 (melanoma growth 
stimulating activity, alpha) 
Chemokine 
NM_001565 CXCL10 
C7/IFI10/INP10/IP-
10/SCYB10/crg-
2/gIP-10/mob-1 
Chemokine (C-X-C motif) 
ligand 10 
Chemokine 
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NM_002090 CXCL3 
CINC-
2b/GRO3/GROg/MI
P-2b/MIP2B/SCYB3 
Chemokine (C-X-C motif) 
ligand 3 
Chemokine 
NM_002994 CXCL5 ENA-78/SCYB5 
Chemokine (C-X-C motif) 
ligand 5 
Chemokine 
NM_002993 CXCL6 
CKA-3/GCP-
2/GCP2/SCYB6 
Chemokine (C-X-C motif) 
ligand 6 (granulocyte 
chemotactic protein 2) 
Chemokine 
NM_002416 CXCL9 
CMK/Humig/MIG/S
CYB9/crg-10 
Chemokine (C-X-C motif) 
ligand 9 
Chemokine 
NM_001953 TYMP 
ECGF/ECGF1/MED
PS1/MNGIE/MTDP
S1/PDECGF/TP/hP
D-ECGF 
Thymidine phosphorylase Growth Factor 
NM_001400 S1PR1 
CHEDG1/D1S3362/
ECGF1/EDG-
1/EDG1/FLJ58121/S
1P1 
Sphingosine-1-phosphate 
receptor 1 
Adhesion molecule  
NM_182685 EFNA1 
B61/ECKLG/EFL1/
EPLG1/LERK1/TN
FAIP4 
Ephrin-A1 Growth factor 
NM_004952 EFNA3 
EFL2/EPLG3/Ehk1-
L/LERK3 
Ephrin-A3 Growth factor 
NM_004093 EFNB2 
EPLG5/HTKL/Htk-
L/LERK5/MGC126
226/MGC126227/M
GC126228 
Ephrin-B2 Growth factor 
NM_001963 EGF HOMG4/URG Epidermal growth factor Growth factor 
NM_000118 ENG 
CD105/END/FLJ41
744/HHT1/ORW/O
RW1 
Endoglin Adhesion molecule 
NM_004444 EPHB4 
HTK/MYK1/TYRO
11 
EPH receptor B4 
Growth factor 
receptor 
NM_001432 EREG ER Epiregulin Growth factor 
NM_000800 FGF1 
AFGF/ECGF/ECGF
-
beta/ECGFA/ECGF
B/FGF-
alpha/FGFA/GLIO7
03/HBGF1 
Fibroblast growth factor 1 
(acidic) 
Growth factor 
NM_002006 FGF2 
BFGF/FGFB/HBGF
-2 
Fibroblast growth factor 2 
(basic) 
Growth factor 
NM_000142 FGFR3 
ACH/CD333/CEK2/
HSFGFR3EX/JTK4 
Fibroblast growth factor 
receptor 3 
Growth factor 
receptor 
NM_004469 FIGF VEGF-D/VEGFD 
C-fos induced growth factor 
(vascular endothelial growth 
factor D) 
Growth factor 
NM_002019 FLT1 FLT/VEGFR1 
Fms-related tyrosine kinase 
1 (vascular endothelial 
growth factor/vascular 
permeability factor 
receptor) 
Growth factor 
receptor 
NM_021973 HAND2 
DHAND2/FLJ16260
/Hed/MGC125303/
MGC125304/Thing2
/bHLHa26/dHand 
Heart and neural crest 
derivatives expressed 2 
Transcription factor 
NM_000601 HGF 
DFNB39/F-
TCF/HGFB/HPTA/S
Hepatocyte growth factor 
(hepapoietin A; scatter 
Growth factor 
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F factor) 
NM_001530 HIF1A 
HIF-1alpha/HIF-
1/HIF-1-
ALPHA/MOP1/PAS
D8/bHLHe78 
Hypoxia inducible factor 1, 
alpha subunit (basic helix-
loop-helix transcription 
factor) 
Transcription factor 
NM_006665 HPSE 
HPA/HPA1/HPR1/H
PSE1/HSE1 
Heparanase Transcription factor 
NM_002165 ID1 ID/bHLHb24 
Inhibitor of DNA binding 1, 
dominant negative helix-
loop-helix protein 
Transcription factor 
NM_002167 ID3 HEIR-1/bHLHb25 
Inhibitor of DNA binding 3, 
dominant negative helix-
loop-helix protein 
Transcription factor 
NM_024013 IFNA1 
IFL/IFN/IFN-
ALPHA/IFN-
alphaD/IFNA13/IFN
A@/MGC138207/M
GC138505/MGC138
507 
Interferon, alpha 1 Cytokine 
NM_002176 IFNB1 
IFB/IFF/IFNB/MGC
96956 
Interferon, beta 1, fibroblast Cytokine 
NM_000619 IFNG IFG/IFI Interferon, gamma Cytokine 
NM_000618 IGF1 IGF-I/IGF1A/IGFI 
Insulin-like growth factor 1 
(somatomedin C) 
Growth factor 
NM_000576 IL1B 
IL-1/IL1-
BETA/IL1F2 
Interleukin 1, beta Cytokine 
NM_000600 IL6 
BSF2/HGF/HSF/IF
NB2/IL-6 
Interleukin 6 (interferon, 
beta 2) 
Cytokine 
NM_000584 IL8 
CXCL8/GCP-
1/GCP1/LECT/LUC
T/LYNAP/MDNCF/
MONAP/NAF/NAP-
1/NAP1 
Interleukin 8 Adhesion molecule 
NM_002210 ITGAV 
CD51/DKFZp686A0
8142/MSK8/VNRA 
Integrin, alpha V 
(vitronectin receptor, alpha 
polypeptide, antigen CD51) 
Adhesion molecule 
NM_000212 ITGB3 CD61/GP3A/GPIIIa 
Integrin, beta 3 (platelet 
glycoprotein IIIa, antigen 
CD61) 
Adhesion molecule 
NM_000214 JAG1 
AGS/AHD/AWS/C
D339/HJ1/JAGL1/M
GC104644 
Jagged 1 Cell differentiation 
NM_002253 KDR 
CD309/FLK1/VEGF
R/VEGFR2 
Kinase insert domain 
receptor (a type III receptor 
tyrosine kinase) 
Growth factor 
receptor 
NM_005560 LAMA5 KIAA1907 Laminin, alpha 5 Matrix 
NM_007015 LECT1 
BRICD3/CHM-
I/CHM1/MYETS1 
Leukocyte cell derived 
chemotaxin 1 
Chemokine 
NM_000230 LEP FLJ94114/OB/OBS Leptin Cytokine 
NM_002391 MDK 
FLJ27379/MK/NEG
F2 
Midkine (neurite growth-
promoting factor 2) 
Growth factor 
NM_004530 MMP2 
CLG4/CLG4A/MM
P-II/MONA/TBE-1 
Matrix metallopeptidase 2 
(gelatinase A, 72kDa 
gelatinase, 72kDa type IV 
collagenase) 
Matrix 
NM_004994 MMP9 
CLG4B/GELB/MA
NDP2/MMP-9 
Matrix metallopeptidase 9 
(gelatinase B, 92kDa 
gelatinase, 92kDa type IV 
collagenase) 
Matrix 
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NM_004557 NOTCH4 
FLJ16302/INT3/MG
C74442/NOTCH3 
Notch 4 Transcription factor 
NM_003873 NRP1 
BDCA4/CD304/DK
FZp686A03134/DK
FZp781F1414/NP1/
NRP/VEGF165R 
Neuropilin 1 
Angiogenesis 
receptor 
NM_003872 NRP2 
MGC126574/NP2/N
PN2/PRO2714/VEG
F165R2 
Neuropilin 2 
Angiogenesis 
receptor 
NM_002607 PDGFA PDGF-A/PDGF1 
Platelet-derived growth 
factor alpha polypeptide 
Growth factor 
NM_000442 PECAM1 
CD31/FLJ34100/FL
J58394/PECAM-1 
Platelet/endothelial cell 
adhesion molecule 
Adhesion molecule 
NM_002619 PF4 
CXCL4/MGC13829
8/SCYB4 
Platelet factor 4 Chemokine 
NM_002632 PGF 
D12S1900/PGFL/PL
GF/PlGF-2/SHGC-
10760 
Placental growth factor Growth factor 
NM_002658 PLAU 
ATF/UPA/URK/u-
PA 
Plasminogen activator, 
urokinase 
Matrix 
NM_000301 PLG DKFZp779M0222 Plasminogen Growth factor 
NM_020405 PLXDC1 
DKFZp686F0937/F
LJ36270/FLJ45632/
TEM3/TEM7 
Plexin domain containing 1 Angiogenesis 
NM_021935 PROK2 
BV8/KAL4/MIT1/P
K2 
Prokineticin 2 Growth factor 
NM_000962 PTGS1 
COX1/COX3/PCOX
1/PGG/HS/PGHS-
1/PGHS1/PHS1/PT
GHS 
Prostaglandin-endoperoxide 
synthase 1 (prostaglandin 
G/H synthase and 
cyclooxygenase) 
Transcription factor 
NM_002615 SERPINF1 EPC-1/PEDF 
Serpin peptidase inhibitor, 
clade F (alpha-2 
antiplasmin, pigment 
epithelium derived factor), 
member 1 
Growth factor 
NM_021972 SPHK1 SPHK Sphingosine kinase 1 Transcription factor 
NM_015136 STAB1 
CLEVER-1/FEEL-
1/FELE-
1/FEX1/KIAA0246/
STAB-1 
Stabilin 1 Endosome trafficking 
NM_000459 TEK 
CD202B/TIE-
2/TIE2/VMCM/VM
CM1 
TEK tyrosine kinase, 
endothelial 
Growth factor 
receptor 
NM_003236 TGFA TFGA 
Transforming growth factor, 
alpha 
Growth factor 
NM_000660 TGFB1 
CED/DPD1/LAP/T
GFB/TGFbeta 
Transforming growth factor, 
beta 1 
Growth factor 
NM_003238 TGFB2 
MGC116892/TGF-
beta2 
Transforming growth factor, 
beta 2 
Growth factor 
NM_004612 TGFBR1 
AAT5/ACVRLK4/A
LK-
5/ALK5/LDS1A/LD
S2A/SKR4/TGFR-1 
Transforming growth factor, 
beta receptor 1 
Growth factor 
receptor 
NM_003246 THBS1 
THBS/THBS-
1/TSP/TSP-1/TSP1 
Thrombospondin 1 Adhesion molecule 
NM_003247 THBS2 TSP2 Thrombospondin 2 Adhesion molecule 
NM_003254 TIMP1 CLGI/EPA/EPO/FLJ TIMP metallopeptidase Matrix 
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90373/HCI/TIMP inhibitor 1 
NM_003255 TIMP2 CSC-21K 
TIMP metallopeptidase 
inhibitor 2 
Matrix 
NM_000362 TIMP3 
HSMRK222/K222/
K222TA2/SFD 
TIMP metallopeptidase 
inhibitor 3 
Matrix 
NM_000594 TNF 
DIF/TNF-
alpha/TNFA/TNFSF
2 
Tumour necrosis factor Cytokine 
NM_006291 TNFAIP2 B94/EXOC3L3 
Tumour necrosis factor, 
alpha-induced protein 2 
Cytokine 
NM_003376 VEGFA 
MGC70609/MVCD
1/VEGF/VPF 
Vascular endothelial growth 
factor A 
Growth factor 
NM_005429 VEGFC Flt4-L/VRP 
Vascular endothelial growth 
factor C 
Growth factor 
NM_004048 B2M - Beta-2-microglobulin Housekeeping 
NM_000194 HPRT1 HGPRT/HPRT 
Hypoxanthine 
phosphoribosyltransferase 1 
Housekeeping 
NM_012423 RPL13A L13A/TSTA1 Ribosomal protein L13a Housekeeping 
NM_002046 GAPDH 
G3PD/GAPD/MGC
88685 
Glyceraldehyde-3-
phosphate dehydrogenase 
Housekeeping 
NM_001101 ACTB PS1TP5BP1 Actin, beta Housekeeping 
 
 
2.4 Analysis of protein expression 
Quantification was performed by Enzyme-linked Immunoassay (secreted protein, in 
supernatants), and by Western Blot (intra-cellular protein from lysed cells). 
2.4.1 ELISA 
At the end of each experiment, supernatants were collected and stored at -20°C. 
Extraction of intra-cellular protein was performed as detailed below (Section 2.4.2.1). 
Supernatants were then thawed at room temperature before measurement of proteins of interest 
using the ELISA sandwich technique. In brief, a capturing antibody to the antigen of interest is 
bound to a polystyrene well in a 96-well plate, and the protein to be measured is then added. An 
immune complex consisting of capturing antibody and protein is then recognised by detecting 
antibody conjugated to biotin with a strong affinity for streptavidin-conjugated to horseradish 
peroxidase enzyme (HRP). A colourimetric reaction with a stable substrate (e.g. 
tetramethylbenzidine (TMB)) enables visualisation of the captured protein by measuring using 
spectrophotometer. 
VEGF 
The wells of a 96-well polystyrene microtitre plate (NUNC, Roskilde, Denmark) was 
coated with 100µL of mouse anti-human capture antibody (R&D Systems, Minneapolis, USA) 
diluted to a working concentration of 1µg/mL in 1% PBS and left to incubate overnight at 4
o
C. 
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The wells were emptied and after 3 washes with PBS/Tween (0.01% solution), the plate was 
blocked with 250µL of 2% bovine serum albumin (BSA) to reduce non-specific protein binding, 
and left to agitate at room temperature for 2 hours. The plate was washed before 100µL of sample 
and standards were pipetted into the wells, and a seven point standard curve was generated using 
3-fold serial dilutions from the highest standard of 10000pg/mL. The plate was left to incubate 
overnight at 4
o
C to optimise capture, and unbound antigens were subsequently washed away with 
wash buffer. 100µL of biotinylated goat antibody specific for VEGF (R&D Systems, 
Minneapolis, USA) diluted to a concentration of 200ng/mL was added to each well and incubated 
for 2 hours at room temperature. The detection antibody binds specifically to the primary antigen-
antibody complex and subsequent addition of 100µL of diluted streptavidin-horseradish 
peroxidase (HRP) (R&D Systems, Minneapolis, USA) reagent results in stable, high affinity 
binding between the biotin and streptavidin components. HRP catalyses a colorimetric change of 
a colourless substrate solution of hydrogen peroxide and TMB (R&D Systems, Minneapolis, 
USA) to turquoise-blue. When the lowest standard concentration changed colour, sulphuric acid 
(R&D Systems, Minneapolis, USA) was added to each well to halt the chromogenic reaction, 
resulting in a change of colour from turquoise blue to bright yellow. Since the colour formed is 
proportional to the amount of antigen in the test solution, the optical density of each well was 
determined using a microplate reader set to a wavelength of 450nm and the protein concentrations 
were determined using software from Ascent (Version 2.6, Thermo Labsystems). 
Carcinoembryonic Antigen (CEA) 
Measurement of CEA was performed using an ELISA kit from BQ Kits (San Diego, 
USA) comprising of a total of 96 microtitre wells (in 12 strips of 8) pre-coated with monoclonal 
anti-CEA antibody. In this solid-phase ELISA, the test sample is allowed to react simultaneously 
with the primary antibody coating the wells and a soluble secondary HRP-conjugated antibody.  
The kit contains 5 pre-diluted CEA standards (2-fold dilutions from a maximum concentration of 
50ng/ml), enzyme conjugate reagent (goat anti-CEA antibody conjugated to HRP), TMB reagent 
and stop solution  (hydrochloric acid). Having placed the desired number of pre-coated well strips 
into the 96-well holder, 50µL of samples (diluted in the appropriate culture medium where 
necessary) and standards were added. 100µL of enzyme conjugate was then added, ensuring 
thorough mixing (1200 rpm on rotating platform for 30 seconds). Following incubation for 60 
minutes at room temperature, the incubation mixture was discarded, and the wells washed with 
distilled water. 100µL/well of TMB solution was added, and the plate was incubated at room 
temperature for 20 minutes or until the lowest standard had changed from colourless to blue 
(whichever was sooner). The reaction was stopped with 100µL/well stop solution. Absorbance 
was read at 450nm, and protein concentrations were determined using Ascent software. 
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2.4.2 Western Blotting 
2.4.2.1 Protein Extraction and Measurement  
At the end of each experiment, once the supernatant had been removed, cells were lysed 
with 100µL of protein lysis buffer, the components of which are detailed in Table 2.6. After 
scraping adherent cells from the well, the sample was transferred to a 2mL conical Eppendorf. 
The sample at this stage is very viscous, and requires homogenisation. This was performed using 
a hand-held homogeniser (IKA-Ultra-Turrax® T8 homogeniser, IKA®-Werke GMBH & CO. 
KG, Staufen, Germany). A Bicinchoninic assay (BCA) (Pierce, Rockford, USA) was performed 
to quantify the total protein in each sample. This was necessary to ensure equal total protein 
loading for Western Blot analysis. The BCA test was performed in a 96-well polystyrene plate 
(NUNC) and duplicates of 10µL volumes of each standard or unknown sample were pipetted into 
the wells. 200µL of the working reagent, comprising of a 50:1 mixture of BCA Reagent A:B were 
added to individual wells and reagents were mixed on a plate agitator for 30 seconds. The plate 
was covered and incubated at 37
o
C for 30 minutes and then cooled to room temperature prior to 
absorbance measurement at 540nm using a plate reader. The concentration of protein within 
individual wells was determined by Ascent software (Version 2.6, Thermo Labsystems) by 
referring to the 7-point standard curve. 
Table 2.6 Constituents of protein lysis buffer 
*Sodium dodecyl sulphate (SDS); **Dithiothreitol (DTT); **Protease inhibitor cocktail P-8340 (Sigma, St 
Louis, MO, USA) which comprises of 4-(2-aminoethyl)-benzenesulfonyl fluoride (AEBSF), pepstatin A, E-
64, bestatin, leupeptin, and aprotinin; †PMSF: phenylmethylsulfonyl fluoride. 
Reagent Concentration/ M Volume 
Urea 10M 7.79mL 
Glycerol  1mL 
SDS* 10% 1mL 
TRIS pH 6.8 1M 100µL 
DTT** 1M 10µL 
Protease Inhibitor Cocktail *** 50mM 100µL 
PMSF
†
 100mM 50µL 
Total  10mL 
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2.4.2.2 Protein Separation, Transfer and Detection 
Gel electrophoresis was performed using the NuPAGE Novex System (Invitrogen, 
Carlsbad, CA, USA) of pre-casted Bis-Tris-HCl buffered polyacrylamide (4-12%) gels to separate 
the denatured proteins according to molecular weight, with a protein “ladder”, consisting of a 
mixture of proteins with defined molecular weights, used to calibrate the gel. To ensure loading of 
equal amounts of protein (30-40µg), lysates were diluted with the appropriate volume of distilled 
H2O. Lanes were each loaded with 25µL of sample (denatured at 95
o
C for 5 minutes) plus 5µL of 
loading buffer. The gel was then immersed within an electrophoresis tub containing running 
buffer (1g/L SDS (Merck, AnalaR, Germany), 3g/L Tris base (Merck) and 14.4g/L Glycine 
(Merck)) and a current of was applied across the gel for 1 hour (140V). The proteins, now 
separated according to size, were blotted onto a polyvinylidene difluoride (PVDF) membrane 
(Merck). The gel and membrane were sandwiched together between blotting paper and sponge 
layers held in a cassette and placed in transfer buffer (10mM Tris base, 100mM glycine, 10% 
methanol, 0.005% SDS). Electroelution of the protein from the gel onto the membrane was 
performed by application of a current at 25V overnight followed by 100V for 90 minutes (at 4°C). 
To reduce non-specific protein binding, the membrane was soaked in blocking buffer (1% 
PBS, 5% fat-free milk powder (Premier Brands, UK), 1% BSA (Sigma, St Louis, MO, USA) and 
0.1% Tween (Sigma, St Louis, MO, USA) for 1 hour on a rotating platform. The membrane was 
then incubated a primary antibody directed at the target protein, followed by a biotinylated 
secondary antibody. The blot was developed with ECL-Plus chemiluminescence detection kit (GE 
Healthcare Lifesciences, Piscataway, NJ, USA) and exposed to photographic film. -tubulin, a 
structural protein, was used as a control to ensure equal total protein loading. Details of the 
antibodies used are shown in Table 2.7. 
Table 2.7 Antibodies used for Western Blotting 
Abbreviations: 1ºAb – primary antibody, 2ºAb – secondary antibody, Mo – monoclonal, Po – polyclonal, 
RAM – rabbit-anti mouse, SAR - swine anti-rabbit antibody (Dako, Glostrup, Denmark). 
1ºAb Company 
1ºAb 
dilution 
2ºAb 
2ºAb 
dilution 
Size 
(kDa) 
MoAb anti-HIF-1α  Becton Dickinson, Oxford, UK 1:250 RAM 1:3000 120 
MoAb anti- HIF-2α  
Santa Cruz Biotechnology, 
Heidelberg, Germany 
1:250 RAM 1:3000 115 
PoAb anti-FIH-1 Abcam, Cambridge, UK 1:1000 SAR 1:5000 40.6 
PoAb anti-PHD-2 Abcam, Cambridge, UK 1:1000 SAR 1:5000 46 
MoAb anti-PHD-3 Millipore, Billerica, USA 1:25 RAM 1:3000 27 
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2.5 Statistical analysis 
Graph Pad Prism 5.04 software package (Graph Pad Software, La Jolla, CA, USA) was 
used in the analyses of the data. To evaluate the effects of the stimuli (hypoxia and DMOG) and 
siRNA transfection on gene expression, analysis of variance (ANOVA), followed by a 
Bonferroni’s Multiple Comparison Test was used to compare more than two groups, or a student 
t-test if two groups were analysed. Results are expressed as the mean ± standard error of the mean 
(SEM) or standard deviation (SD) as indicated. P values less than 0.05 were considered 
significant (*p<0.05, **p <0.01, ***p≤0.001). 
 
 
MoAb anti-BNIP-3 Abcam, Cambridge, UK 1:1000 RAM 1:4000 30 
PoAb anti-GLUT-1 
Alpha Diagnostic Intl, San 
Antonio, USA 
1:750 SAR 1:3000 40 - 80 
PoAb anti-CA-IX Abcam, Cambridge, UK 1:1000 SAR 1:3000 54, 58 
MoAb anti- α -tubulin Sigma-Aldrich, Poole, UK 1:3000 RAM 1:3000 50 
Chapter 3 
79 
 
 
 
 
 
 
 
Chapter 3 
  
Chapter 3 
80 
3 CHARACTERISATION OF CACO-2 CELL RESPONSES TO 
HYPOXIA 
3.1 Introduction 
The Caco-2 cell-line was originally isolated from a male patient with colorectal 
adenocarcinoma, and it is widely used as an in vitro model of CRC (Fogh et al. 1977). While it 
has been reported to have low malignant potential in comparison with other cell-lines, invasive 
behaviour has been demonstrated in certain conditions (Caro et al. 1995; Kermorgant et al. 2001). 
Furthermore, subcutaneous injection of Caco-2 cells leads to tumour formation in SCID mice 
(Oikonomou et al. 2007). Tumourigenicity of the cell-line is demonstrated by the development of 
moderately-well differentiated adenocarcinoma following inoculation into nude mice, although 
low “take” rates have been reported, limiting its use in xenograft models (de Bruïne et al. 1993; 
Liu et al. 2007). Other adherent CRC cell-lines such as SW480, SW620 and HT-29 are also 
derived from adenocarcinoma, and have been reported to exhibit more aggressive behaviour than 
Caco-2 cells (Both et al. 1999).  
In common with approximately 50% of colorectal tumours, Caco-2 cells have a mutant 
p53 oncogene, which is known to be associated with increased VEGF production (Olofsson et al. 
1998; Liu and Bodmer 2006). Accordingly, the cell-line is known to express VEGF, which is 
upregulated by a number of stimuli including hypoxia (Morote-Garcia et al. 2008; Gentile et al. 
2011). p53 has an important role in the regulation of apoptosis through its interaction with BNIP-
3 (BCL2/adenovirus E1B 19kDa interacting protein 3), a member of the Bcl-2 family. HIF-1α has 
been shown to stabilise p53, and hypoxia upregulates BNIP-3 in a p53-dependent manner in 
various cell-lines (Fei et al. 2004; Greijer and van der Wall 2004). Two other important 
oncogenes in CRC are K-ras and BRAF, mutations of which are present in 45% and 15% of 
colorectal tumours respectively (Kikuchi et al. 2009). Both oncogenes can modulate the HIF 
pathway. K-ras mutation has been shown to enhance HIF-1α protein synthesis, while BRAF 
mutation enhances both HIF-1α and HIF-2α synthesis. Both mutations are associated with 
resistance to the anti-EGFR antibody cetuximab and with poorer prognosis. Caco-2 cells contain 
the wild-type of both oncogenes (Brink et al. 2003; Kikuchi et al. 2009), and have been reported 
to express both HIF-1α and HIF-2α, although weak HIF-2α expression (with minimal induction 
by hypoxia) has been reported by some groups (Mizukami et al. 2004; Bruning et al. 2011). 
3.2 Objectives 
The first part of this study aimed to characterise the responses to hypoxia and the hypoxia 
mimetic and HIF hydroxylase inhibitor Dimethyloxalylglycine (DMOG) of Caco-2 cells. 
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Expression of HIF-α isoforms, known HIF targets, and genes involved in apoptosis and cell 
adhesion was investigated. In addition, a PCR array was used to characterise the response of 84 
angiogenesis genes to hypoxia and DMOG. The cells used in these studies were purchased from 
ATCC and frozen in liquid nitrogen before thawing for use. It has been estimated that up to 35% 
of cell-lines may be cross-contaminated or mis-identified (Hughes et al. 2007). As well as 
standardising experimental procedures for subsequent experiments, characterisation of Caco-2 
responses had the additional benefit of addressing these risks. 
3.3 Results 
3.3.1 Expression of HIF-α Isoforms and Known HIF Targets in Caco-2 Cells 
Initial experiments sought to establish the presence of the HIF-α isoforms in Caco-2 cells, 
and to investigate the effect of hypoxia on HIF-α protein expression. Figure 3.1 shows expression 
of HIF-1α and HIF-2α protein following 24 hours stimulation with DMOG (1mM) or exposure to 
hypoxia (1% O2). 
 
Figure 3.1 HIF-1α and HIF-2α protein stabilisation by DMOG and hypoxia 
Caco-2 cells were exposed to hypoxia (1% O2) or DMOG (1mM) for 24 hours, in duplicate, with normoxia 
(21% O2) control. Figure shows HIF-1α (120kD) and HIF-2α (119kD) protein expression from a 
representative experiment performed in duplicate wells, evaluated by Western Blot. α-tubulin (50kD) is 
shown as loading control.  
Both isoforms are expressed weakly in normoxia, with HIF-2α being barely detectable. 
However, both isoforms show strong induction by both DMOG and hypoxia. The effect of 
hypoxia on known HIF targets was then investigated. 
Figure 3.2 shows expression of VEGF, BNIP-3, GLUT-1 and CA-IX mRNA following 
stimulation with DMOG or hypoxia. These are considered to be standard levels of stimulation in 
21% O2
DMOG 
1mM 1% O2
HIF-1α
HIF-2α
α-tubulin
120 kD
119 kD
50 kD
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in vivo hypoxia studies and are generally taken to be comparable in terms of induction of HIF-
dependent responses. 
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Figure 3.2 Upregulation of known HIF target genes by DMOG and hypoxia 
Caco-2 cells were treated with DMOG (1mM) or exposed to hypoxia (1% O2) for 24 hours with untreated 
normoxia control. mRNA expression was evaluated by Q-PCR using the 2-ΔΔCt method. Graphs show 
VEGF, BNIP-3, GLUT-1 and CA-IX expression normalised to untreated normoxia (dashed line). Data are 
mean ± SEM from 3 experiments performed in triplicate wells, analysed by 1-way ANOVA (ΔCt versus 
normoxia, non-significant unless stated; * p<0.05, ** p<0.01, *** p<0.001).  
 
VEGF mRNA was upregulated more strongly by DMOG (7.43±0.82) than by hypoxia 
(4.96±0.50) (p<0.001 versus normoxia for both; p<0.05 DMOG versus hypoxia). There was no 
significant difference in upregulation by DMOG and hypoxia for BNIP-3 (7.47±1.71 versus 
7.78±0.06; both p<0.01 versus normoxia), GLUT-1 (2.40±0.24 versus 2.15±0.10; both p<0.001 
versus normoxia) or CA-IX (6.29±2.26 versus 6.49±2.15; both p<0.05 versus normoxia).  
The effect of hypoxia and DMOG stimulation on these HIF targets at the protein level is 
shown in Figure 3.3. After stimulation with either DMOG or hypoxia, supernatants were 
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collected, cells lysed and protein extracted. Secreted VEGF protein in the supernatants was 
measured by ELISA, and other proteins measured by Western Blotting of cell lysates.  
                                                                                               
Figure 3.3 Protein expression of HIF targets in normoxia, DMOG and hypoxia 
Caco-2 cells were treated with DMOG (1mM) or exposed to hypoxia (1% O2) for 24 hours in duplicate 
wells, with untreated normoxia (21% O2) control. The left panel shows VEGF protein expression in 
supernatants as evaluated by ELISA. Data are mean ± SD from a representative experiment performed in 
duplicate wells (**p<0.01 versus normoxia). The right panel shows Western Blots from the same 
experiment for BNIP-3 (31kD), GLUT-1 (30-60kD) and CA-IX (54/58kD) protein expression in cell 
lysates, with α-tubulin (50kD) loading control. 
 
From a basal level of 19.29±0.56pg/mL in control (normoxic) samples, VEGF protein 
was upregulated more than 5-fold to 101.1±2.45pg/mL (p<0.01) by DMOG, with a more modest 
1.8-fold to 34.79±11.76pg/mL by hypoxia (not statistically significant). Both BNIP-3 and CA-IX 
were expressed weakly in normoxia, while GLUT-1 which characteristically appears as a smear 
rather than a discrete band, was abundantly expressed. DMOG appeared to be marginally more 
potent in stimulating BNIP-3 than hypoxia, while CA-IX and GLUT-1 were upregulated to a 
similar extent by both stimuli. 
The response of these four genes to hypoxia was examined further, firstly investigating 
the effect of increasing durations of hypoxia exposure in a time-course experiment with 2, 6 and 
24 hour time points (Figure 3.4). 
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Figure 3.4 Time course of HIF target mRNA expression in hypoxia 
Caco-2 cells were exposed to hypoxia (1% O2) for 2, 6 or 24 hours. mRNA expression was evaluated by Q-
PCR, normalised to normoxia at 2 hours. Graphs show VEGF, BNIP-3, GLUT-1 and CA-IX expression. 
Data are mean ± SD from a representative experiment performed in triplicate wells. 
 
Overall, mRNA expression of all four genes was maximal at 24 hours. VEGF was 
upregulated earliest, with a fold-change of 2.33±0.11 at 2 hours, rising to 5.35±0.35 at 6 hours. A 
small further increase to 6.83±0.39 was seen at 24 hours. A more linear time-course was seen with 
BNIP-3, which was initially downregulated (0.69±0.11) at 2 hours, then upregulated to 2.05±0.20 
at 6 hours, with a further rise to 6.04±0.76 at 24 hours. GLUT-1 and CA-IX both reached a 
plateau between 6 and 24 hours. GLUT-1 was modestly upregulated at 2 hours (1.44±0.02), 
increasing to 2.42+0.12 at 6 hours followed by a modest drop to 2.31±0.12 at 24 hours. CA-IX 
was essentially unchanged at 2 hours (0.99±0.1), reaching 4.63±0.46 and 4.96±0.46 at 6 and 24 
hours respectively.  
The effect of increasing levels of hypoxia was investigated in subsequent experiments 
(Figure 3.5). 
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Figure 3.5 HIF target mRNA expression in decreasing oxygen tensions 
Caco-2 cells were exposed to 10%, 5%, 3% or 1% O2 for 24 hours. mRNA expression was evaluated by Q-
PCR using the2-ΔΔCt method. Graphs show VEGF, BNIP-3, GLUT-1 and CA-IX expression normalised to 
normoxia (dashed line). Data are mean ± SEM from 2 experiments performed in triplicate wells, analysed 
by 1-way ANOVA (ΔCt versus normoxia; ** p<0.01, *** p<0.001). 
 
Upregulation of VEGF mRNA expression was seen at 10% O2 and 5% O2 (2.02±0.39 and 
2.99±0.74 respectively) without reaching statistical significance. Further upregulation was seen at 
3% O2 (5.40±0.87), almost doubling at 1% O2 (10.02±1.11) (p<0.001 versus normoxia for both 
oxygen tensions). BNIP-3 expression was unchanged at 10% O2 (0.96±0.06), but increased 
sharply to 4.36±0.2 (p<0.001) at 5% O2, with only modest further increases at 3% O2 and 1% O2 
(5.33±0.05 and 5.36±0.03; p<0.001 for both). GLUT-1 was marginally increased at 10% O2 
(1.15±0.03; p<0.01), increasing to 1.74±0.03 at 5% O2, 2.71±0.08 at 3% O2, with a modest further 
increase to 2.85±0.03 at 1% O2 (p<0.001 for all three). CA-IX was modestly and increasingly 
upregulated at 10%, 5% and 3% O2 (2.15±0.12, 2.26±0.08 and 2.99±0.30 respectively), with a 
much greater increase at 1% O2 (11.84±0.41) (p<0.001 for all four oxygen tensions). Of note, 
VEGF and CA-IX expression at 1% O2 (10.02 and 11.84 respectively) was significantly greater in 
this experiment than in Figure 3.2 (4.96 and 6.49). This discrepancy may be due to a difference in 
passage number of cells used in the two experiments (see Discussion, section 3.4).  
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Variations in the time course and oxygen sensitivity of these HIF-dependent genes 
suggest that they may not be regulated by identical mechanisms. In the next experiment, the effect 
of stimulation with different DMOG concentrations was investigated (Figure 3.6). 
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Figure 3.6 HIF target mRNA expression in different DMOG concentrations 
Caco-2 cells were treated with 0.5mM or 1mM DMOG for 24 hours with untreated control. mRNA 
expression was evaluated by Q-PCR. Graphs show VEGF, BNIP-3, GLUT-1 or CA-IX expression 
normalised to control (dashed line). Data are mean ± SEM from replicate experiments performed in 
triplicate wells, analysed by 1-way ANOVA (ΔCt versus untreated; * p<0.05, ** p<0.01, *** p<0.001). 
 
A dose-dependent relationship between DMOG concentration and mRNA expression was 
seen for all four genes. Fold-change for VEGF expression was 3.67±0.16 at 0.5mM DMOG and 
7.79±0.10 at 1.0mM (p<0.001 for both). For BNIP-3, fold-changes were 3.44±0.25 and 5.01±0.43 
respectively (p<0.001 for both). GLUT-1 expression was 1.62±0.04 (p<0.01) for 0.5mM and 
2.71±0.54 (p<0.001) for 1.0mM DMOG. For CA-IX fold-changes were 1.79±0.12 (p<0.01) for 
0.5mM and 3.62±0.74 (p<0.001) for 1.0mM DMOG.  
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3.3.2 Hypoxia-Induced Expression of Apoptosis and Cell-Adhesion Genes 
Having established the effect of DMOG and hypoxia on known HIF targets, genes 
involved in apoptosis (Figure 3.7) and cell-adhesion (Figure 3.8) were studied next. 
Survivin
DMOG 1mM 1% O2
0.0
0.2
0.4
0.6
0.8
1.0
*** ***
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
BAX
DMOG 1mM 1% O2
0.0
0.2
0.4
0.6
0.8
1.0
***
***
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
XIAP
DMOG 1mM 1% O2
0.0
0.5
1.0
1.5
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
Bcl-2
DMOG 1mM 1% O2
0.0
0.5
1.0
1.5
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
 
Figure 3.7 Effect of hypoxia and DMOG on apoptosis genes 
Caco-2 cells were treated with DMOG or exposed to hypoxia (1% O2) for 24 hours with untreated normoxia 
control. mRNA expression was evaluated by Q-PCR. Graphs show survivin, BAX, XIAP and Bcl-2 
expression normalised to untreated normoxia (dashed line). Data are mean ± SEM from 3 experiments 
performed in triplicate wells, analysed by 1-way ANOVA (ΔCt versus normoxia; *** p<0.001). 
 
Survivin and BAX mRNA were both down-regulated by DMOG and hypoxia, to a similar 
degree. Survivin expression was 0.64±0.06 relative to untreated cells in response to DMOG and 
0.67±0.04 in response to hypoxia (p<0.001 for both). BAX expression in DMOG- and hypoxia-
treated cells was 0.68±0.06 and 0.61±0.03 respectively (p<0.001). Expression of XIAP 
(0.97±0.09 DMOG, 0.97±0.08 hypoxia) and Bcl-2 (1.02±0.13 DMOG, 1.10±0.10 hypoxia) were 
unaffected by either stimulus. 
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Figure 3.8 Effect of hypoxia and DMOG on cell-adhesion molecule genes 
Caco-2 cells were treated with DMOG or exposed to hypoxia (1% O2) for 24 hours with untreated or 
normoxia control. mRNA expression was evaluated by Q-PCR. Graphs show STAB-1, VE-Cadherin and 
CD-151 expression normalised to untreated normoxia (dashed line). Data are mean ± SEM from replicate 
experiments performed in triplicate wells, analysed by 1-way ANOVA (ΔCt versus normoxia; *** p<0.001, 
ns = not significant). 
 
STAB-1 was strongly upregulated by DMOG stimulation, with a fold-change of 
7.49±0.06 (p<0.001). Greater upregulation was seen with hypoxia (11.75±0.83; p<0.001). Both 
VE-Cadherin and CD-151 were unchanged. VE-Cadherin expression was 1.19±0.19 in DMOG-
treated cells and 1.17±0.17 in hypoxia-treated cells, while CD-151 expression was 1.10±0.09 and 
1.05±0.09 respectively.  
 
3.3.3 Hypoxia-Induced Angiogenesis Response: Identification of Novel Hypoxia-
Regulated Genes 
The primary focus of this study was to explore Caco-2 angiogenesis responses. To this 
end, the RT
2
Profiler™ PCR Angiogenesis Array (SA Biosciences) was used to analyse mRNA 
extracted from cells stimulated with DMOG (Figure 3.9) or hypoxia (Figure 3.10) and compared 
with normoxia controls. A full list of the genes included in the array is presented in  
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Table 2.5. The manufacturer’s software was used to calculate fold-changes by the 2-ΔΔCt 
method, with greater than two-fold up- or down-regulation taken as a meaningful change. The 
results are displayed in a scatter plot, as in Figure 3.9, in which 2
-ΔCt
 values in hypoxia/DMOG (y-
axis) are plotted against normoxia controls (x-axis). The solid line represents equal expression, 
and the upper and lower dashed lines represent two-fold up- or downregulation respectively. 
Genes lying towards the top right of the graph are more abundantly expressed than those to the 
bottom left. 31 of the 84 genes were not detected in Caco-2 cells (Ct >30) (Table 5.7 final 
column, and Table 7.1). 
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Figure 3.9 Expression pattern of angiogenesis genes following DMOG exposure 
Caco-2 cells were treated with DMOG 1mM for 24 hours. mRNA expression was evaluated in duplicate by 
RT2 Profiler Angiogenesis PCR Array and 2-ΔCt values plotted against untreated control. Figure shows a 
scatter plot from a representative experiment. Solid line indicates no change; dashed lines indicate two-fold 
increase (upper) and decrease (lower). Genes upregulated more than two-fold are labelled and shown in 
black. HIF-1α is also shown in black (HIF-1A).  
 
Following DMOG stimulation, 9 genes were upregulated greater than two-fold. These 
were ANGPT-1 (fold-change 2.09), ANGPTL-3 (2.31), ANGPTL-4 (2.61), EFNA-1 (2.41), 
EFNA-3 (6.63), FLT-1 (2.81), MMP-9 (2.42), TGF-β1 (TGF-B1, 4.30), and VEGF-A (3.42). 
HIF-1α expression was unchanged (1.08). No gene was downregulated more than two-fold. 
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Figure 3.10 Expression pattern of angiogenesis genes following exposure to hypoxia 
Caco-2 cells were treated exposed to hypoxia (1% O2) for 24 hours with normoxia control. mRNA 
expression was evaluated in duplicate by RT2 Profiler Angiogenesis PCR Array and 2-ΔCt values in hypoxia 
plotted against normoxia control. Figure shows a scatter plot from a representative experiment. Solid line 
indicates no change; dashed lines indicate two-fold increase and two-fold decrease. Selected genes that 
were upregulated more than two-fold are labelled and shown in black. HIF-1α is also shown in black (HIF-
1A). 
 
A similar pattern was seen following hypoxia stimulation. The same 9 genes that were 
upregulated by DMOG were also induced by hypoxia. ANGPT-1 was upregulated by 2.26, 
ANGPTL-3 by 2.10, ANGPTL-4 by 3.11, EFNA-1 by 2.55, EFNA-3 by 7.19, FLT-1 by 3.70, 
MMP-9 by 2.11, TGF-β1 by 5.39, and VEGF-A by 3.07. A further 8 genes were upregulated by 
hypoxia between 2 to 3-fold: ANGPT-2 (2.18), EGF (2.69), Heparanase (HPSE, 2.02), Insulin-
like growth factor 1 (IGF, 2.10), interleukin-1 beta (IL1-β, 2.13), plexin-domain-containing-1 
(PLXDC1, 2.15), prokineticin-2 (PROK-2, 2.73), and VEGF-C (2.60). HIF-1α was 
downregulated (fold-change 0.66; fold-regulation -1.52).  
Both hypoxia and DMOG are known to induce genes in a non-HIF-dependent manner 
(Wood et al. 1996; Elvidge et al. 2006). From the above experiments, the 9 genes that were 
upregulated by both hypoxia and DMOG and are thus likely to be HIF-dependent, are represented 
in Figure 3.11. 
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Figure 3.11 Angiogenesis genes upregulated by both DMOG and hypoxia 
Caco-2 cells were treated with DMOG or exposed to hypoxia (1% O2) for 24 hours with untreated normoxia 
control. mRNA expression was evaluated by RT2 Profiler Angiogenesis PCR Array and fold-changes versus 
normoxia calculated. Figure shows genes upregulated at least two-fold by both DMOG and hypoxia. This 
figure is derived from the data shown in Figure 3.9 and Figure 3.10. 
 
The hypoxic regulation of VEGF in CRC angiogenesis and its importance is well 
described. Although it has been reported that ANGPTL-4 is hypoxia-dependent in other CRC 
cell-lines, this is a novel finding in Caco-2 cells (Imamura et al. 2009). Two recent studies report 
hypoxic induction of TGF-β1 protein in SW480 (Xian et al. 2011) and Caco-2 cells (Abajo et al. 
2012). Neither study investigated mRNA levels. The hypoxia-regulation of ephrin-A3 has not 
been previously described in cancer CRC. Further investigation of angiogenesis responses 
focused on these three novel genes.  
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Figure 3.12 Q-PCR validation of selected hypoxia-induced angiogenesis genes 
Caco-2 cells were treated with DMOG or exposed to hypoxia (1% O2) for 24 hours with untreated normoxia 
control. mRNA expression was evaluated by Q-PCR. Graphs show ANGPTL-4, EFNA-3 and TGF-
β1expression normalised to normoxia (dashed line). Data are mean ± SEM from at least 3 experiments 
performed in triplicate, analysed by 1-way ANOVA (*** p<0.001 versus normoxia, ns = not significant). 
 
Firstly, the array results were validated by Q-PCR (Figure 3.12). All three genes were 
upregulated by both DMOG and hypoxia. For ANGPTL-4 and TGF-β1, DMOG was a more 
potent stimulus than hypoxia. ANGPTL-4 upregulation was 30.45±3.59 (p<0.001) for DMOG 
and 16.22±1.87 (p<0.001) for hypoxia (p<0.001 for DMOG versus hypoxia). Fold-change for 
TGF-β1 expression was 23.76±2.98 (p<0.001) by DMOG and 16.96±2.05 (p<0.001) by hypoxia, 
although this difference did not reach statistical significance. Ephrin-A3 expression was similar 
following DMOG (6.08±0.85; p<0.001) and hypoxia (5.34±0.77; p<0.001). 
Response to DMOG stimulation was dose-dependent as shown in Figure 3.13.  
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Figure 3.13 Novel angiogenesis genes –effect of DMOG concentration 
Caco-2 cells were treated with 0.5mM or 1mM DMOG for 24 hours with untreated control. mRNA 
expression was evaluated by Q-PCR. Graphs show ANGPTL-4, TGF-β1 and EFNA-3 expression 
normalised to untreated control (dashed line). Data are mean ± SEM from replicate experiments performed 
in triplicate, analysed by 1-way ANOVA (ΔCt versus untreated; *** p<0.001). 
Fold-change for ANGPTL-4 expression was 21.48±0.45 at 0.5mM DMOG and 
47.99±2.61 at 1.0mM (both p<0.001). For EFNA-3, fold-changes were 3.28±0.07 and 5.41±0.53 
respectively (both p<0.001). TGF-β1 was upregulated by 13.82±0.14 for 0.5mM and 27.94±1.23 
for 1.0mM (both p<0.001).  
The experiments described thus far sought to characterise the response of downstream 
HIF targets to both DMOG and hypoxia. The results are summarised in Table 3.1. To complete 
characterisation of Caco-2 hypoxia-mediated responses, the expression of the HIF-regulating 
enzymes was investigated (next section). 
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Table 3.1 Characterisation of Caco-2 mRNA Response to Hypoxia 
Table shows Caco-2 mRNA responses to hypoxia (1% O2) and DMOG 1mM stimulation of genes involved 
in apoptosis, cell-adhesion and angiogenesis. Only genes that were evaluated by Q-PCR are shown. ↑ = 
increase, ↓ = decrease, ↔ = no change 
 Gene DMOG Hypoxia 
Known HIF Targets 
VEGF ↑ ↑ 
GLUT-1 ↑ ↑ 
CA-IX ↑ ↑ 
BNIP-3 ↑ ↑ 
Apoptosis 
Survivin ↓ ↓ 
BAX ↓ ↓ 
XIAP ↔ ↔ 
Bcl-2 ↔ ↔ 
Cell-adhesion 
STAB-1 ↑ ↑ 
VE-Cad ↔ ↔ 
CD-151 ↔ ↔ 
Angiogenesis 
ANGPTL-4 ↑ ↑ 
EFNA-3 ↑ ↑ 
TGF-β1 ↑ ↑ 
 
 
3.3.4 Expression of HIF-Regulatory Enzymes 
The expression of the HIF-regulating enzymes PHD-2, PHD-3 and FIH-1 was 
investigated at mRNA (Figure 3.14) and protein level (Figure 3.15). 
There was a trend towards greater mRNA upregulation with hypoxia stimulation than 
with DMOG, but this did not reach statistical significance. PHD-3 mRNA was more strongly 
upregulated than PHD-2, with fold-changes of 3.75±0.12 after DMOG and 4.52±0.43 after 
hypoxia stimulation (p<0.001 versus normoxia for both; DMOG versus hypoxia not significant). 
There was a small downregulation of FIH-1 mRNA after DMOG stimulation (0.82±0.02) and 
mild upregulation after hypoxia (1.12±0.22), but these changes were not statistically significant. 
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Figure 3.14 HIF hydroxylase mRNA expression in DMOG and hypoxia 
Caco-2 cells were exposed to DMOG or hypoxia (1% O2) for 24 hours with untreated normoxia control. 
mRNA expression was evaluated by Q-PCR. Graphs show PHD-2, PHD-3 and FIH-1 expression 
normalised to normoxia (dashed line). Data are mean ± SD from a representative experiment, analysed by 
1-way ANOVA (ΔCt versus normoxia; * p<0.05, ** p<0.01, *** p<0.001, ns = not significant). 
 
At the protein level, while PHD-2 was expressed in normoxia, PHD-3 was barely detected 
by Western Blot (Figure 3.15). There was strong induction of both PHDs with DMOG and 
hypoxia. In contrast to mRNA levels, DMOG appeared to be a more potent inducer of the PHD 
proteins than hypoxia. Normoxic FIH-1 protein expression was not significantly altered by either 
DMOG or hypoxia stimulation. 
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Figure 3.15 HIF hydroxylase protein expression in DMOG and hypoxia 
Caco-2 cells were treated with DMOG or exposed to hypoxia for 24 hours with untreated normoxia control. 
Figure shows PHD-2 (46kD), PHD-3 (27kD) and FIH-1 (40kD) protein expression from a representative 
experiment, evaluated by Western Blot. α-tubulin (50kD) is shown as loading control. 
 
  
40kD
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27kDPHD3
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50kDα-tubulin
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3.4 Discussion 
The objective of this part of my study was to characterise the response of Caco-2 CRC 
cells to hypoxia and to the hypoxia mimetic DMOG. Initial experiments sought to confirm HIF-α 
isoform expression in these cells. Expression of well-known HIF targets was examined in some 
detail, evaluating dose response and kinetics. Results indicated that at 24 hours, the HIF-pathway 
was maximally activated by 1% O2 or DMOG 1mM. Subsequent experiments evaluated the 
hypoxia- and DMOG-induced expression of genes involved in apoptosis, cell-adhesion and 
angiogenesis, as well as the HIF regulatory enzymes. Genes that have been previously reported to 
be hypoxia regulated, particularly those for which there is evidence of involvement in CRC 
pathogenesis, were selected for evaluation. In addition, an angiogenesis PCR array identified three 
novel hypoxia-regulated angiogenesis which were subsequently evaluated by Q-PCR. A summary 
of these results is provided in Table 3.1. 
A general observation of note is that there was some inconsistency between experiments 
in terms of the degree of induction of certain genes. For example in Figure 3.2, expression of 
VEGF and CA-IX at 1% O2 (4.96 and 6.49 respectively) was approximately half of that in Figure 
3.5 (10.02 and 11.84). Similarly, ANGPTL-4 expression at 1mM DMOG was 30.45 in Figure 
3.12 and 47.99 in Figure 3.13. This discrepancy may be due to passage number, which has been 
shown to influence functional characteristics of cell-lines (Wenger et al. 2004; Hughes et al. 
2007). This phenomenon may contribute to variations across different studies, as passage number 
is not commonly referred to (Sambuy et al. 2005). In Caco-2 cells, passage-dependent variations 
in mRNA expression of glucose transporter protein GLUT-3 (2.4-fold) and the enzyme sucrose-
isomaltase (7- to 10-fold) have been reported (Chantret et al. 1994; Anderle et al. 2003). The 
range of passage number in my experiments was small (1 to 5) in comparison to these studies (30 
to 200), and unfortunately passage number was not routinely recorded for data analysis purposes. 
Data from 2 to 3 separate experiments were commonly pooled. To require that data pooling be 
restricted to experiments using cells of identical passage number would have required a 
significant increase in experiment number or size (more replicates per experiment). In the analysis 
and discussion of these results, the emphasis is on differences between experimental conditions 
within an experiment, rather than differences between experiments which may be confounded by 
passage number. 
It was clearly demonstrated in my study that in Caco-2 cells both HIF-α isoforms are 
expressed, and strongly upregulated by 24 hours stimulation with both DMOG 1mM and hypoxia 
(1% O2) (Figure 3.1). This is in contrast to Mizukami et al. (Mizukami et al. 2004), who described 
weak normoxic expression with minimal hypoxia (1% O2) induction of HIF-2α in Caco-2 at 12 
hours, and concluded that this isoform was unlikely to play a role in hypoxia-regulation in this 
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cell-line. Bracken et al, using the same antibody as Mizukami et al but a lower oxygen tension 
(0.5% O2), showed moderate but clear hypoxia-induction of HIF-2α at 16 hours (Bracken et al. 
2006). Both these studies used a different antibody to that used in my study, which in the case of 
both 1% O2 and 24 hour stimulation produced a consistently strong HIF-2α response. Passage 
number, which is not quoted in these studies, might also contribute to these discrepancies. In 
contrast to HIF-α protein, mRNA levels were downregulated by hypoxia. This data is presented 
and discussed in Chapter 4.  
My data show that normoxic Caco-2 cells express PHD-2 protein while PHD-3 is barely 
detected. PHD-2 is the dominant HIF-regulating enzyme in normoxia in most cell types (Berra et 
al. 2003). In CRC, while PHD-2 expression is equal in tumour and adjacent normal tissue, 
downregulation of PHD-3 in the tumour has been reported, and correlates with increased 
tumourigenesis and metastasis (Xue et al. 2010). PHD-3 knockdown in CRC cell-lines resulted in 
cytokine resistance and enhanced tumourigenesis, leading the authors to conclude that PHD-3 
may have a tumour suppressor role. Of note, these experiments were conducted in normoxic 
conditions, and the mechanism involved inhibition of the transcription factor nuclear factor 
kappa-B (NF-κB) rather than HIF hydroxylation. The significance of this effect in the context of 
hypoxia is unclear. In Caco-2 cells PHD-2 and PHD-3 were induced by both hypoxia and DMOG 
at mRNA and protein level. Hypoxic induction of PHD-2 and PHD-3 has been previously 
reported in several cancer cell-lines, including CRC (Berchner-Pfannschmidt et al. 2008; Yan et 
al. 2011), and an HRE has been identified in both gene promoters (Metzen et al. 2005; Pescador et 
al. 2005). In Caco-2 cells, upregulation of PHD-2 mRNA by hypoxia (Bruning et al. 2011), and of 
PHD-2 and PHD-3 mRNA by iron-deprivation, which has a hypoxia-mimetic effect, has been 
reported (Hu et al. 2010), but neither study examined protein expression. Since the PHDs are 
inactivated by hypoxia, their upregulation leads to rapid clearance of accumulated HIF once 
normal oxygen levels are restored (D'Angelo et al. 2003; Marxsen et al. 2004). However, it has 
also been reported that in prolonged hypoxia (1% O2, 24-48 hours), PHD-2 and PHD-3 can reduce 
HIF protein levels in glioblastoma cells (Henze et al. 2010). It therefore seems likely that they are 
not completely inactive at 1% O2, and that their upregulation by hypoxia serves to protect cells 
from HIF accumulation in chronic hypoxia. 
FIH-1 expression in Caco-2 cells has been previously reported (Bracken et al. 2006), 
although the effect of hypoxia was not investigated as in my study. FIH-1 expression has also 
been demonstrated in several cancer cell-lines from different tissues including CRC, and, in 
support of my data, was not found to be induced by hypoxia even at 0.2% O2 (Stolze et al. 2004). 
In lung cancer cells, however, Ke et al. reported downregulation of FIH-1 mRNA by the hypoxia-
mimetic cobalt chloride (Ke et al. 2005), which is known to inhibit FIH-1 hydroxylation of HIF-α 
Chapter 3 
99 
(Hewitson et al. 2002), suggesting that there may be HIF-1α-dependent hypoxic regulation of FIH 
in these cells. 
As might be anticipated based on the expression of HIF-α proteins, the known HIF targets 
VEGF, BNIP-3 and CA-IX were all upregulated at both the mRNA and protein levels by DMOG 
and hypoxia stimulation. For VEGF (and to a lesser extent BNIP-3), DMOG was a more potent 
stimulus than hypoxia (Figure 3.3). This may be explained by the relative oxygen sensitivities of 
the HIF regulating enzymes (Koivunen et al. 2004; Tian et al. 2011). Using siRNA techniques, 
Stolze et al. reported that PHD-2 retains full activity at 2% O2, but this was barely discernible at 
0.5% O2 (Stolze et al. 2004). In contrast, FIH-1 retained significant activity even at 0.2% O2.. Tian 
et al. investigated enzyme activity using antibodies to the specific proline and asparagine residues 
hydroxylated by the PHDs and FIH respectively. They showed that prolyl hydroxylation occurs 
even at 0.25% O2, albeit markedly attenuated, whereas significant asparagine hydroxylation 
persisted at 0.1% O2. By contrast, DMOG 1mM inhibited both proline and asparigine 
hydroxylation completely (Tian et al. 2011). The fact that CA-IX and GLUT-1 were equally 
stimulated by both DMOG and hypoxia suggests that the action of FIH-1 may be less important 
than that of the PHDs, whereas for VEGF (and to a lesser extent BNIP-3), FIH-1 may play an 
important role. Further information may be gleaned by co-stimulation experiments, to see if the 
addition of DMOG to hypoxic cells increases target gene expression. 
FLT-1 (FMS-like tyrosine kinase, also known as VEGFR-1) is one of three known VEGF 
receptor tyrosine kinases (VEGFR-1, -2 and -3). Most cellular responses to VEGF are mediated 
by VEGFR-2 (KDR/Flk-1) (Ferrara et al. 2003). FLT-1 has complex, context-dependent functions 
(Chung and Ferrara 2011). It can negatively regulate VEGFR-2 by sequestering VEGF, thus 
acting as a “decoy receptor” (Kendall and Thomas 1993; Park et al. 1994; Roberts et al. 2004). It 
can regulate monocyte migration as well as endothelial cell production of growth factors and 
proteases (Barleon et al. 1996; Hiratsuka et al. 2002; LeCouter et al. 2003). FLT-1 is expressed in 
cancer cell-lines and tissues including CRC (Masood et al. 2001; Fan et al. 2005) and its 
activation leads to increased migration and invasion in CRC cell-lines (Fan et al. 2005; Lesslie et 
al. 2006). In agreement with my data, hypoxia has been shown to induce FLT-1 expression both 
in vitro and in vivo, and an HRE has been identified in the FLT-1 promoter (Tuder et al. 1995; 
Gerber et al. 1997).  
Upregulation of BNIP-3 by hypoxia is well-established (Mellor and Harris 2007). It has 
been described in Caco-2 cells (Bacon et al. 2006), reflecting the data from the present study, as 
well as in several other cancer cell-lines (Sowter et al. 2001). BNIP-3 upregulation in tumour 
tissue is associated with several cancers including, and correlates with more aggressive tumours 
(Burton and Gibson 2009). In CRC, BNIP-3 expression is associated with local invasion and 
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lymph node metastasis (Koukourakis et al. 2006). However, Bacon et al. reported reduced BNIP-
3 expression in 64% of CRC tumour samples, with increased expression in 12% (Bacon et al. 
2006). A non-significant trend towards increasing tumour grade with decreasing BNIP-3 
expression was seen. In eight CRC cell-lines investigated, only three (Caco-2, LS14T and Colo-
741) showed hypoxic BNIP-3 induction (Bacon et al. 2006). In hypoxia-responsive LS14T cells, 
silencing of BNIP-3 reduced hypoxia-induced apoptosis, indicating that BNIP-3 does indeed have 
a pro-apoptotic role in these cells. Cell-lines in which BNIP-3 was unresponsive to hypoxia were 
resistant to hypoxia-induced cell death. Thus it may be that down-regulation of BNIP-3, and/or 
preventing its hypoxia-induction, is a mechanism by which tumours can evade apoptosis. Other 
mechanisms of bypassing BNIP-3-induced apoptosis have been suggested, such as nuclear 
sequestration of BNIP-3 in lung cancer (Giatromanolaki et al. 2004) and inhibition of BNIP-3 
function in endothelial cells by growth factors such as EGF and IGF (Kothari et al. 2003).  
In addition, a direct pro-survival role in the context of hypoxia has been postulated for 
BNIP-3, through the promotion of autophagy (Mathew et al. 2007). This intracellular degradation 
process clears damaged proteins or organelles, resulting in the recycling of intracellular 
constituents which can serve as an alternative energy source for metabolically stressed cells, for 
example in hypoxia. In the context of defective apoptosis, autophagy can prolong survival by 
mitigating metabolic stress and genome damage (Degenhardt et al. 2006; Karantza-Wadsworth 
and White 2007). Hypoxia can induce autophagy, and BNIP-3 plays an important role in this 
mechanism (Bellot et al. 2009).  
My data showed BAX suppression by hypoxia in Caco-2 cells, while Bcl-2 was 
unaffected. This is in agreement with Erler et al who found that hypoxia downregulated BAX in 
three CRC cell-lines (SW480, HT29, and HCT116), and had no effect on Bcl-2 expression in two 
of the cell-lines (Bcl-2 was moderately increased by hypoxia in HCT116) (Erler et al. 2004). 
Survivin, a member of the Inhibitor of Apoptosis Protein (IAP) family, negatively regulates 
apoptosis. It has been shown to be upregulated in most tumours and in CRC is associated with 
poorer prognosis (Abd El-Hameed 2005; Sah et al. 2006). In the CRC cell-lines LS174T and 
SW480, HIF-1α has been reported to upregulate survivin expression at both mRNA and protein 
level (Fan et al. 2008; Wu et al. 2010). This is at odds with the results presented here, in which 
survivin mRNA was downregulated in Caco-2 cells. XIAP (X-linked inhibitor of apoptosis 
protein), another member of the IAP family, is overexpressed in CRC tissue (Krajewska et al. 
2005). It has been shown to protect against hypoxia-induced apoptosis in cholangiocarcinoma 
which is particularly resistant to hypoxia, but little is known about its role in CRC (Marienfeld et 
al. 2004). In Caco-2 cells, neither hypoxia nor DMOG affected XIAP mRNA levels. Thus, 
hypoxia had opposing effects on the pro-apoptotic genes BNIP-3 (induced) and BAX (supressed), 
while anti-apoptotic genes were either supressed (survivin) or unchanged (Bcl-2, XIAP). 
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Discrepancies between my data and the literature suggests cell-specificity in the hypoxia response 
of apoptosis genes. Functional studies are indicated in order to elucidate the consequence of these 
alterations.  
Due to their induction in hypoxic tissue and limited expression in normal tissue, both CA-
IX and GLUT-1 are used as experimental markers of hypoxia (Swinson et al. 2003; Chung et al. 
2009). Overexpression of both is seen in CRC, and is associated with poor prognosis (Cooper et 
al. 2003; Korkeila et al. 2009). CA-IX induction by hypoxia has been reported to enhance 
invasiveness and resistance to hypoxia-induced cell death in HT-29 cells (Sansone et al. 2009). 
GLUT-1 hypoxia-induction in Caco-2 cells, as seen in my data, has been previously reported at 
protein level following 48 hours of hypoxia or cobalt chloride stimulation (Carrière et al. 1998).  
Alterations in cancer cell adhesion to neighbouring cells and surrounding extracellular 
matrix are necessary in order for invasion and metastasis to occur, and there is evidence that this 
is influenced by hypoxia (Paschos et al. 2009). Hypoxia has also been shown to downregulate 
CD151 protein and mRNA in CRC cell-lines derived from both primary (SW480 and HCT116) 
and metastatic tumours (SW620), leading to a reduction in the strength of cell-cell and cell-matrix 
adhesion (Chien et al. 2008). However my study found no change in CD151 expression in Caco-2 
cells.  
Upregulation of CAMs by hypoxia in cancer has also been reported, as in the case of VE-
Cadherin in melanoma cells (Zhao et al. 2012). VE-Cadherin is normally expressed by endothelial 
rather than epithelial cells, but its expression in cancers of epithelial origin a feature of 
vasculogenic mimicry (VM) (section 1.3.2.3) (Maniotis et al. 1999). While VM has been 
described in CRC and found to correlate with poor prognosis, the role of VE-Cadherin and 
hypoxia in CRC is not known (Baeten et al. 2009). According to my data, as with CD151, VE-
Cadherin does not appear to be affected by hypoxia in Caco-2 cells.  
My Q-PCR data showed significant upregulation of stabilin-1 (STAB-1) by both hypoxia 
and DMOG. The array data differed in that no change was seen in DMOG treated cells (fold-
change 1.10), although less than 2-fold upregulation was seen in hypoxia (1.94). STAB-1 is a 
large multifunctional protein, with roles related to scavenging, lymphocyte migration, cell-
adhesion and angiogenesis (Salmi et al. 2004; Karikoski et al. 2009). Its role in cancer is poorly 
understood. It has been found to be upregulated in lymphatic vessels in breast cancer tissue, 
where it was associated with increased lymph node metastasis (Ammar et al. 2011). VEGF has 
been found to induce STAB-1 expression in endothelial cells, while in breast cancer hypoxia has 
been reported to upregulate STAB-1 in tumour associated macrophages (Wary et al. 2003; 
Movahedi et al. 2010). Conversely, in other cell types such as monocytes and bone-marrow-
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derived stem-cells, hypoxia has been shown to downregulate STAB-1 expression (Bosco et al. 
2006; Ong et al. 2010). To my knowledge, expression of STAB-1 has not been previously 
reported in CRC. Of note, previous work in our lab using the same angiogenesis array had shown 
downregulation of STAB-1 by DMOG in Caco-2 (hypoxia was not investigated). Expression of 
cell adhesion molecules can be influenced by cell-cell contact (Kobayashi et al. 1992; Kunz et al. 
1996), so that confluence levels in adherent cells such as Caco-2 may be expected to affect 
expression. It was noted that previous experiments had been conducted with cells at 30% 
confluence, whereas cells in my experiments were at 50%. In an experiment with cells exposed to 
hypoxia at 15%, 30% and 60% confluence, STAB-1 expression relative to normoxia was reduced 
in the first two conditions, but was increased at 60% (data not shown). This suggests that cell-cell 
contact can alter the direction of hypoxia response. Further experiments are required to confirm 
this finding, and it would be interesting to explore the underlying mechanisms. 
Angiopoietin-1 and -2 (ANGPT-1, ANGPT-2), which are functionally antagonistic, and 
play a central role in angiogenesis. ANGPT-1 recruits mural cells, and promotes assembly and 
maturation of blood vessels leading to vessel stabilisation and normalisation; conversely, 
ANGPT-2 is stored by endothelial cells and destabilises vessels, inducing vascular sprouting and 
branching (Brindle et al. 2006; Fagiani et al. 2011). Overexpression of ANGPT-1 suppresses 
angiogenesis and tumour growth in CRC, while ANGPT-2 has the opposite effect (Ahmad et al. 
2001b; Stoeltzing et al. 2003). However, in other cancers ANGPT-1 can enhance angiogenesis 
(Machein et al. 2004), and the aberrant vessels resulting from ANGPT-2 overexpression can lead 
to reduced tumour growth (Yu and Stamenkovic 2001). Hypoxic induction of both ANGPT-1 and 
ANGPT-2 has been reported in endothelial cells (Skuli et al. 2009), and of ANGPT-2 in CRC 
cell-lines (Gu et al. 2006). Interestingly, marked hypoxic downregulation of ANGPT-1 has been 
reported in rat glioma cells (Enholm et al. 1997; Abdulmalek et al. 2001). In my array data, 
ANGPT-1 was upregulated by both hypoxia and DMOG in Caco-2 cells. ANGPT-2 was also 
upregulated by hypoxia, but not by DMOG. This suggests a HIF-independent component to 
hypoxic ANGPT induction, although it is interesting to note that an HRE has been identified in 
the ANGPT-2 promoter (Simon et al. 2008). 
ANGPTL-4 has remarkably diverse functions, and in addition to angiogenesis, it is 
involved in lipid metabolism, cell-differentiation, vascular permeability and wound healing (Zhu 
et al. 2012). The structural complexity of the ANGPTL-4 protein underlies this multifunctionality. 
Its role in cancer is reviewed by Tan et al. (Tan et al. 2012). Elevated expression levels have been 
detected in several cancers, including CRC, in which expression correlates with venous invasion 
and metastasis (Nakayama et al. 2011). ANGPTL-4 is induced by fasting and can be upregulated 
by TGF-β1 (see below) (Padua et al. 2008). There is evidence that ANGPTL-4 can be both pro- 
and anti-tumourigenic. It enhances tumour proliferation, inhibits apoptosis, and promotes 
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metastasis (Padua et al. 2008; Zhang et al. 2008; Huang et al. 2011; Kim et al. 2011). However, it 
has also been reported to inhibit angiogenesis and metastasis (Ito et al. 2003; Galaup et al. 2006). 
The controversy as to its roles may be due in part to context or tissue specificity, and to the 
complexity of its structure (it is often unclear which isomer is under investigation). HIF-
dependent hypoxia upregulation is seen in breast cancer cells, and an HRE has been identified in 
the ANGPTL-4 promoter (Hu et al. 2009; Zhang et al. 2012). Upregulation by hypoxia has not 
been previously reported in Caco-2, although it has been seen in other CRC cell-lines (Kim et al. 
2011). The role of HIF in regulating ANGPTL-4 is investigated in Chapter 4.  
ANGPTL-3, which is closely related to ANGPTL-4 but is much less well understood. 
There are differences in expression patterns, regulation and function (Li 2006). As well as being 
involved in lipid metabolism, ANGPTL-3 has been reported to stimulate endothelial cell adhesion 
and migration with similar potency to VEGF (Camenisch et al. 2002). Hypoxic induction of 
ANGPTL-3, as shown here in Caco-2 cells, has not been previously reported. 
As described in the Chapter 1 (section 1.2.3), the Eph/ephrin family is the largest family 
of receptor tyrosine kinase (RTK) systems. The 13 receptors (Eph) and 9 ligands (ephrins) are 
classified as either class A or B based on sequence homology and binding preferences. Ligands 
generally bind receptors in the same class, but interactions across the classes can occur (Himanen 
et al. 2004), thus a large number of receptor-ligand combinations is thus possible. In addition to 
the unique bidirectionality of Eph-ephrin interactions, this contributes to the ability of the 
Eph/ephrin family to regulate numerous diverse functions including axonal guidance, cell 
migration and angiogenesis. Aberrant Eph/ephrin expression is seen in several cancers including 
CRC, and correlates with stage and prognosis (Miyazaki et al. 2003; Fox and Kandpal 2004; Jubb 
et al. 2005; Herath et al. 2006; Herath et al. 2009). The precise role of Eph-ephrin interactions in 
CRC is complex, and is reviewed by Herath  and Boyd (Herath and Boyd 2010). In general terms, 
several Eph receptors which may play an oncogenic role are upregulated in early CRC. 
Subsequent gene silencing is seen in more advanced tumours, which may play a role in invasion 
and metastasis. Ephrin-A3 is one of the least investigated ephrin ligands. In normal tissues, it is 
most abundantly expressed in the brain (Davis et al. 1994). Low levels are seen in normal colon, 
with equal expression in colon tumours (Hafner et al. 2004). In the lung, marked upregulation is 
seen in tumour versus normal tissue. Hypoxic induction of ephrin-A3 mRNA has been reported in 
endothelial cells, although interestingly ephrin-A3 protein was downregulated (Fasanaro et al. 
2008). In our laboratory, hypoxic induction of ephrin-A3 mRNA has been shown in rheumatoid 
fibroblasts (Larsen et al. 2012). Upregulation of several Eph receptors and ephrins by hypoxia has 
been reported in hepatoma and prostate cancer cell-lines (Vihanto et al. 2005), although this study 
did not investigate ephrin-A3. To my knowledge, the hypoxic induction of ephrin-A3 seen in 
Caco-2 has not been previously reported in CRC, and is further investigated in Chapter 4.  
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As well as degrading of ECM proteins (exposing ECM-bound receptor binding sites and 
regulatory molecules), MMPs can interact directly with growth factor binding proteins, cell-
adhesion molecules and other proteinases (Egeblad and Werb 2002; Rupp et al. 2008). As well as 
having critical functions in normal physiology, they play a central role in cancer invasion and 
metastasis. Upregulation of MMPs is seen in most types of cancer, including CRC, and is 
associated with poor prognosis (Egeblad and Werb 2002). Both MMP-2 and MMP-9, which are 
produced by stromal cells as well as cancer cells, are upregulated in CRC and associated with 
angiogenesis, advanced tumour stage, increased metastasis and poorer survival (Grigioni et al. 
1994; Zeng and Guillem 1996; Zeng et al. 1996; Kim and Kim 1999; Kikuchi et al. 2000). 
Conversely, decreased TIMP-3 expression in CRC tissue has been reported to be associated with 
advanced stage, poorer differentiation and increased metastasis (Bai et al. 2007). Hypoxia 
induction of both MMP-2 and MMP-9 has been previously reported in the CRC cell-line LoVo 
(Wu et al. 2008). However in this current study, only MMP-9 was induced by hypoxia in Caco-2 
cells. 
TGF-β1 is a multifunctional cytokine which plays an important role in regulating immune 
responses to cancer, as well as controlling numerous cellular processes in virtually all cell types. 
It has a tumour suppressive effect in the early stages of cancer, but promotes tumourigenicity as 
cancers progress (Massagué 2008). CRC patients have elevated serum TGF-β1 levels, and the 
overexpression seen in tumour tissue correlates with VEGF expression, MVD and metastasis 
(Tsushima et al. 1996; Xiong et al. 2002a; Xiong et al. 2002b). TGF-β1 overexpression is also 
related to poor prognosis, but the correlation is seen in early rather than late stage CRC (Gulubova 
et al. 2010). Lower TGF-β1 expression is seen in high grade tumours and those with lymph node 
metastases than in early tumours (Bacman et al. 2007). Similarly, Abajo et al. have reported that 
cell-lines derived from CRC metastases show lower TGF-β1 expression than those from primary 
tumours such as Caco-2 (Abajo et al. 2012). There is little published data on the effect of hypoxia 
on TGF-β1. Correlation of TGF-β1 and HIF-1α expression has been reported in CRC (Wincewicz 
et al. 2010). Direct evidence of hypoxic TGF-β1 induction is scarce, with a single study using 
SW480 CRC cells reporting upregulation of TGF-β1 protein (Xian et al. 2011). Hypoxic 
upregulation of TGF-β1 mRNA, as shown in Caco-2 cells herein, has not previously been 
reported. The role of HIF in this induction is investigated in Chapter 4. 
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Summary 
In this chapter, the responses of Caco-2 cells to hypoxia and DMOG were characterised. 
Expression of both HIF isoforms, and their upregulation at the protein level by both hypoxia and 
DMOG was confirmed. This was associated with upregulation of known HIF targets. Hypoxia 
responses of genes involved in apoptosis and cell-adhesion were also characterised. Using a gene 
array, a group of 9 angiogenesis genes that were upregulated by both hypoxia and DMOG were 
identified. In this cell-line, hypoxia-dependence of ANGPTL-4 and TGF-β1 has not been 
previously described. To my knowledge, this is the first report of regulation of EFNA-3 by 
hypoxia in a cancer cell-line. In the subsequent chapter, the role of the HIF-α isoforms in the 
regulation of some of these genes was investigated further.  
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4 ROLE OF HIF-α ISOFORMS IN THE HYPOXIA-MEDIATED 
RESPONSE OF CACO-2 CELLS 
4.1 Introduction 
While the two main HIF-α isoforms were initially thought to be functionally redundant, 
there is increasing evidence that they play different roles in cellular responses to changes in 
oxygen tension (Esteban et al. 2006). Generally, HIF-1α is thought to regulate genes involved in 
metabolism, regulating glycolysis and glucose uptake, as well as angiogenesis, while HIF-2α has 
been reported to regulate genes involved in cell proliferation and tumourigenesis (Muz et al. 
2009). The controversy in the published literature regarding the role of HIF-α isoforms in CRC 
has been reviewed in Chapter 1. While some studies suggest that HIF-1α but not HIF-2α 
expression is associated with markers of angiogenesis and poor prognosis, others propound the 
opposite view (Yoshimura et al. 2004; Rasheed et al. 2009). In vitro studies of cell proliferation 
are similarly contradictory (Franovic et al. 2009; Imamura et al. 2009). 
My results described in Chapter 3 demonstrate that hypoxia and DMOG upregulate HIF-α 
protein and induce expression of genes involved in angiogenesis in Caco-2 cells. Studies 
examining the relative role of HIF-α isoforms in Caco-2 hypoxia responses are limited. Bruning et 
al. found that HIF-1α but not HIF-2α suppressed hypoxic upregulation of micro-RNAs, showing 
that this interaction is important in the regulation of HIF-1α levels in prolonged hypoxia (Bruning 
et al. 2011). Kikuchi et al. used Caco-2 cells in a study showing that K-ras and BRAF mutations 
can affect HIF-1α and HIF-2α expression differentially, but this required induction of ectopic 
expression of the mutations, since these cells have wild-type forms of both genes (Kikuchi et al. 
2009). With regard to angiogenesis, Mizukami et al. demonstrated that hypoxic induction of 
VEGF in Caco-2 cells was only partly due to HIF-1α activity, but in this study significant levels 
of HIF-2α were not detected (Mizukami et al. 2004). A study by Zgouras et al. showing that HIF-
1α regulates butyrate-induced normoxic VEGF expression in Caco-2 cells did not investigate the 
possible involvement of HIF-2α (Baba et al. 2010). Moreover, while studies have linked HIF-1α 
expression with apoptosis in Caco-2, none examined the role of HIF-2α (Yoshimura et al. 2004; 
Franovic et al. 2009).  
4.2 Objectives 
The discovery of the gene-regulating properties of dsRNA by Fire and Mello (Fire et al. 
1998) led to the award of the Nobel Prize for Medicine in 2006. RNA interference (RNAi) has 
since become a valuable tool for studying the function of specific genes (Cleven et al. 2008). 
Introducing short-interfering RNA (siRNA) sequences identical to a specific mRNA allows the 
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silencing of the target gene. This technique was selected to investigate the effect of selectively 
silencing either HIF-1α or HIF-2α on the Caco-2 responses mediated by hypoxia and DMOG 
described in Chapter 3. 
4.3 Results 
4.3.1 Optimisation Of Transfection Protocol 
Gene silencing using siRNA transfection was utilised to investigate the relative 
contributions of the HIF-α isoforms to the Caco-2 hypoxia responses described in Chapter 3. A 
series of optimisation experiments were first carried out using siHIF-1α, varying siRNA 
concentrations, transfection agents, cell density and serum starvation. Transfection efficiency, 
expressed as percent knockdown (% KD) was calculated as follows:  
                               
where [HIF-1α]siHIF-1α is HIF-1α mRNA expression after siHIF-1α treatment, and [HIF-1α]siControl is 
HIF-1α mRNA expression after siControl treatment at the same concentration.  
In the first experiment, two different concentrations of siRNA and three different volumes 
of lipofectamine were used (Figure 4.1). As recommended by the manufacturer, a lipofectamine 
volume of 1µL (in a final transfection volume of 600µL) was used, as well as 0.5µL and 1.5µL. 
Cells were at 50% confluence at time of transfection, and were serum-starved for 4 hours prior to 
addition of the serum- and antibiotic-free transfection mix. After 6 hours transfection, medium 
was supplemented with serum and antibiotics. Experiments were carried out in 24-well plates. 
Using 50nM siRNA, HIF-1α knockdown was 35% with 0.5µL lipofectamine (siHIF-1α 
expression 0.67±0.06 versus 1.00±0.09 siControl; p<0.01), 47% with 1.0µL (0.56±0.06 versus 
1.05±0.11; p<0.001), and 39% with 1.5µL (0.63±0.05 versus 1.02±0.08; p<0.01). At 100nM 
siRNA, differences between siHIF-1α and siControl did not reach statistical significance. With 
0.5µL lipofectamine HIF-1α expression was slightly increased by transfection (1.17±0.20 versus 
1.01±0.02, −16% KD), and was weakly knocked down with 1.0µL (0.39±0.01 versus 0.51±0.09, 
23% KD; not significant), and 1.5µL (0.65±0.04 versus 0.82±0.01, 21% KD; not significant). The 
greatest transfection efficiency was seen using 50nM siRNA and 1.0µL lipofectamine (47% KD), 
and these conditions were used in subsequent experiments. This same siRNA against HIF-1α 
consistently resulted in >85% KD in other cell types in our laboratory. 
[HIF-1α] siHIF-1α
% KD   =   1  - x 100
[HIF-1α] siControl
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Figure 4.1 Transfection with different siRNA concentrations and lipofectamine volumes 
Caco-2 cells were seeded at a density of 1.5x105 cells/cm2. On reaching 50% confluence, cells were serum-
starved for 4 hours before transfection with siHIF-1α or siControl at 50 or 100nM, using 0.5, 1.0 or 1.5µL 
of lipofectamine transfection agent, in serum- and antibiotic-free medium. After 6 hours, medium was 
supplemented with serum and antibiotics. 48 hours from the start of transfection, RNA was extracted and 
mRNA expression evaluated by Q-PCR. Cells were incubated in normoxia throughout the experiment. 
Graphs show HIF-1α expression at 50nM (left) and 100nM (right) siRNA, normalised to siControl at 0.5µl 
lipofectamine (dashed line). Data are mean ± SEM from 3 replicate experiments, with ΔCt analysed by 1-
way ANOVA versus siControl (** p<0.01, *** p<0.001, ns = not significant). 
 
Next, the effect of confluence at the time of transfection and of prolonged serum 
starvation was investigated. Cells were seeded in order to reach 25% or 50% confluence at the 
time of transfection. They were serum-starved for a period of either 4 or 20 hours before 
transfection with 50nM siRNA with 1.0µL lipofectamine for 6 hours (Figure 4.2). mRNA was 
extracted after 48 hours. 
The greatest transfection efficiency, resulting in 71% KD, was seen in cells transfected at 
50% confluence and serum-starved for 4 hours (0.29±0.03 for siHIF-1αversus 1.0 for siControl; 
p<0.001). These were the same conditions that achieved 47% KD in the first experiment (Figure 
4.1). 20 hours of serum-starvation resulted in 41% KD (0.28±0.02 versus 0.48±0.03; p<0.01). For 
cells transfected at 25% confluence, 4 hour starvation resulted in 29% KD (0.49±0.01 versus 
0.69±0.06; not significant), while 20 hour starvation led to 56% KD (0.26±0.03 versus 0.58±0.01; 
p<0.01). However, it appears that longer serum starvation and transfection at lower confluence 
also reduces HIF-1α mRNA levels in cells transfected with siControl. 
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Figure 4.2 Effect of confluence and serum starvation using lipofectamine 
Cells were seeded at a density of 1.5 or 0.75x105 cells/cm2, in order to reach 50% or 25% confluence 
respectively at the time of transfection. Medium was replaced with serum-free medium 4 or 20 hours before 
the start of transfection with 50nM siHIF-1α or siControl, using 1.0µL lipofectamine in serum- and 
antibiotic-free medium. After 6 hours, medium was supplemented with serum and antibiotics.48 hours from 
the start of transfection, RNA was extracted and mRNA expression evaluated by Q-PCR. Cells were 
incubated in normoxia throughout the experiment. Graphs show HIF-1α expression in cells transfected at 
50% (left) and 25% (right) confluence, normalised to siControl 50% confluence with 4 hour serum 
starvation (dashed line). Data are mean ± SEM from 2 replicate experiments, with ΔCt analysed by 1-way 
ANOVA versus siControl (** p<0.01, *** p<0.001, ns = not significant). 
To determine the effect of transfection agent, the same experiment was repeated using 
oligofectamine (Figure 4.3). Following manufacturer’s instructions, 200nM siRNA was used with 
1.0µL oligofectamine in a final volume of 250µL (1:250 dilution). Conditions were otherwise 
identical to Figure 4.2. In contrast to lipofectamine, the greatest transfection efficiency was seen 
with 20 hours serum-starvation at 50% confluence, where 77% KD was achieved (0.30±0.02 
versus 1.30±0.07; p<0.001). 4 hours starvation at 50% confluence resulted in 47% KD (0.53±0.04 
versus 1.0; p<0.001). At 25% confluence, 54% KD was seen after 20 hours serum-starvation 
(0.57±0.05 versus 1.22±0.02; p<0.001), while at 4 hours, there was no significant knockdown 
(0.57±0.04 versus 0.60±0.13, 5% KD; not significant). 
To ensure that the lack of greater transfection efficiency was not due to a mechanistic 
effect of silencing the HIF-1α gene, the effect of using a different siRNA was then investigated. 
After 4 hours serum-starvation, cells were transfected at 50% confluence with siFIH-1 at 50, 100 
and 200nM using oligofectamine (Figure 4.4). At 50nM siFIH-1, FIH-1 expression was knocked 
down by 36% relative to control (0.64±0.03 versus 1.0±0.10; p<0.001). At 100nM knockdown 
was 44% (0.59±0.03 versus 1.01±0.08; p<0.001) and at 200nM it was also 44% (0.69±1.21 versus 
1.21±0.07; p<0.001). 
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Figure 4.3 Effect of confluence and serum starvation using oligofectamine 
Cells were seeded at a density of 1.5 or 0.75x105 cells/cm2, in order to reach 50% or 25% confluence 
respectively at the time of transfection. Medium was replaced with serum-free medium 4 or 20hours before 
the start of transfection with 200nM siHIF-1α or siControl, using 1.0µL oligofectamine in 250µL serum- 
and antibiotic-free medium. After 6 hours, 2mL of full medium was added. 48 hours from the start of 
transfection, RNA was extracted and mRNA expression evaluated by Q-PCR. Cells were incubated in 
normoxia throughout the experiment. Graphs show HIF-1α expression in cells transfected at 50% (left) and 
25% (right) confluence, normalised to siControl 50% confluence with 4 hour serum starvation (dashed 
line). Data are mean ± SEM from 2 replicate experiments, with ΔCt analysed by 1-way ANOVA versus 
siControl (*** p<0.001, ns = not significant). 
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Figure 4.4 Transfection efficiency with siFIH-1 using oligofectamine 
Cells were seeded in order to reach 50% confluence at the time of transfection. Medium was replaced with 
serum-free medium 4 hours before the start of transfection with 50, 100 or 200nM sFIH-1 or siControl, 
using 1.0µL oligofectamine in 250 Lserum- and antibiotic-free medium. After 6 hours, 2mL full medium 
was added. 48 hours from the start of transfection, RNA was extracted and mRNA expression evaluated by 
Q-PCR. Cells were incubated in normoxia throughout the experiment. Graphs show FIH-1 expression 
normalised to 50nM siControl (dashed line). Data are mean ± SEM from 3 replicate experiments, with ΔCt 
analysed by 1-way ANOVA versus siControl (*** p<0.001). 
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In these preliminary experiments, the greatest transfection efficiency (77%) was seen 
using oligofectamine with cells serum-starved for 20 hours. However, serum-starvation had a 
profound effect on cell adherence (Figure 4.5), which was taken as a surrogate for viability 
(section 2.1.1). Cell detachment was seen after 4 hours, which significantly increased with 
prolonged serum-starvation. In addition, the 77% KD was achieved using the manufacturer’s 
recommended siRNA concentration of 200nM. This was not dissimilar to the 71% KD achieved 
with 50nM siRNA and 1.0µL lipofectamine (Figure 4.2), a level of transfection that compares 
favourably with the literature (Mizukami et al. 2004; Morel et al. 2008). Therefore the use of 
oligofectamine was abandoned for subsequent experiments, and cells were not serum-starved 
prior to transfection, to preserve viability. 
 
Figure 4.5 Effect of serum starvation on cell attachment 
Cells were seeded at 1.5 x 105 cells/cm2 in order to reach 50% confluence at transfection. At 4 or 20 hours 
prior to the start of transfection using oligofectamine, medium was replaced with serum-free medium (or 
full-medium in the no starvation control, top left). Figure shows photomicrographs taken immediately 
before the start of transfection. There were progressively fewer adherent cells with increasing duration of 
starvation. Scale bar represents 100µm. 
The next step was to scale up the experiments in order to ensure adequate mRNA and 
protein quantities for hypoxia experiments (Figure 4.6, Figure 4.7). Initially, cells were plated in 
6-well plates and were transfected at 50% confluence with no serum starvation. Transfection with 
50nM siHIF-1α, siHIF-2α or siControl was carried out using 6.0uL lipofectamine in a final 
volume of 2mL (1:300 dilution) of serum- and antibiotic-free medium. After 6 hours, medium 
Scale bar = 100µm
No starvation 4 hrs
20 hrs
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was supplemented with serum and antibiotics. After 24 hours, cells were exposed to hypoxia for a 
further 24 hours before supernatants were collected, cells lysed and mRNA and protein extracted. 
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Figure 4.6 Hypoxic HIF-α mRNA expression following selective knockdown 
Cells were transfected in triplicate at 50% confluence for 6 hours with 50nM siHIF-1α, siHIF-2α or 
siControl using 1.0µL lipofectamine. 24 hours from the start of transfection, cells were placed in hypoxia 
(1% O2) for 24 hours with untransfected normoxia (21% O2) controls. Cells were then lysed, RNA was 
extracted, and expression evaluated by Q-PCR. Graph shows HIF-1α (left) and HIF-2α (right) mRNA 
expression normalised to untransfected normoxia (dashed line). Data are mean ± SEM from 3 experiments, 
with ΔCt analysed by 1-way ANOVA versus siControl unless otherwise shown (** p<0.01, ns = not 
significant). 
Figure 4.6 shows HIF-α mRNA expression. With siHIF-1α treatment, HIF-1α expression 
was knocked down by 75% relative to control (fold-change 0.18±0.02 versus 0.71±0.06; p<0.01) 
while HIF-2α expression was unchanged (0.29±0.03 versus 0.31±0.02, 5% KD; not significant). 
With siHIF-2α treatment, HIF-1α was unchanged (0.67±0.06 versus 0.71±0.06, 6% KD; not 
significant) while HIF-2α was knocked down by 72% (0.08±0.01 versus 0.31±0.02; p<0.01). 
Protein expression was then analysed by Western Blot (a representative experiment is 
shown in Figure 4.7). siHIF-1α suppressed HIF-1α protein expression almost completely but did 
not affect HIF-2α expression. Conversely, siHIF-2α significantly reduced HIF-2α protein but did 
not affect HIF-1α. This did not significantly affect cell attachment (Figure 4.8), suggesting that 
the cells remained viable. This transfection protocol gave a transfection efficiency of greater than 
70%, despite the lack of serum starvation, and therefore it was maintained throughout remaining 
transfection experiments. 
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Figure 4.7 Hypoxic HIF-α protein expression following selective HIF knockdown 
Cells were transfected at 50% confluence for 6 hours with 50nM siHIF-1α, siHIF-2α or siControl using 
1.0µl lipofectamine, with untransfected control (U). After incubation in normoxia for 24 hours from the 
start of transfection, cells were placed in hypoxia (1% O2) for 24 hours, with untreated normoxia (N) 
control. Cells were then lysed, protein extracted, and expression evaluated by Western Blot. Figure shows 
HIF-1α (120kD) and HIF-2α (119kD) protein expression from a representative experiment, with α-tubulin 
(50kD) loading control. The blot was cut between N and U to remove an irrelevant lane. 
 
Figure 4.8 Transfected cells remain adherent after 24hours hypoxia 
Cells were transfected at 50% confluence for 6 hours with 50nM siHIF-1α, siHIF-2α or siControl using 
1.0µL lipofectamine with untransfected control (U). After incubation in normoxia for 24 hours from the 
start of transfection, cells were placed in hypoxia (1% O2) for 24 hours with normoxia (21% O2) control 
(N). Figure shows photomicrographs taken at 100x magnification. Scale bar represents 100µm. 
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4.3.2 HIF-α Isoform Knockdown In Hypoxia-Treated Caco-2 Cells 
Having established a reliable transfection protocol, the effect of HIF-α isoform 
knockdown on target genes was investigated. 
4.3.2.1 Known HIF Targets 
Following transfection with siHIF-1α or siHIF-2α, expression of VEGF and BNIP-3 
mRNA were evaluated (Figure 4.9). In cells treated with siControl, VEGF mRNA was 
upregulated by a fold-change of 9.50±1.54 in hypoxia after 24 hours. Expression after siHIF-1α 
treatment was significantly reduced to 5.80±0.76 (p<0.01), while there was a more modest 
reduction with siHIF-2α, at 7.36±0.97 (not significant). BNIP-3 mRNA expression was markedly 
reduced by siHIF-1α compared to siControl (1.83±0.40 versus 5.81±0.82; p<0.05), but unchanged 
by siHIF-2α (4.94±0.92; not significant). 
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Figure 4.9 HIF-α knockdown effect on hypoxia-induction of known HIF target mRNA 
Cells were transfected at 50% confluence for 6 hours with siHIF-1α, siHIF-2α or siControl. After 24 hours 
of incubation, cells were placed in hypoxia (1% O2) for 24 hours with normoxia controls. RNA was 
extracted and expression evaluated by Q-PCR. Graph shows VEGF and BNIP-3 mRNA expression 
normalised to untransfected normoxia (21% O2, dashed line). Data are mean ± SEM from at least 3 replicate 
experiments, analysed by 1-way ANOVA versus siControl unless otherwise shown (* p<0.05, ** p<0.01, 
ns = not significant). 
 
4.3.2.2 Novel Angiogenesis Genes 
The role of HIF-α isoforms in the hypoxia-induced upregulation of the novel genes 
ANGPTL-4, EFNA-3 and TGF-β1 was next examined (Figure 4.10). Hypoxia-induced ANGPTL-
4 mRNA expression in siControl-treated Caco-2 cells (fold-change 12.19±1.01 relative to 
untreated normoxic control) was attenuated by siHIF-1α (5.80±0.48; p<0.001). Expression was 
increased slightly by siHIF-2α (14.38±0.56), but this was not statistically significant. For EFNA-
3, mRNA expression was again attenuated by siHIF-1α relative to siControl (3.65±0.42 versus 
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5.50±0.81 respectively; p<0.05), and to a lesser, statistically non-significant extent, by siHIF-2α 
(4.28±0.60). Hypoxic TGF-β1 expression was attenuated both by siHIF-1α (2.38±0.17 versus 
3.37±0.19; p<0.01), and by siHIF-2α (2.69±0.17; p<0.05).  
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Figure 4.10 Effect of HIF-α isoform knockdown on novel angiogenesis genes 
Cells were transfected siHIF-1α, siHIF-2α or siControl. After 24 hours of incubation, cells were placed in 
hypoxia (1% O2) for 24 hours with normoxia controls. RNA was extracted and expression evaluated by Q-
PCR. Graph shows ANGPTL-4, EFNA-3 and TGF-β1 mRNA expression normalised to untransfected 
normoxia (21% O2, dashed line). Data are mean ± SEM from 5 experiments conducted in triplicate, 
analysed by 1-way ANOVA versus siControl unless otherwise shown (* p<0.05, ** p<0.01, *** p<0.001, 
ns = not significant).  
4.3.2.3 Apoptosis Genes 
The effect of HIF-α isoform knockdown on hypoxia-induced apoptosis gene expression 
was analysed next. As previously shown (Figure 3.7), survivin mRNA expression was reduced in 
hypoxia (siControl fold-change 0.70±0.05 versus untreated normoxic control), and this was 
unaffected by either siHIF-1α or siHIF-2α (0.68±0.07 and 0.70±0.12 respectively; both non-
significant). Similarly for BAX, a more modest reduction by hypoxia (0.84±0.11 relative to 
normoxia; see also Figure 3.7) was unaffected by siHIF-1α and siHIF-2α (0.85±0.07 and 
0.74±0.08 respectively; both non-significant). XIAP expression was unaffected by hypoxia 
(siControl 0.95±0.13 versus normoxia; see also Figure 3.7), siHIF-1α (1.16±0.18) or siHIF-2α 
(0.91±0.24; all non-significant). Bcl-2 expression was similarly unaffected by hypoxia 
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(0.99±0.08; see also Figure 3.7) or siHIF-1α (1.03±0.11). A modest reduction in the presence of 
siHIF-2α was not statistically significant (0.81±0.12). 
Survivin
siControl siHIF-1 siHIF-2
0.0
0.2
0.4
0.6
0.8
1.0
ns
ns
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
BAX
siControl siHIF-1 siHIF-2
0.0
0.2
0.4
0.6
0.8
1.0
ns
ns
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
XIAP
siControl siHIF-1 siHIF-2
0.0
0.5
1.0
1.5
ns
ns
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
Bcl-2
siControl siHIF-1 siHIF-2
0.0
0.5
1.0
1.5
ns
ns
R
e
la
ti
v
e
 m
R
N
A
 e
x
p
re
s
s
io
n
 
Figure 4.11 Effect of HIF-α isoform knockdown on apoptosis gene expression 
Cells were transfected siHIF-1α, siHIF-2α or siControl. After 24 hours of incubation, cells were placed in 
hypoxia (1% O2) for 24 hours with normoxia controls. RNA was extracted and expression evaluated by Q-
PCR. Graph shows BAX, Bcl-2, Survivin and XIAP mRNA expression normalised to untransfected 
normoxia (21% O2, dashed line). Data are mean ± SEM from 2 experiments conducted in triplicate, 
analysed by 1-way ANOVA versus siControl (ns = not significant). 
 
4.3.3 HIF-α isoform knockdown in DMOG-Treated Caco-2 Cells 
The experiments in the previous section were repeated using DMOG stimulation rather 
than hypoxia. Cells were transfected using the protocol developed in Section 4.3.2. After 24 
hours, cells were treated with DMOG 1mM for 24 hours before supernatants were collected, cells 
lysed and mRNA and protein extracted. Figure 4.12 shows HIF-α mRNA expression. 
With siHIF-1α treatment, HIF-1α expression was knocked down by 81% relative to 
control (fold-change 0.22±0.11 versus 1.11±0.09; p<0.05) while HIF-2α expression was 
unchanged (1.00±0.21 versus 1.11±0.09, -10% KD; not significant). With siHIF-2α treatment, 
HIF-1α was unchanged (0.99±0.31 versus 0.86±0.14, -15% KD; not significant) while HIF-2α 
was knocked down by 92% (0.065±0.02 versus 0.86±0.14; p<0.05).  
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Figure 4.12 DMOG-induced HIF-α mRNA expression following selective knockdown 
Cells were transfected in duplicate at 50% confluence for 6 hours with 50nM siHIF-1α, siHIF-2α or 
siControl using lipofectamine. 24 hours from the start of transfection, cells were treated with DMOG 1mM 
for 24 hours. Cells were then lysed, RNA was extracted, and expression evaluated by Q-PCR. Graph shows 
HIF-1α (left) and HIF-2α (right) mRNA expression normalised to untransfected untreated control (dashed 
line). Data are mean ± SEM from 1 experiment conducted in triplicate, with ΔCt analysed by 1-way 
ANOVA versus siControl unless otherwise shown (* p<0.05, ns = not significant). 
Protein expression was analysed by Western Blot (a representative experiment is shown 
in Figure 4.13). siHIF-1α suppressed HIF-1α protein expression markedly. HIF-2α expression was 
perhaps marginally enhanced. Conversely, siHIF-2α significantly reduced HIF-2α protein while 
slightly increasing HIF-1α expression.  
            
Figure 4.13 DMOG-induced HIF-α protein expression following transfection 
Cells were transfected at 50% confluence for 6 hours using lipofectamine only (mock), or with 50nM 
siHIF-1α, siHIF-2α or siControl, or left untransfected (U). 24 hours from the start of transfection, cells were 
treated with 1mM DMOG for a further 24 hours with untreated “normoxia” (N) controls. Cells were then 
lysed, protein extracted, and expression evaluated by Western Blot. Figure shows HIF-1α (120kD) and HIF-
2α (119kD) protein expression from a representative experiment, with α-tubulin (50kD) loading control. 
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4.3.3.1 Known HIF Targets 
Following transfection with siHIF-1α or siHIF-2α, expression of VEGF and BNIP-3 were 
evaluated at mRNA (Figure 4.14) and protein level (Figure 4.15). In cells treated with siControl, 
VEGF mRNA was upregulated by a fold-change of 8.83±0.94 in hypoxia. Expression after siHIF-
1α treatment was significantly reduced to 4.02±1.18 (p<0.05), while there was no reduction with 
siHIF-2α, at 10.59±0.75 (not significant). BNIP-3 mRNA expression was markedly reduced by 
siHIF-1α compared to siControl (0.95±0.24 versus 7.32±1.46; p<0.01), but unchanged by siHIF-
2α (9.65±2.39; not significant). 
To determine whether changes in mRNA were also reflected at the protein levels, 
supernatants were assayed for VEGF, and cell lysates for BNIP-3 (Figure 4.15). VEGF protein 
was undetected in normoxia. In DMOG-treated cells, expression was upregulated to a similar 
extent for untransfected, mock and siControl, at 25.71±0.96, 24.41±3.1 and 26.35±3.89pg/mL 
respectively. siHIF-1α resulted in a 0.46-fold reduction of VEGF expression to 14.1±0.53pg/mL 
(p<0.05), while siHIF-2α increased expression 1.44-fold to 37.94±3.89pg/mL, although this was 
not statistically significant. Low BNIP-3 expression in normoxia was markedly and equally 
upregulated for untransfected, mock and siControl. This was substantially reduced by siHIF-1α, 
but unaffected by siHIF-2α. 
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Figure 4.14 DMOG-induced HIF target mRNA expression 
Cells were transfected at 50% confluence for 6 hours with 50nM siHIF-1α, siHIF-2α or siControl. After 
incubation in normoxia for 24 hours from the start of transfection, cells treated with 1mM DMOG for 24 
hours with normoxia (untreated) controls. Cells were then lysed, mRNA extracted, and expression 
evaluated by Q-PCR. Graph shows VEGF (left) and BNIP-3 (right) mRNA expression normalised to 
untransfected normoxia (dashed line). Data are mean ± SEM from 1 experiment conducted in triplicate, 
with ΔCt analysed by 1-way ANOVA (* p<0.05, ** p<0.01, *** p<0.001, ns = not significant, versus 
siControl unless otherwise shown).  
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Figure 4.15 HIF-α knockdown effect on known HIF target proteins 
Cells were transfected for 6 hours with lipofectamine only (mock) or with 50nM siHIF-1α, siHIF-2α or 
siControl and incubated in normoxia (N). 24 hours from the start of transfection, cells treated with 1mM 
DMOG for 24 hours with untreated controls. Supernatants were collected, cells lysed and protein extracted, 
and protein expression was evaluated. VEGF protein in the supernatant was measured by ELISA (left). 
Data are mean±SD from 1 experiment, with ΔCt analysed by 1-way ANOVA (* p<0.05, *** p<0.001, ns = 
not significant, versus siControl unless otherwise shown). BNIP-3 protein expression (31kD) was evaluated 
by Western Blot (right), with α-tubulin (50kD) loading control. U = untransfected cells exposed to DMOG. 
 
4.3.3.2 Novel Angiogenesis Genes 
The HIF-α isoform dependence of novel genes identified in Chapter 3 is shown in Figure 
4.16. DMOG was a potent inducer of ANGPTL-4 mRNA, with a fold-change of 31.82±2.23 for 
siControl relative to untreated control. siHIF-1α reduced this substantially to 5.74±1.07, while 
siHIF-2α increased it to 52.37±3.52 (p<0.001 for both). A fold-change in EFNA-3 expression of 
7.35±0.76 for siControl was reduced by siHIF-1α (4.36±0.49), and to a lesser extent by siHIF-2α 
(5.20±0.51), but did not reach statistical significance in either case. TGF-β1 expression was 
21.48±0.52 for siControl, which was reduced to 2.46±0.74 (p<0.001) by siHIF-1α. siHIF-2α had 
little effect (14.73±2.38, non-significant). 
Data from Chapter 3 showed that PHD-2 and PHD-3 were upregulated by hypoxia and 
DMOG. Differential regulation of these enzymes by HIF-1α and HIF-2α has been reported in 
glioblastoma (Henze et al. 2010). The effect of selective HIF-α knockdown in Caco-2 cells was 
investigated next. 
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Figure 4.16 Effect of HIF-α isoform knockdown on novel angiogenesis genes in DMOG 
Cells were transfected at 50% confluence for 6 hours with 50nM siHIF-1α, siHIF-2α or siControl. 24 hours 
from the start of transfection, cells treated with 1mM DMOG for 24 hours with normoxia (untreated) 
controls. Cells were then lysed, mRNA extracted, and expression evaluated by Q-PCR. Graph shows 
ANGPTL-4 (top left) EFNA-3 (top right) and TGF-β1 (bottom) mRNA expression normalised to 
untransfected normoxia (dashed line). Data are mean ± SEM from 1 experiment conducted in triplicate, 
with ΔCt analysed by 1-way ANOVA (*** p<0.001, ns = not significant, versus siControl unless otherwise 
shown). 
The results of these experiments, which sought to characterise the relative roles of HIF-1α 
and HIF-2α in the regulation of downstream HIF targets, are summarised in Table 4.1 below. 
Isoform-specificity in the HIF-dependent regulation of HIF regulatory enzymes was also 
investigated (next section). 
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Table 4.1 Isoform dependence of HIF-targets in Caco-2 cells 
Table summarises HIF-α isoform dependence at mRNA level in Caco-2 cells stimulated with either hypoxia 
or DMOG. ND = not determined. (Brackets indicate statistically non-significant; * also seen at protein 
level.) 
GENE Hypoxia DMOG 
ANGPTL-4 
HIF-1 α 
(HIF-2α negative role) 
HIF-1 α 
HIF-2α negative role 
EFNA-3 
HIF-1 α  
(HIF-2α) 
(HIF-1 α, HIF-2α) 
TGF- 1 
HIF-1 α  
HIF-2α 
HIF-1 α 
(HIF-2α negative role) 
VEGF 
HIF-1α  
(HIF-2α)  
HIF-1* 
(HIF-2α negative role)* 
BNIP-3 HIF-1α HIF-1 α* 
 
4.3.3.3 HIF Regulatory Enzymes 
DMOG-induced expression of PHD-2 and PHD-3 mRNA following HIF-α knockdown is 
shown in Figure 4.17. PHD-2 expression for siControl was 3.07±0.34, and was markedly reduced 
to 0.80±0.11 (p<0.001) by siHIF-1α but unaffected by siHIF-2α at 3.15±0.54 (not significant). 
PHD-3 was strongly upregulated in siControl at 7.96±1.29. This was markedly suppressed by 
siHIF-2α at 3.24±0.31 (p<0.01). A more modest effect was seen with siHIF-1α at 4.81±0.96, 
which did not reach statistical significance. 
It has been previously reported that PHD-2 is exclusively HIF-1α dependent, as shown 
here, while PHD-3 is a target for both HIF-α isoforms (Aprelikova et al. 2004). Since HIF-1α 
suppression of PHD-3 was not statistically significant at mRNA level, expression at the protein 
level was evaluated by Western Blot (Figure 4.18). The modest reduction of PHD-3 mRNA by 
siHIF-1α was not seen at protein level, but there was significant protein downregulation following 
siHIF-2α treatment. 
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Figure 4.17 Effect of HIF-α isoform knockdown on DMOG-induced HIF regulatory 
enzymes at mRNA level 
Cells were transfected at 50% confluence for 6 hours with 50nM siHIF-1α, siHIF-2α or siControl. 24 hours 
from the start of transfection, cells treated with 1mM DMOG for 24 hours with normoxia (untreated) 
controls. Cells were then lysed, mRNA extracted, and expression evaluated by Q-PCR. Graph shows PHD2 
(left) and PHD3 (right) mRNA expression normalised to untransfected normoxia (dashed line). Data are 
mean ± SEM from 1 experiment conducted in triplicate, with ΔCt analysed by 1-way ANOVA (** p<0.01, 
*** p<0.001, ns = not significant, versus siControl unless otherwise shown). 
 
                        
Figure 4.18 Effect of HIF-α isoform knockdown on DMOG-induced PHD-3 protein  
Cells were transfected at 50% confluence for 6 hours using lipofectamine only (mock) or with 50nM siHIF-
1α, siHIF-2α or siControl, or left untransfected (U). 24 hours from the start of transfection, cells were 
treated with 1mM DMOG for 24 hours with untreated “normoxia” (N) controls. Cells were then lysed, 
protein extracted, and PHD-3 (27kD) expression was evaluated by Western Blot, with α-tubulin (50kD) 
loading control.  
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4.4 Discussion 
In contrast to other cell-types with which our lab has experience (e.g. synovial fibroblasts, 
skin fibroblasts, endothelial cells, smooth muscle cells), Caco-2 cells initially proved to be 
difficult to transfect. The manufacturer’s literature provided only general guidelines for 
optimising transfection, while the published literature was often unhelpful, in that transfection 
protocols lacked sufficient detail. Despite variation in siRNA concentration, transfection agent 
type and concentration, cell-confluence and serum-starvation, mRNA transfection efficiencies 
remained initially between 50 and 70%. This is comparable to some of the literature. For example 
Mizukami et al. and Morel et al. reported transfection efficiencies of 50-60% (Mizukami et al. 
2004; Morel et al. 2008). However, as the experiments were scaled up, and perhaps as proficiency 
with the technique improved, knockdown efficiencies of 70-90% were achieved. Of note, at these 
levels, HIF-α protein expression was markedly reduced. 
It is interesting to note that although HIF-1 protein levels were upregulated by hypoxia, 
mRNA expression was significantly downregulated. This supports predominance of post-
translational regulation of HIF-α by PHD and FIH-1) under hypoxic conditions. Hypoxic mRNA 
suppression was more pronounced for HIF-2α than for HIF-1α, but was not seen with DMOG 
stimulation. This is in contrast to a study by Bruning et al., who reported HIF-1α suppression, but 
no change in HIF-2α in Caco-2 cells. In this study, cells were fed with preconditioned media to 
achieve instantaneous hypoxia, whereas in my study, hypoxia was achieved gradually – whether 
this explains the discrepancy is unclear. Hypoxic suppression of HIFα mRNA has been described 
previously in mouse liver (Wenger et al. 1998) and for both HIF-1α (Larsen et al. 2012) and HIF-
2α in rheumatoid synoviocytes in our own laboratory Dr. Barbara Muz, unpublished data) (Table 
4.2). Interestingly, in lung tissue while HIF-1α was downregulated, HIF-2α was in fact 
upregulated (Uchida et al. 2004; Chen et al. 2006) by hypoxia. Further studies reveal variation in 
HIF-α isoform responses to chemical inhibition of PHD and FIH-1. Differential regulation was 
observed in DMOG-stimulated synoviocytes by Muz, and in hepatoma cells stimulated with 2,2 
dipyridyl (DP, a PHD- and FIH-1-inhibiting hypoxia-mimetic) by Warnecke et al. (Warnecke et 
al. 2008). 
The downregulation of HIF-1α mRNA may be explained by negative feedback involving 
the naturally-occurring antisense transcript (aHIF), which destabilises HIF-1α mRNA by 
recognising homologous sequences (Thrash-Bingham and Tartof 1999). Our group has shown that 
hypoxia, and more potently by DMOG, upregulate aHIF in synoviocytes, subsequently decreasing 
HIF-1  mRNA (Dr Helene Larsen, unpublished data). Moreover, aHIF contains an HRE and is 
HIF-1 -dependent, implicating it in a negative feedback loop with HIF-1α. A further mechanism 
by which HIF-1α mRNA may be downregulated by hypoxia involves a so-called reverse HRE 
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(rHRE) sequence reported in the HIF-1α promoter region (Xu et al. 2012). rHREs are 
conventional HRE sequences found on the minus DNA strand, and are associated with 
transcriptional repression by hypoxia (Narravula and Colgan 2001; Mazure et al. 2002). Xu et al. 
reported that both HIF-1α and HIF-2α protein can bind the rHRE in the HIF-1α promoter, 
resulting in epigenetic modifications that suppress HIF-1α transcription. This was observed in 
renal cancer cells that are deficient in vHL, and resulted in a shift from HIF-1α to HIF-2α 
dominance, resulting in tumour progression. Whether a similar mechanism exists in vHL-
competent cells such as Caco-2 is unknown. 
Table 4.2 Regulation of HIF-α mRNA by hypoxia and enzyme inhibitors 
There is variation in HIF-1α and HIF-2α mRNA expression in response to hypoxia and/or hypoxia-mimetic 
drugs in different tissues. (DMOG: Dimethyloxalylglycine; DP: 2,2dipyridyl. ND = not determined.) 
Tissue HIF-1α HIF-2α Reference 
 Hypoxia 
PHD/FIH-1 
inhibition 
Hypoxia 
PHD/FIH-1 
inhibition 
 
Synoviocytes ↓ ↓↓ ↓ ↑ Muz 2011 (DMOG) 
Liver ↓a →b ND ↑b 
a
Wenger 1998 
b
Warnecke 2008 (DP) 
Lung ↓ ND ↑ ND 
Uchida 2004, Chen 
2006 
Colon ↓ ND → ND Bruning 2011 
 
Further insight into the complex regulation of HIF-1  comes from the hypoxic induction 
of microRNAs (miRNAs) which has been reported in breast and colon cancer cell-lines (Camps et 
al. 2008; Bruning et al. 2011). miRNAs are short non-coding RNA sequences that bind 
complementary sequences on target mRNA resulting in translational repression and/or target 
degradation. Bruning et al. described the HIF-1 -dependence of miRNA-155 in Caco-2 cells, 
concluding that it is involved in a negative feedback loop that suppresses HIF-1α activity in cells 
exposed to prolonged hypoxia.  
The experiments described herein show greater suppression of HIF-2α than HIF-1α 
mRNA by hypoxia. It seems likely that there is a negative feedback mechanism that regulates 
HIF-2α in a similar manner to HIF-1α, but neither an antisense transcript, an rHRE nor an miRNA 
has been described.  
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Of the PHD enzymes, PHD-1 and PHD-3 are distinct from PHD-2. The latter, which is 
older in evolutionary terms (Rytkönen et al. 2011), is more involved in the regulation of HIF-1α 
(also more “primitive” than HIF-2α), and is itself a HIF-1α rather than a HIF-2α target 
(Aprelikova et al. 2004), as supported by the data in the current study. Aprelikova et al. also 
reported that regulation of PHD-2 levels was biphasic, with HIF-independent mechanisms 
responsible for initial induction (up to 4 hours), and HIF-1α coming into play in prolonged 
hypoxia. By contrast PHD-1 and PHD-3 are involved in HIF-2α regulation (Takeda et al. 2007; 
Aragones et al. 2008; Takeda et al. 2008). However, as in the current study, PHD-3 can be 
regulated by both HIF-1α and HIF-2α (Aprelikova et al. 2004), although HIF-2α is the more 
potent.  
HIF-α isoform dependence of HIF target genes is shown in Table 4.1. In experiments 
conducted in hypoxia, HIF-1α knockdown was consistently found to reduce hypoxic VEGF 
expression at the mRNA level. HIF-2α knockdown had a similar but weaker effect, which did not 
reach statistical significance. However following DMOG stimulation, while HIF-1α knockdown 
again downregulated VEGF, there was a trend towards upregulation of VEGF following HIF-2α 
knockdown. This was more pronounced at mRNA than at protein level (although again did not 
reach statistical significance). The results in hypoxia are supported by data from Imamura et al. 
(Imamura et al. 2009). Using the CRC cell-line SW480, HIF-1α or HIF-2α were stably knocked 
down and the cells introduced into immunodeficient mice. VEGF protein expression in the 
resulting tumours was 50% lower than controls in HIF-1α deficient tumours, and 20% lower in 
HIF-2α deficient tumours. In the breast cancer cell-line MCF-7, however, while HIF-1α 
knockdown suppressed VEGF protein expression, HIF-2α knockdown in fact increased it, 
reflecting my findings in DMOG stimulated Caco-2 (Carroll and Ashcroft 2006).  
This reciprocal relationship between the HIF-α isoforms has also been reported in 786-O 
cells (Raval et al. 2005). Carroll and Ashcroft also found VEGF to be almost exclusively HIF-2α 
dependent in the renal carcinoma cell-lines RCC4 and 786-0. Both of these cell-lines lack a 
functioning vHL, and HIF-2α exclusivity of VEGF regulation in vHL deficiency has also been 
reported in liver tissue (Rankin et al. 2008). In the canonical HIF pathway, vHL-mediated 
ubiquitination leads to degradation of both HIF-α isoforms. However, that vHL function is closely 
related to HIF-α isoform selectivity is supported by data from Koh et al. who described a novel 
E3-ubiquitin ligase, the hypoxia-associated factor (HAF) (Shahrzad et al. 2010). HAF selectively 
targets HIF-1α for vHL-independent degradation, while promoting HIF-2α activity (Dang et al. 
2006). In addition, p53 is a negative regulator of HIF-1α (Ravi et al. 2000). It may be that 
suppression of HIF-1α in these tumours promotes a switch to HIF-2α-dependent hypoxia 
responses (Koh et al. 2011; Seton-Rogers 2011).  
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Regulation of TGF-β1 closely resembled that of VEGF, with both HIF-α isoforms 
regulating it in hypoxia (HIF-1α slightly predominating), and a trend towards a suppressive role 
for HIF-2α following DMOG stimulation. This is supported by a study in lung epithelial cells 
which showed that hypoxic induction of TGF-β1 is dependent on both HIF-α isoforms (DMOG 
not investigated) (Zhou et al. 2009). The interaction between TGF-β1, hypoxia and HIF is 
complex. In normoxic conditions, TGF-β1 can induce both HIF-α isoforms (Chae et al. 2011) and 
VEGF (Sánchez-Elsner et al. 2001). TGF-β1 signalling is mediated by the Smad family of 
transcriptional co-modulators, one of which (Smad3) can cooperate with both HIF-1α and HIF-
2α. However, the interactions have opposing effects, with HIF-2α interaction increasing TGF-β1-
induced VEGF, and HIF-1α suppressing it.  
Of the 5 apoptosis genes investigated, only BNIP-3 showed HIF-dependence. The 
hypoxic induction of BNIP-3 is well-described in the literature. As in the current study, BNIP-3 
has been widely described as a HIF-1α target (Sowter et al. 2001; Greijer and van der Wall 2004). 
In the presence of acidosis, such as is seen in prolonged hypoxia, BNIP-3 leads to the elimination 
by apoptosis of stressed cells (Wang 2012). This requires the presence of wild-type p53, which is 
itself stabilised by HIF-1α. The pro-apoptotic effect of BNIP-3 is abrogated if p53 is mutated, as 
in Caco-2 cells and in many cancers, protecting the cells from hypoxia-induced cell-death (Fei et 
al. 2004). As discussed in Chapter 3, both up- and downregulation of BNIP-3 expression has been 
described in CRC (Bacon et al. 2006). In this study, BNIP-3 was induced by hypoxia in some 
CRC cell-lines but not others. Cell-lines that did not upregulate BNIP-3 were resistant to hypoxia-
induced apoptosis. However, Bacon et al. found no correlation between BNIP-3 hypoxia response 
and p53 status. Of note, in the vHL-deficient renal cancer cell-line RCC4, which constitutively 
overexpresses HIF-1α and HIF-2α, BNIP-3 is unresponsive to HIF-1α but strongly down-
regulated by HIF-2α (Raval et al. 2005).  
The three novel hypoxia-induced angiogenesis genes identified by PCR array in Chapter 
3 were all found to be HIF targets. My data show clear HIF-1α regulation of ANGPTL-4 in Caco-
2. In addition, a reciprocal effect was seen with HIF-2α (as with VEGF). This was seen in both 
hypoxia and DMOG stimulation, while for VEGF it was seen following DMOG only. HIF-1α 
dependence of ANGPTL-4 has been reported in endothelial cells and cardiomyocytes (Belanger et 
al. 2002; Manalo et al. 2005). These studies did not investigate HIF-2α. Two studies have shown 
downregulation of ANGPTL-4 following inhibition of either HIF-α isoform, in breast cancer 
(Zhang et al. 2012) and CRC (Burkitt et al. 2009). 
The function of Ephrin-A3 has been discussed in detail in Chapter 3. Bidirectional 
signalling of the ephrin ligand-receptor system regulate cell motility by modulating changes in 
attraction and repulsion between cells, guiding migrating cells along precise paths. Aberrant 
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expression of ephrin receptors in CRC correlates with prognosis (Jubb et al. 2005; Herath et al. 
2009). Hypoxia induction of ephrin-A3 has been described in prostate and hepatoma cell-lines 
(Vihanto et al. 2005) but not in CRC. The involvement of HIF in ephrin-A3 regulation has not 
previously been investigated in cancer. Recent work in our laboratory identified ephrin-A3 as a 
HIF-1α target in rheumatoid fibroblasts, with no involvement of HIF-2α (Larsen et al. 2012). 
While my experiments confirm that ephrin-A3 is HIF regulated in Caco-2 cells, the data suggests 
that both isoforms may play a role, although the effect of HIF-2α did not reach statistical 
significance. 
The difference between HIF-α isoform specificity in hypoxia versus DMOG stimulated 
cells, such as is most clearly seen with VEGF and TGF-β1, indicates that there may be HIF-
independent mechanisms involved in the regulation of these genes. HIF-independent mechanisms 
of hypoxic VEGF regulation have been postulated (Mizukami et al. 2007).  This may be through 
HIF-independent hypoxic induction of other transcription factors such as NF-κB and AP-1 
(Schmidt et al. 2007), or through miRNAs (Hua et al. 2006). HIF-independence of VEGF and 
TGF-β1 hypoxia induction in Caco-2 could be confirmed by double knockdown of HIF-1α and 
HIF-2α, or knockdown of HIF-β. 
Preliminary experiments to investigate effects of HIF knockdown on Caco-2 cell function 
were performed (section 0). Firstly, Caco-2 cells transfected with siHIF-1α or siHIF-2α were 
incubated in normoxia for 5 days (photographed daily, Figure 7.1), and trypsinised and counted at 
the end of the experiment. Cell counts were reduced approximately equally in siHIF-1α and 
siHIF-2α treated cells (by 34% and 40% respectively; Figure 7.2). This may have been due to 
reduced proliferation or increased cell-death/apoptosis. Therefore a BrdU (bromodeoxyuridine) 
proliferation assay was used, in which the labelled thymidine analog (BrdU) is incorporated into 
cellular DNA in proportion to proliferation. Proliferation was measured at 24 and 48 hours in cells 
transfected with siHIF-1α or siHIF-2α (Figure 7.3). At both time-points, siHIF-2α reduced 
proliferation (by 26.9% at 24 hours, and 32% at 48 hours; p<0.01 versus siControl for both), 
while small changes for siHIF-1α were statistically not significant (9% reduction at 24 hours, 14% 
increase at 48hrs). These experiments need to be repeated in hypoxia. Cautious interpretation of 
these preliminary results suggests that HIF-2α may have an anti-proliferative role in Caco-2 cells, 
as has been reported in HCT116 cells (Franovic et al. 2009). Attempts to examine HIF isoform 
roles in angiogenic function, by investigating the effect of conditioned media on endothelial cell 
migration, encountered technical difficulties, and further work is required to optimise the assay. 
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Summary 
The objective of this chapter was to investigate the relative contributions of the HIF-α 
isoforms in CRC tumourigenesis. Some studies point to the primacy of HIF-1α regulation, while 
others suggest that HIF-2α is dominant. The data from my experiments demonstrate that of 
angiogenesis-related genes investigated, all were subject to HIF-1α-mediated upregulation when 
stimulated by either hypoxia or DMOG. For some genes, namely ephrin-A3, TGF-β1 and PHD-3, 
HIF-2α also contributed to hypoxia induction. An interesting finding was a possible reciprocal 
role of the isoforms, particularly in DMOG stimulated cells, which has been previously suggested 
in breast and renal cancer. The importance of the HIF pathway in cancer makes it an attractive 
target for therapeutic inhibition. This data suggests that selective HIF-1α inhibition may be 
undesirable. Further work, including simultaneous knockdown of HIF-α isoforms and functional 
studies, is required to further examine the significance of these results.  
As with other cancers, it is clear that CRC is a highly heterogeneous disease, and that 
tumour cells from different patients, and within a single tumour, differ significantly in genotype 
and phenotype. Translation of results derived from a monoclonal cell-line is therefore potentially 
problematic. This can be partly addressed by the use of multiple cell-lines. In order to address this 
issue, I adopted an alternative strategy. The experiments in Chapter 5 sought to establish primary 
cultures derived directly from tumour tissue, in order to compare hypoxia-responses with those of 
Caco-2 cells. Concordance between results from the two cell-types would lend support to the 
validity of the results in Chapter 3 and Chapter 4. 
 
Chapter 5 
130 
 
 
 
 
 
 
 
 
Chapter 5 
  
Chapter 5 
131 
5 TUMOUR-DERIVED CULTURES OF PRIMARY CRC CELLS: 
CHARACTERISATION OF RESPONSES TO HYPOXIA 
5.1 Introduction 
In the experiments described in Chapter 3 and Chapter 4, the roles of the HIF-α isoforms 
in the regulation of angiogenic genes in CRC were explored using the Caco-2 cell-line. Cell-lines 
are invaluable in furthering our understanding of tumour biology and elucidating potential targets 
for therapies. Their ubiquity in cell biology research stems from a number of factors, including 
ease of use, ready availability and relatively low financial cost. They allow the focussed 
investigation of dynamic cell responses to myriad stimuli in carefully controlled experimental 
conditions. Perhaps their most valuable feature is their clonogenic capability, which allows them 
to consistently reproduce cell populations with identical properties. The homogeneity and stability 
of these cell-systems allows consistent experimental observations, strengthening the validity of 
comparisons between different studies. In addition, the biology of commonly-used lines is well-
characterised, and careful selection of the appropriate cell-line allows isolation of certain factors 
for investigation, such as the presence or absence of particular mutations. 
However, cell-lines suffer considerable limitations. Most importantly, the homogeneity 
that yields the benefits described above means that the in vitro experimental environment is, by 
necessity, far from representative of the in vivo milieu. The tumour microenvironment consists of 
a wide variety of both cellular and non-cellular elements, all of which interact in a dynamic and 
highly complex manner. It has a significant contributory role in the transformation, survival, 
proliferation, invasion and metastasis of cancer cells. The ability to translate findings from cell-
line experiments is therefore significantly limited by the very lack of complexity that makes cell-
line cultures so useful. Furthermore, a fundamental concept in the use of such models is that the 
cell-line selected represents its originating cell-type. However, the genetic stability of cell-lines is 
by no means absolute. Over time, cell-lines may acquire multiple genetic mutations. losing 
important characteristics of the original cell and gaining novel ones. Since genetic instability is 
one of the hallmarks of cancer, this “genotypic drift” is of particular concern in lines derived from 
cancer cells. In addition to this, cross-contamination and misidentification has been reported to 
affect up to a third of cell-lines held in major repositories (Hughes et al. 2007). Finally, in recent 
years it has become clear that CRC is a highly heterogeneous disease, with a great degree of 
variation between tumours from different patients, and even between synchronous tumours in the 
same patient (Mizukami et al. 2004). Indeed, even within a single tumour, a high degree of 
genotypic and phenotypic diversity is seen (Morel et al. 2008). This further limits the ability of a 
homogenous cell-line to model the behaviour of “real” cancer cells. The use of several cell-lines 
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can only partially mitigate this deficiency. Taken together, these factors may call into question the 
validity of data obtained from cell-line work. 
One way to address some of these limitations is to establish de novo cell cultures directly 
from patient tissue. Such cultures retain differentiated features of the originating tissue, allowing 
more robust translation of experimental data. To this end, a variety of methods have been 
employed to establish CRC from ascitic effusions, metastatic tissues (regional lymph nodes and 
distant metastatic sites), and primary tumours. While cell-lines are more readily established from 
ascitic fluid than from primary tumours, these usually contain non-epithelial cells (e.g. 
mesothelial cells, lymphocytes) which, although more readily propagated, do not originate from 
the site of primary tumour, and thus are not representative of the primary cancer. Alternative 
methods of establishing cell cultures directly from tumour tissue include explantation techniques, 
or dissociation of cancer cells from primary tissue either by enzymatic digestion or mechanical 
spill-out technique. The procedure of disaggregating solid colorectal tumours to produce cell 
suspensions by enzymatic digestion, typically with collagenase, has previously been described 
(Thrash-Bingham and Tartof 1999; Aragones et al. 2008; Camps et al. 2008; Rankin et al. 2008; 
Rytkönen et al. 2011). A similar technique has been successfully employed in our laboratory to 
culture cells from human atherosclerotic plaques and rheumatoid arthritic (RA) tissue, allowing 
the study of pathways underlying their pro-inflammatory components (Brennan et al. 1989a; 
Feldmann and Maini 2003; Monaco et al. 2004). Significantly, the technique employed in our 
laboratory did not aim to establish de novo cell-lines, but used short-term cultures of less than 7 
days. Also significant is that these cultures are heterogeneous, since they are not purified or 
enriched to isolate a particular cell-type. Therefore they more accurately model in vivo inter-
cellular interactions. 
The establishment of CRC cell cultures from primary tissue is challenging. Problems 
encountered include microbial infection, contamination and overgrowth of fibroblasts, selective 
isolation of viable clusters of cancer cells from a milieu of dead and dying cells, and the inability 
of cell-lines to grow and propagate (Franks 1976; Park et al. 2004). The difficulty in overcoming 
these challenges in order to sustain such cultures beyond a few days is borne out by previous 
work in our laboratory (Mr. T. Khong, MD(Res) thesis, Imperial College London, 2009; 
unpublished data). 
In this study, the decision was taken to bypass the difficulties of attempting to maintain 
tumour-derived cultures (TDCs) indefinitely, but instead to use the cultures while they remained 
viable (within 48 hours of being isolated), to investigate hypoxia-responses. In addition to the 
TDCs more closely resembling in vivo behaviour than Caco-2 cells, the use of the same hypoxia-
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stimulation system in both cell-types would allow more robust comparisons to be drawn, 
providing a degree of validation for the results presented in Chapters 3 and 4. 
5.2 Objectives 
The objective of this part of my study was to establish short-term ex-vivo cultures of a 
heterogeneous cell population isolated from CRC tissue following surgical resection of the 
tumour. These tumour-derived cultures (TDCs) would be characterised by assessing morphology, 
as well evaluating expression of epithelial cell markers Ep-CAM (Epithelial Cell Adhesion 
Molecule) and VE-Cadherin, and the CRC tumour marker carcinoembryonic antigen (CEA). 
Subsequently, TDCs would be maintained for less than 48 hours during which time hypoxia-
stimulation studies would be performed, with a focus on angiogenic gene expression. Results 
would then be compared with those of Caco-2 cells described in Chapter 3. 
5.3 Results 
5.3.1 Demographics of CRC patients in study 
Tissue was obtained from a total of 34 patients, of which 15 were male and 19 were 
female (Table 5.1). The male to female ratio was 0.79:1, which is lower than the national figure of 
1.23:1, but this difference was not statistically significant (p=0.19, Chi-squared test). The median 
age overall was 70.5 (range 51-91, mean±SEM 69.9±1.7 years) which is close to the national 
median age at diagnosis of 71. There was no difference in mean age between genders (male 
69.9±2.4 years, female 69.1±2.4 years; p=0.68, unpaired t-test). 
Table 5.1 Patient demographics for tumour samples 
Table shows age and sex information for patients from whom tumour samples were obtained. 
Parameter All Male Female 
n 34 15 19 
% - 44.1 55.9 
Mean Age, years ± SEM 
(range) 
69.9 ± 1.7 
(51-91) 
69.1 ± 2.4 
(56-85) 
70.5 ± 2.4 
(51-91) 
 
Pathological characteristics obtained from the histopathology reports for all 34 patients 
are shown in Table 5.2. A total of 17 (50%) of the tumours were located in the right colon 
(proximal to splenic flexure), 8 (23.5%) were in the left colon (between splenic flexure and recto-
sigmoid junction), and 9 (26.5%) were rectal (distal to recto-sigmoid). National figures from 
2007-2009 show a more even distribution than in this cohort (right 32.9%, left 35.2% and rectum 
31.9%) (Cancer Research U.K. 2012).  
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There were 4 Dukes’ A (12.1%), 12 Dukes’ B (36.4%), 13 Dukes’ C (39.4%) and 4 
Dukes’ D tumours (12.1%). One tumour was a mucinous cystadenoma, a benign tumour of the 
appendix, and therefore the Dukes’ staging was not applicable. National figures for Dukes’ Stage 
distribution are incomplete, with 34% of cases being unclassified (National Cancer Intelligence 
Network 2009). When unknown cases are excluded, the distribution of Dukes’ Stage in national 
data is very similar to this cohort (Table 5.2).  
Table 5.2 Pathological characteristics of tumours 
Table shows pathological data obtained from histopathological reports for all 34 tumours (n/a = not 
applicable). Data in the literature is shown for comparison: a(Cancer Research U.K. 2012), b(National 
Cancer Intelligence Network 2009),c(Athas 2004). 
Parameter n % Literature (%) 
Site 
Right (Proximal) colon 17 50.0 32.9
a
 
Left (Distal) colon 8 23.5 31.9
 a
 
Rectum 9 26.5 35.2
 a
 
Dukes’ Stage 
A 4 12.1 13.8
 b
 
B 12 36.4 36.9
b
 
C 13 39.4 35.4
b
 
D 4 12.1 13.8
b
 
n/a 1  
Differentiation 
well 0 0 12.4
 c
 
moderate 21 63.6 60.5
 c
 
poor 11 33.3 25.9
 c
 
undifferentiated 1 3.0 1.3
 c
 
 
In this cohort 21 tumours (63.6%) were moderately differentiated, 11 were poorly 
differentiated (33.3%) and 1 (3.0%) was undifferentiated. There were no well-differentiated 
tumours. National data on differentiation for the UK is not available. A British study by Roxburgh 
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et al. found a lower rate of higher grade tumours (13% poor or undifferentiated) than in the 
current cohort (Roxburgh et al. 2010). However Dukes’ D cancers were excluded in that study. 
An American study using national cancer registry data found comparable rates, the main 
difference being the absence of any well-differentiated tumours in the current cohort (Athas 
2004). 
5.3.2 Characterisation Of TDCs 
Following a process of mechanical and enzymatic digestion, cells were separated from 
undigested tissue by filtration. After density-gradient separation to remove red blood cells, the 
remaining cells were counted. Cell yields varied considerably, from 2.5x10
5
 to 1x10
7
cells/ml. The 
amount of starting material also varied considerably (from 0.08 to 2.62g), and was correlated to 
the total cell yield (R
2
= 0.35, p<0.01; data not shown). Cells were then seeded, in duplicate or 
triplicate wells where possible, aiming for a cell density of 5x10
4
 cells/cm
2
, and incubated in 
normoxia. In subsequent hypoxia experiments, a second plate was seeded. Because of the 
variation in total cell yields and preference for replicate wells, the actual cell density ranged from 
2.0x10
4
 to 7.5x10
4
cells/cm
2
 (mean 4.6x10
4
 cells/cm
2
). Each TDC comprised cells from an 
individual patient. 
The cell population was of mixed morphology and size, with some single cells as well as 
many forming clumps, as illustrated in Figure 5.1. While some cells were adherent, many of the 
smaller cells remained in suspension. At low magnification, the smaller cells resembled adherent 
Caco-2 cells at low confluence. At higher magnification, some of the smaller cells appeared to be 
anucleate, suggesting that some RBCs remained despite the density-gradient separation step.  
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Figure 5.1 Phase-contrast microscopy of tumour-derived cell culture after 24 hours 
Cells obtained following mechanical and enzymatic digestion of tissue from a single CRC specimen were 
seeded at a cell density of 5x104 cells/cm2and incubated in normoxia. Photos taken at 24 hours at 40x (top 
left), 100x (bottom left) and 200x (bottom right) magnification show a heterogeneous population of cells. 
Caco-2 cells at low confluence (40x magnification) are shown in the top right panel for comparison. Scale 
bar represents 50µm. 
 
When the cultures were maintained for 7 days, this heterogeneity persisted. There 
appeared to be some proliferation, particularly of the larger adherent cells, with some cells 
aggregating into islands (Figure 5.2). Caco-2 proliferated at a much higher rate, and by this time-
point were fully confluent. There was an increased amount of acellular debris, indicating 
significant cell-death. This was similar to previous experience in our laboratory in a study by Mr. 
T. Khong, who found that despite using various specialised culture media, these cells were 
difficult to maintain beyond a few days (unpublished data), with infection being common 
problem. This experience contributed to the decision to limit the objectives of this study to the 
maintenance of cultures for less than 48 hours, which was sufficient time for hypoxia-stimulation 
experiments. 
 
TDC
TDC TDC
Caco-2
Scale bar = 50µm
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Figure 5.2 Phase contrast microscopy of TDCs after 7 days 
Cells obtained following mechanical and enzymatic digestion of tissue from a CRC specimen were seeded 
at a cell density of 5x104 cells/cm2and incubated in normoxia, with medium refreshed every 48hours. 
Photos are of the same culture as in Figure 5.1, taken after 7 days at 40x (top left), 100x (bottom left) and 
200x (bottom right) magnification. Some aggregation of large polygonal cells into islands is seen, notably 
in the centre of the image, with a small number of isolated cells peripherally, some with spindle-like 
morphology. Caco-2 cells close to confluence (40x magnification) are shown in the top right panel for 
comparison. Scale bar represents 50µm. 
 
In order to further characterise these mixed cultures, expression of epithelial cell-markers 
Ep-Cam and VE-Cadherin, and the CRC tumour marker CEA, were evaluated. After overnight 
incubation in normoxia, supernatants were collected and RNA extracted. RNA was obtained for 
22 of the 34 TDCs, with RNA yields per condition ranging from 297ng (9.89ng/µL) to 6.62mg 
(220ng/µL). Of these, 9 yielded less than the minimum RNA concentration required to make 
cDNA (22.72ng/µL for one RT-PCR reaction). RNA yield and cell yield showed a linear 
correlation (R
2
 = 0.55, p<0.001; data not shown) 
As shown in Figure 5.3, Ep-CAM was expressed in all TDCs tested, with significant 
variation in expression levels between different donors (2
-ΔCt
 range 1.22x10
-6
 to 6.75x10
-4
). The 
expression level in TDCs was very similar to that in Caco-2 cells, the mean 2
-ΔCt
 values being 
1.01±0.41x10
-4 
and 0.84±0.17x10
-4
 respectively (not significant, unpaired t-test). VE-Cadherin 
was more weakly expressed (assuming comparable primer efficiencies) than Ep-CAM both in 
both Caco-2 cells and TDCs. It was expressed in all TDCs, with greater donor variation than for 
TDC TDC
TDC Caco-2
Scale bar = 50µm
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Ep-CAM (2
-ΔCt
 value range 2.02x10
-8
 to 3.71x10
-6
). Caco-2 cells expressed higher levels of VE-
Cadherin than TDCs (mean 3.29±0.41x10
-5
 versus 2.04±0.37x10
-6
; p<0.001, unpaired t-test). 
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Figure 5.3 Expression of Epithelial Markers in TDCs 
TDCs from 5 donors were incubated in normoxia for 24 hours, in duplicate wells where cell yields allowed. 
RNA was extracted, and mRNA expression was evaluated by Q-PCR. 2-ΔCt values, which correspond to 
gene abundance, were calculated normalised to 18S. The graphs show 2-ΔCt values for Ep-CAM (left) and 
VE-Cadherin (right), with values for Caco-2 shown as reference. Each data point represents a single well, 
and the solid line and error bars show the overall mean ± SEM. 
 
Because of the relatively low cell yields, it was not possible to extract both RNA and 
protein from cell lysates. Therefore CEA protein was measured in the supernatants by ELISA 
(Figure 5.4). CEA was detected in all TDCs tested, and as with Ep-CAM and CE-Cadherin, levels 
were highly donor dependent (mean 550±157ng/mL, range 8.14±1.27 to 1870±130ng/mL). CEA 
secretion was unaffected by hypoxia. CEA expression was not detected in supernatants from 
Caco-2 cells (data not shown). 
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Figure 5.4 CEA secretion by TDCs 
TDCs were exposed to hypoxia for 24 hours with normoxia controls, and supernatants were collected. CEA 
expression was evaluated in duplicates by ELISA. Left: CEA concentration in all conditions is plotted to 
illustrate the range of expression levels. Each point represents mean concentration from duplicate 
measurements, and solid lines show the overall mean ± SEM (n = 8). Right: CEA concentration in 
normoxia and hypoxia for individual donors is plotted (data are mean ± SEM); analysis by 2-way ANOVA 
showed the difference between donors to be statistically significant (p<0.001), but the difference between 
normoxia and hypoxia for each donor was not. 
 
These characterisation experiments demonstrated that the protocol employed allowed the 
establishment of TDCs from individual donor tumours, and that these cultures contained cells of 
epithelial origin. Furthermore, for 50% of the cohort, the cultures yielded RNA of sufficient 
amount and quality to perform Q-PCR.  
 
5.3.3 Hypoxia-Induced Angiogenesis Genes 
5.3.3.1 Preliminary Q-PCR Data 
The next objective was to examine the effect of hypoxia on the expression of 
angiogenesis genes. Due to the limited amount of RNA, it was not possible to perform both 
hypoxia- and DMOG-stimulation experiments. Initially, Q-PCR was used to evaluate expression 
of four angiogenesis genes (VEGF, ANGPTL-4, EFNA-3 and TGF-β1) for two donors (Figure 
5.5, Figure 5.6).  
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Figure 5.5 Effect of hypoxia on angiogenesis gene expression in TDC from a single 
donor (Donor 2) 
TDC from Donor 2 was exposed to hypoxia for 24 hours with normoxia control. mRNA expression was 
evaluated by Q-PCR. Figure shows VEGF, ANGPTL-4, EFNA-3 and TGF-β1 expression normalised to 
normoxia (dashed line). Data are mean ± SD from 1 experiment (ΔCt versus normoxia; ** p<0.01, ns = not 
significant; unpaired t-test). 
 
For Donor 2, all four genes were upregulated by hypoxia, although this was only 
statistically significant for EFNA-3 and TGF-β1. VEGF was increased by a fold-change of 
1.86±0.57, ANGPTL-4 by 2.69±0.42, EFNA-3 by 2.65±0.39 (p<0.01) and TGF-β1 by 2.31±0.26 
(p<0.01). The hypoxia response was weaker for Donor 3. Expression was 1.26±0.27 for VEGF, 
1.74±1.24 for ANGPTL-4, 1.38±0.10 (p<0.05) for EFNA-3 and 0.95±0.34 for TGF-β1 (not 
significant unless otherwise stated). 
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Figure 5.6 Effect of hypoxia on angiogenesis gene expression in TDC from a single 
donor (Donor 3) 
TDC from Donor 3 was exposed to hypoxia for 24 hours with normoxia control. mRNA expression was 
evaluated by Q-PCR. Figure shows VEGF, ANGPTL-4, EFNA-3 and TGF-β1 expression normalised to 
normoxia (dashed line). Data are mean ± SD from 1 experiment (ΔCt versus normoxia; * p<0.05, ns = not 
significant; unpaired t-test). 
 
These initial data showed that the method allowed the evaluation of hypoxia-responses 
for TDCs at mRNA level. They also suggested that there was a variation in hypoxia response 
between TDCs from different donors. In order to investigate this further, the PCR Angiogenesis 
Array was employed. 
5.3.3.2 Array Data 
As with Caco-2 cells, the RT
2
 Profiler™ PCR Angiogenesis Array (SABiosciences, 
Frederick, MD, USA) was used to analyse mRNA extracted from hypoxia-stimulated TDCs and 
compared with normoxia controls. The array required enough RNA for a minimum of 3 RT-PCR 
reactions, which limited the number TDCs that were suitable. TDCs from 6 consecutive donors 
that yielded sufficient RNA were selected. 
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5.3.3.2.1 Array Donor Demographics 
The donor and tumour characteristics for the 6 samples used in the array are shown in 
Table 5.3. There were 4 male and 2 female patients, with an overall mean age of 64.2 ± 6.4 years 
(male 66.0 ± 5.9, female 60.5 ± 7.8; p = 0.38 by unpaired t-test) (Table 5.4).  
Table 5.3 Demographic and pathology characteristics of donors used in array 
Table shows age, gender, site (proximal or distal colon, or rectum) and differentiation grade for the 6 
donors analysed by Angiogenesis Array. 
 Donor 
 1 2 3 4 5 6 
Age (yrs) 66 73 68 64 59 55 
Gender F M M M M F 
Site Rectum Proximal Distal Rectum Distal Distal 
Dukes’ Stage A B A C C C 
Differentiation moderate moderate moderate moderate moderate moderate 
 
 
Table 5.4 Array patients demographics statistics 
Table shows age and sex statistics for donors analysed by Angiogenesis Array. 
Parameter Male Female All 
n 4 2 6 
% 66.7 33.3 100 
Mean Age, years ± SEM 66.0 ± 3.0 60.5 ± 5.5 64.2 ± 2.6 
 
As shown in Table 5.5 and Table 5.6 the donors were representative of the full cohort of 
34 patients. Due to the low number of donors, they were grouped into colon versus rectum, and 
Dukes’ A and B versus Dukes’ C and D for statistical analysis. Compared to the full cohort, p 
values for male versus female distribution and age were 0.18 and 0.40 respectively. In the array 
group, there was 1 proximal colon tumour, 3 distal colon and 2 rectal tumours. P value for colon 
versus rectum compared to the full cohort was 1.00. 2 array group tumours were Dukes’ A, 1 was 
Dukes’ B and 3 were Dukes’ D (p=1.00 for ratio of (Dukes’ A and B) to (Dukes’ C and D); array 
group versus full cohort). All array group tumours were moderately differentiated (p=0.15 for 
moderate versus poor/undifferentiated compared to full cohort). 
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Table 5.5 Array patients pathology statistics 
Table shows pathology statistics for donors analysed by array. 
Parameter n % 
Site 
Proximal colon 1 16.7 
Distal colon 3 50.0 
Rectum 2 33.3 
Dukes’ Stage 
A 2 33.3 
B 1 16.7 
C 3 50.0 
D 0 0 
Differentiation 
well 0 0 
moderate 6 100 
poor 0 0 
undifferentiated 0 0 
 
 
Table 5.6 Demographics and pathology statistics – Array Donors versus Full Cohort 
Characteristics of 6 donors from whom TDCs were analysed by array are compared to the full cohort of 34 
patients. 
†
Fisher’s exact test. 
Parameter Array 
Full 
Cohort 
P value
†
 
Age (years± SD) 64.2± 6.4 69.9 ± 9.7 0.18 
Gender: male versus female 
4:2 
(2:1) 
15:19 
(0.8:1) 
0.40 
Site: colon versus rectum 
4:2 
(2:1) 
25:9 
(2.8:1) 
1.00 
Dukes’ Stage: (A & B) versus (C & D) 
3:3 
(1:1) 
16:17 
(0.9:1) 
1.00 
Differentiation: moderate versus poor/undifferentiated 6:0 21:12 0.15 
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5.3.3.2.2 Array Results 
mRNA extracted from hypoxia-stimulated TDCs was compared with normoxia controls. 
A full list of the genes included in the array, and their functions, is presented in Table 2.5. The 
manufacturer’s software was used to calculate fold-regulation by the 2-ΔΔCt method, with greater 
than two-fold up- or down-regulation taken as a meaningful change. Fold-regulations for all genes 
and donors are shown in Table 5.7 (changes that were less than two-fold are represented thus: ↔). 
Gene expression for hypoxia-stimulated Caco-2 cells is also shown in the same table. Individual 
scatter plots for each donor are shown subsequently in Figure 5.7 to Figure 5.12. 
Table 5.7 Hypoxia-induced changes in expression of genes in the Human Angiogenesis 
RT² Profiler™ PCR Array in TDCs from 6 donors and in Caco-2 cell-line 
See Table 2.5 for full list and function of genes in the Angiogenesis RT² Profiler™ PCR Array. Data are 
fold up- or down-regulation. ↔ = change > -2.0 and < 2.0. ND = not detected. (* = upregulation was also 
seen in DMOG-stimulated Caco-2 cells.) 
Symbol 
Donor Number 
Caco-2 
1 2 3 4 5 6 
AKT1 -13.69 2.60 ↔ ↔ -2.57 5.13 ↔ 
ANGPT-1 ND ND ND ND 8.43 ND 2.26* 
ANGPT-2 ↔ ND -5.02 ↔ ↔ 29.99 2.10 
ANGPTL3 3.72 4.10 4.50 ↔ ↔ 2.31 2.10* 
ANGPTL-4 7.19 2.39 ↔ 7.19 3.40 3.45 3.11* 
ANPEP 4.76 4.63 ↔ 2.06 ↔ 2.62 ↔ 
BAI1 ND ND ND ND -2.58 -3.40 ND 
CCL11 9.38 ND ND 5.28 ↔ 5.41 ND 
CCL2 2.18 ND ND 2.33 ↔ -2.02 ↔ 
CDH5 75.06 -43.68 15.24 ↔ ↔ ND ND 
COL18A1 ↔ ND ↔ 2.35 ↔ -2.91 ↔ 
COL4A3 -9.48 ND ND ↔ -4.97 ND ↔ 
CXCL1 2.27 ↔ ↔ 2.08 ↔ ↔ ND 
CXCL10 3.82 ND ↔ ↔ ↔ ↔ ND 
CXCL3 9.03 ND 14.23 6.39 -4.11 ↔ ND 
CXCL5 11.24 ND ND 2.06 ↔ ↔ ND 
CXCL6 11.96 ND ↔ 2.17 ↔ ND ND 
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CXCL9 16.56 19.60 ↔ 2.42 ↔ 13.34 ND 
TYMP ↔ -2.04 ↔ ↔ ↔ ↔ ND 
S1PR1 2.25 ↔ -2.66 ↔ ↔ -3.10 ↔ 
EFNA1 6.99 ↔ -2.18 ↔ ↔ ↔ 2.55* 
EFNA-3 10.63 2.00 ↔ ↔ ↔ 3.21 7.19* 
EFNB2 2.27 ↔ -2.43 ↔ ↔ ↔ ↔ 
EGF ND ND ND 3.42 ND ND 2.69 
ENG 2.91 ↔ ↔ ↔ ↔ ↔ ↔ 
EPHB4 2.97 ↔ ↔ 2.59 ↔ ↔ ↔ 
EREG 2.43 ND ↔ ↔ ↔ ↔ ↔ 
FGF1 15.14 ND ND ↔ ↔ ND ND 
FGF2 3.53 ND ↔ ↔ ↔ ↔ ND 
FGFR3 ↔ ↔ 2.10 ↔ -6.06 ↔ ↔ 
FIGF 16.97 ND 18.27 ND -2.27 ↔ ND 
FLT1 10.70 62.57 14.63 2.06 ↔ 3.26 3.68* 
HAND2 18.83 -48.21 ND -4.89 -11.82 ↔ ND 
HGF 6.13 15.68 32.47 ↔ -2.45 13.34 ND 
HIF-1A 22.09 5.00 2.03 ↔ ↔ ↔ ↔ 
HPSE 4.96 ND ↔ ↔ -3.40 ND 2.01 
ID1 ↔ ↔ ↔ ↔ ↔ ↔ ↔ 
ID3 ↔ 3.21 ↔ ↔ ↔ ↔ ↔ 
IFNA1 4.36 ND 20.34 -19.16 -2.07 ND ND 
IFNB1 13.78 75.65 46.89 -18.90 -2.25 ND ND 
IFNG 4.91 46.09 13.37 -6.70 -3.74 ND ND 
IGF1 6.80 ND 9.89 ↔ -2.01 ND 2.08 
IL1B ↔ -14.86 2.24 -2.02 ↔ ↔ 2.14 
IL6 4.14 62.57 3.14 ↔ -2.65 7.00 ND 
IL8 4.81 3.66 ↔ 4.39 ↔ ↔ ↔ 
ITGAV 3.25 ↔ ↔ 2.23 ↔ 2.47 ↔ 
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ITGB3 21.19 39.84 15.41 2.11 -3.18 2.34 ↔ 
JAG1 13.09 2.11 ↔ 2.94 ↔ ↔ ↔ 
KDR 7.46 79.69 25.39 ↔ -2.81 -2.49 ↔ 
LAMA5 3.47 ND ↔ 2.44 ↔ ↔ ↔ 
LECT1 20.53 227.15 78.05 ND -2.94 5.41 ND 
LEP 580.04 27.71 4.42 ND 26.84 ↔ ND 
MDK 8.31 ↔ 2.29 ↔ ↔ 2.49 ND 
MMP2 4.39 7.14 ↔ 3.51 ↔ 2.63 ↔ 
MMP-9 12.51 5.72 8.20 ↔ ↔ ↔ 2.11* 
NOTCH4 3.94 2.89 ↔ 2.35 ↔ ND ND 
NRP1 2.66 36.03 5.34 ↔ ↔ ↔ ↔ 
NRP2 3.82 ND 4.76 ↔ ↔ ↔ ↔ 
PDGFA 3.52 ND 3.89 ↔ ↔ ↔ ↔ 
PECAM1 ↔ ND ND ↔ -2.24 ↔ ↔ 
PF4 9.71 15.74 32.14 -8.28 ↔ -2.47 ND 
PGF 81.01 146.14 21.20 -17.69 2.51 ↔ ND 
PLAU 22.39 28.27 6.73 2.17 ↔ ↔ ↔ 
PLG 92.41 137.31 ND -191.34 -66.26 ND ND 
PLXDC1 -4.72 ND 2.64 2.31 ↔ -2.12 2.14 
PROK2 ND ND ND ND ↔ ND 2.74 
PTGS1 ↔ 3.53 2.26 -15.14 ↔ ↔ ND 
SERPINF1 -2.85 ND -3.72 2.56 ↔ -2.52 ↔ 
SPHK1 ↔ ↔ ↔ ↔ ↔ ↔ ↔ 
STAB1 -4.92 ND ↔ ↔ ↔ ↔ ↔ 
TEK -2.53 ND ND -2.87 ↔ ND ND 
TGFA ↔ ↔ ↔ ↔ ↔ ↔ ↔ 
TGFB1 -2.21 ↔ 2.17 ↔ ↔ ↔ 5.39* 
TGFB2 ↔ ND -2.07 ↔ ↔ 10.48 ↔ 
TGFBR1 ↔ ND ↔ ↔ ↔ 8.38 ↔ 
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THBS1 ↔ -8.45 ↔ -5.96 ↔ ↔ ↔ 
THBS2 ↔ ND -3.63 -5.94 ↔ -2.44 ↔ 
TIMP1 ↔ ↔ ↔ ↔ ↔ ↔ ↔ 
TIMP2 -2.11 ↔ 2.31 -2.96 ↔ ↔ ↔ 
TIMP3 -3.03 ND ↔ -39.40 ↔ ↔ ND 
TNF -9.55 ND ND -108.76 ↔ ↔ ND 
TNFAIP2 -4.11 ↔ ↔ -4.04 ↔ ↔ ND 
VEGFA ↔ ↔ ↔ ↔ 2.32 2.38 3.07* 
VEGFC -4.00 ND 6.50 ↔ ↔ 3.90 2.60 
 
 
The results for each donor are displayed in scatter plots in which 2
-ΔCt
 values in hypoxia 
(y-axis) are plotted against normoxia controls (x-axis). The solid line represents equal expression, 
and the upper and lower dashed lines represent two-fold up- or downregulation respectively. 
Genes lying towards the top right of the graph are more abundantly expressed than those to the 
bottom left. In order to simplify comparison of TDCs and Caco-2 responses, the expression of the 
9 genes that were upregulated by both hypoxia and DMOG in Caco-2 is highlighted (ANGPT-1, 
ANGPTL-3, ANGPTL-4, EFNA-1, EFNA-3, FLT-1, MMP-9, TGF-β1 and VEGF-A; Figure 
3.11). In each scatter plot, these Caco-2 signature genes (CSGs) are labelled and shown in black.  
For donor 1 (Figure 5.7), the expression of 63 genes was changed in response to hypoxia, 
compared to 17 for Caco-2. Of these 63 genes, 51 were upregulated and 12 were downregulated, 
while in Caco-2, none were downregulated. One of the 9 CSGs was downregulated (TGF-β1, 
fold-regulation -2.21), one was unchanged (VEGF-A), and 6 were upregulated (fold-regulation 
3.72 for ANGPTL-3, 7.19 for ANGPTL-4, 6.99 for EFNA-1, 10.63 for EFNA-3, 10.70 for FLT-1, 
12.51 and for MMP-9). ANGPT-1 was not detected (Ct > 30). Fold-regulations were generally 
higher than for Caco-2. The relative abundance of these 9 genes was similar in both cell-types, 
with VEGF, TGF-β1 and the ephrins being more abundant than MMP-9, FLT-1 and the 
angiopoietins. Overall, only 4 genes were undetected in donor 1. 
Chapter 5 
148 
Donor 1
10 - 5 10 - 4 10 - 3 10 - 2 10 - 1 100 101 102
10 - 5
10 - 4
10 - 3
10 - 2
10 - 1
100
101
102
ANGPTL3 
ANGPTL4 
EFNA1 
EFNA3 
FLT1 
MMP9 
TGFB1 
VEGFA 
Control (2- Ct)
H
y
p
o
x
ia
 (
2
-
C
t )
 
Figure 5.7 Hypoxia-induced angiogenesis gene expression Donor 1 
The TDC from donor 1 was exposed to hypoxia (1% O2) for 24 hours. mRNA was extracted and expression 
evaluated in duplicate by RT2 Profiler Angiogenesis PCR Array. Figure shows the scatter plot with 2-ΔCt 
values plotted against untreated control. Solid line indicates no change; dashed lines indicate two-fold 
increase (upper) and decrease (lower). Genes that were upregulated more than two-fold in Caco-2 cells 
(CSGs) are labelled and shown in black. 
 
For donor 2 (Figure 5.8), fewer genes were detected, with 34 having Ct values greater 
than 30. Of the remaining 50, 28 were upregulated, 5 were downregulated and 17 unchanged. Of 
the CSGs, 5 were upregulated (fold-regulation 4.10 for ANGPTL-3, 2.39 for ANGPTL-4, 2.00 for 
EFNA-3, 62.57 for FLT-1 and 5.72 for MMP-9). No change was seen for EFNA-1, TGF-β1 and 
VEGF-A, and ANGPT-1 was again undetected. 
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Figure 5.8 Hypoxia-induced angiogenesis gene expression Donor 2 
The TDC from donor 2 was exposed to hypoxia (1% O2) for 24 hours. mRNA was extracted and expression 
evaluated in duplicate by RT2 Profiler Angiogenesis PCR Array. Figure shows the scatter plot with 2-ΔCt 
values plotted against untreated control. Solid line indicates no change; dashed lines indicate two-fold 
increase (upper) and decrease (lower). Genes that were upregulated more than two-fold in Caco-2 cells 
(CSGs) are labelled and shown in black. 
 
For donor 3 (Figure 5.9), while 70 genes were detected, 32 of these were unchanged. Of 
the remaining 38, 31 were upregulated and 7 were downregulated. Of the CSGs, 4 were 
upregulated (fold-regulation 4.50 for ANGPTL-3, 14.63 for FLT-1, 8.20 for MMP-9 and 2.17 for 
TGF-β1) and one was downregulated (fold-regulation -2.18 for EFNA-1). ANGPTL-4, EFNA-3 
and VEGF-A were unchanged, while ANGPT-1 was not detected. 
For donor 4 (Figure 5.10), only 6 genes were not detected. Half of the 78 detected genes 
(39) were unchanged. Of the remainder, 23 were upregulated, and 16 were downregulated. Only 2 
of the CSGs were upregulated (fold-regulation 7.19 for ANGPTL-4 and 2.06 for FLT-1). 6 were 
unchanged (ANGPTL-3, EFNA-1, EFNA-3, MMP-9, TGF-β1and VEGF-A) while ANGPT-1 was 
again undetected. 
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Figure 5.9 Hypoxia-induced angiogenesis gene expression Donor 3 
The TDC from donor 3 was exposed to hypoxia (1% O2) for 24 hours. mRNA was extracted and expression 
evaluated in duplicate by RT2 Profiler Angiogenesis PCR Array. Figure shows the scatter plot with 2-ΔCt 
values plotted against untreated control. Solid line indicates no change; dashed lines indicate two-fold 
increase (upper) and decrease (lower). Genes that were upregulated more than two-fold in Caco-2 cells are 
labelled and shown in black. 
 
Only one gene was undetected in donor 5 (Figure 5.11). 24 genes changed, with 5 
upregulated and 19 downregulated. Unlike the other donors, all CSGs including ANGPT-1 were 
detected. Of the 9, ANGPT-1, ANGPTL-4 and VEGF-A were upregulated (fold-regulation 8.43, 
34.0 and 2.32 respectively) and the remaining 6 were unchanged.  
There were 31 undetected genes for donor 6 (Figure 5.12). Of the remaining 53, 17 were 
upregulated and 36 were unchanged, while none were downregulated. 5 of the CSGs were 
upregulated (fold-regulation 2.31 for ANGPTL-3, 3.45 for ANGPTL-4, 3.21 for EFNA-3, 3.26 
for FLT-1 and 2.38 for VEGF-A). No change was seen for EFNA-1, MMP-9 and TGF-β1, while 
ANGPT-1 was undetected. 
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Figure 5.10 Hypoxia-induced angiogenesis gene expression Donor 4 
The TDC from donor 4 was exposed to hypoxia (1% O2) for 24 hours. mRNA was extracted and expression 
evaluated in duplicate by RT2 Profiler Angiogenesis PCR Array. Figure shows the scatter plot with 2-ΔCt 
values plotted against untreated control. Solid line indicates no change; dashed lines indicate two-fold 
increase (upper) and decrease (lower). Genes that were upregulated more than two-fold in Caco-2 cells 
(CSGs) are labelled and shown in black. 
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Figure 5.11 Hypoxia-induced angiogenesis gene expression Donor 5 
The TDC from donor 5 was exposed to hypoxia (1% O2) for 24 hours. mRNA was extracted and expression 
evaluated in duplicate by RT2 Profiler Angiogenesis PCR Array. Figure shows the scatter plot with 2-ΔCt 
values plotted against untreated control. Solid line indicates no change; dashed lines indicate two-fold 
increase (upper) and decrease (lower). Genes that were upregulated more than two-fold in Caco-2 cells 
(CSGs) are labelled and shown in black. 
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Figure 5.12 Hypoxia-induced angiogenesis gene expression Donor 6 
The TDC from donor 6 was exposed to hypoxia (1% O2) for 24 hours. mRNA was extracted and expression 
evaluated in duplicate by RT2 Profiler Angiogenesis PCR Array. Figure shows the scatter plot with 2-ΔCt 
values plotted against untreated control. Solid line indicates no change; dashed lines indicate two-fold 
increase (upper) and decrease (lower). Genes that were upregulated more than two-fold in Caco-2 cells 
(CSGs) are labelled and shown in black. 
 
 
As illustrated in Figure 5.7 to Figure 5.12, there was significant heterogeneity in the 
pattern of hypoxia-induced angiogenic gene expression between donors. Data from the six scatter 
plots are presented in Table 5.8. For each donor, the number of genes detected (“Detected 
Genes”), and the number whose expression changed by greater than ±2-fold (“Altered genes”) 
was tabulated. There was significant variation in the total number of genes detected per donor, 
ranging from 83 in donor 5 (99% of the 84 genes on the array) to 50 in donor 2 (60%). “Altered 
genes” ranged from 63 (75% of the 84 genes) for donor 1, to 24 (29%) for donor 5. Of the 
“Altered genes”, the proportion that were upregulated varied from 85% in donor 2 (28 of 33 
genes) to 21% for donor 5 (5 of 19 genes).  
 
 
Chapter 5 
154 
Table 5.8 Patterns of Hypoxia-Induced Angiogenesis Gene expression 
Table summarises hypoxia-induced changes in expression of the 84 genes on the Angiogenesis Array. For 
the 6 donors analysed, the number of genes that were detected, upregulated or downregulated is shown. 
(*Genes that were not altered by ± 2-fold are excluded.) Figures for Caco-2 are included for comparison. 
 
Donor 
Caco2 
 
1 2 3 4 5 6 
Detected Genes  80 50 70 78 83 69 53 
% of total (n=84) 95 60 83 93 99 82 63 
*Altered Genes 63 33 38 39 24 29 17 
% of total (n=84) 75 39 45 46 29 35 20 
*Upregulated 51 28 31 23 5 20 17 
% of altered genes  81 85 82 59 21 69 100 
*Downregulated 12 5 7 16 19 9 0 
% of altered genes 19 15 18 41 79 31 0 
 
 
The pooled expression of CSGs in all six donors is shown in Figure 5.13. 3 genes were 
upregulated greater than two-fold in the TDCs, namely ANGPTL-3 (fold-regulation 2.63), 
ANGPTL-4 (2.79) and FLT-1 (5.22). EFNA-3 and MMP-9 had fold-regulations close to 2 (1.94 
and 1.86 respectively). The remaining three had minimal fold-regulations (1.39 for EFNA-1, 1.19 
for TGF-β1, and 1.09 for VEGF-A). ANGPT-1 was only detected in one donor. 
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Figure 5.13 TDC Expression of Caco-2 Signature Genes – Pooled data 
TDC were exposed to hypoxia (1% O2) for 24 hours. mRNA was extracted, and following cDNA 
amplification by RT-PCR, gene expression was evaluated by RT2 Profiler Angiogenesis PCR Array in 
duplicate. Figure shows the scatter plot with 2-ΔCt values plotted against untreated control. Only genes 
upregulated greater than two-fold by hypoxia in Caco-2 are shown (CSGs). Data are mean ± SEM from 6 
donors. Solid line indicates no change; dashed lines indicate two-fold increase (upper) and decrease (lower). 
 
Figure 5.14 shows genes that were up- or down-regulated greater than two-fold in 3 or 
more donors. To exclude genes where expression levels varied greatly between donors, only those 
for which the SEM of 2
-ΔCt
 values was less than half of the mean were included. In addition to the 
3 genes shared with Caco-2, a further 15 novel genes were identified, giving a total of 18 putative 
TDC Signature Genes (TSGs). 5 were downregulated (fold-regulations: COL4A3 -4.12, HAND2 
-5.81, TEK -2.47, TIMP-3 -3.89 and TNF -8.81). The remaining 13 genes were upregulated 
(ANPEP 2.06, CCL11 2.61, CXCL3 2.95, CXCL9 3.24, HIF1A 2.51, IFNG 2.67, IL8 2.15, 
MMP2 2.44, PDGFA 2.13 and PLAU 3.22). 
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Figure 5.14 Hypoxia-responsive genes in TDCs - pooled data 
TDC were exposed to hypoxia (1% O2) for 24 hours. mRNA was extracted and expression evaluated in 
duplicate by RT2 Profiler Angiogenesis PCR Array. Figure shows the scatter plot with 2-ΔCt values plotted 
against untreated control. Data are mean ± SEM from 6 donors. Solid line indicates no change; dashed lines 
indicate two-fold increase (upper) and decrease (lower). 
 
5.3.3.2.3 Q-PCR Validation 
In order to validate the array data, it was necessary to independently evaluate gene 
expression by Q-PCR. Of the 34 donors in the full cohort, sufficient RNA for cDNA 
amplification was obtained in 13. Yields for several of these donors were only sufficient for one 
RT-PCR reaction, which limited the number of genes that could be tested. Therefore, in order to 
maximise use of limited cDNA, and to allow meaningful comparisons to be made across all 13 
patients, four of the nine CSGs were selected for which validated primers were available, namely 
ANGPTL-4, EFNA-3, TGF-β1and VEGF. Demographic and pathological data for all 13 patients 
is shown in the APPENDIX (Table 7.2 and Table 7.3). 
Using the same primers that were used in Caco-2 cells, Q-PCR was performed on the 
same cDNA that was used in the arrays. The results for these 6 donors were pooled, and are 
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shown in Figure 5.15. The Q-PCR data paralleled that from the array in Figure 5.13, with mean 
ANGPTL-4 expression being greater than two-fold, while EFNA-3, TGF-β1 and VEGF 
expression was unchanged. Of note, for donors 5 and 6, VEGF was not detected by Q-PCR in 
either normoxia or hypoxia. Fold-change was 2.52±0.55 for ANGPTL-4 (mean ± SEM, range 
0.19 to 3.89), 1.43±0.32 for EFNA-3 (range 0.43 to 2.63), 1.06±0.28 for TGF-β1 (range 0.39 to 
2.30) and 1.08±0.32 for VEGF (range 0.23 to 1.79).  
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Figure 5.15 Q-PCR Validation of Array data 
mRNA used in the preceding array experiments was analysed by Q-PCR. Figure shows a box-whisker plot 
of ANGPTL-4, EFNA-3, TGF-β1 and VEGF fold-changes for all 6 patients normalised to normoxia 
(dashed line). The dotted line represents a fold-change of 2, greater than which upregulation was taken to be 
meaningful. Data are 25%, 50% (median) and 75% percentiles (box), with + representing the mean, and 
whiskers representing maximum and minimum values. 
 
Q-PCR analysis of these four genes was also performed for the 7 donors that were not 
analysed by array. The individual fold-changes for all 13 donors are presented in Figure 5.16. 
Each data point corresponds to the fold-change for an individual donor, with open triangles 
representing the donors analysed by array. A similar pattern was seen for ANGPTL-4, EFNA-3 
and TGF-β1, with mean upregulation the latter two genes being below two-fold. However, 4 of the 
additional donors showed higher upregulation of VEGF, with one reaching a fold-change of 12.1, 
leading to an overall mean that was greater than 2-fold. Fold-change was 2.84±0.53 for ANGPTL-
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4 (mean ± SEM, range 0.13 to 6.58), 1.65±0.28 for EFNA-3 (range 0.43 to 3.27), 0.91±0.13 for 
TGF-β1 (range 0.39 to 2.30) and 2.59±1.03 for VEGF (range 0.23 to 12.07). There was no 
correlation between gene induction and clinical parameters. 
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Figure 5.16 Q-PCR data for all donors 
For all 13 donors that yielded sufficient RNA, angiogenesis gene expression was analysed by Q-PCR. 
Figure shows a scatter plot of ANGPTL-4, EFNA-3, TGF-β1and VEGF fold-changes normalised to 
normoxia (dashed line). Each data point represents mean fold-change for a single donor, with open triangles 
representing donors which were also analysed by array. The dotted line represents a fold-change of two, 
greater than which upregulation was taken to be meaningful. Solid lines and error bars represent the grand 
mean ± SEM for each gene.  
 
The array data demonstrated that in response to hypoxia, TDCs upregulated a number of 
angiogenesis genes. While there was significant variation between donors, a total of 18 TDC 
“signature genes” (TSGs) were consistently altered (Figure 5.17). 3 of these genes were also 
upregulated in Caco-2 cells. Thus a total of 24 genes were found to be hypoxia-regulated in CRC. 
The functions of these genes broadly fall into 5 groups, namely transcription factors, cytokines, 
growth factors, vascular remodelling factors and matrix remodelling/adhesion factors (Figure 
5.18). 
Chapter 5 
159 
 
Figure 5.17 Angiogenesis genes induced by hypoxia in Caco-2 cells and TDCs 
Figure shows genes that were up- or downregulated by more than 2-fold (downregulated genes are shown in 
italics). 3 genes featured in the response signature of both cell-types, while 6 were only upregulated in 
Caco-2 cells, and 15 were exclusive to TDCs.  
 
     
       
Figure 5.18 Functions of hypoxia-induced genes 
Angiogenesis genes that changed greater than two-fold following hypoxia stimulation in both Caco-2 and 
TDCs fall into 5 groups in terms of function. Genes in italics were downregulated.  
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5.4 Discussion 
The use of ex vivo short-term cultures of mixed cell populations derived from whole 
diseased tissue has been used successfully in our laboratory to study rheumatoid arthritis and 
atherosclerosis (Brennan et al. 1989b; Monaco et al. 2004). Following enzymatic digestion of 
synovial membranes and disaggregation of cell clusters by filtration, cultures are maintained for 
up to 7 days. A major benefit of this technique is that it generates a heterogeneous cell population 
which models cellular interactions that take place in vivo significantly more accurately than 
homogenous cell-lines. The potential therapeutic benefit of TNF-α blockade in rheumatoid 
arthritis was first identified in such cultures, derived from synovial membranes of rheumatoid 
arthritis patients (Brennan et al. 1989a). This discovery heralded a new era of targeted and highly 
effective therapeutics for rheumatoid arthritis and other chronic inflammatory diseases (Feldmann 
2002; Feldmann and Maini 2003). Subsequent adaptation of the technique to establish cultures 
derived from atherosclerotic plaques has been used to elucidate the role of NF-κB (Monaco et al. 
2004) and toll-like receptors in the pathophysiology of atherosclerosis (Monaco et al. 2009).  
As described in the introduction to this chapter, the use of de novo cell-cultures from 
primary tumour tissue addresses some of the limitations of established cell-lines such as 
homogeneity and “genotypic drift”. Adaption of the methodology used in rheumatoid and 
atherosclerotic tissue to CRC tumour samples has previously been attempted in our laboratory (T. 
Khong, unpublished data). While isolating cells from CRC tissue was shown to be feasible, the 
objective of that study was to establish and propagate long-term cultures, which was thwarted by 
significant technical challenges. However, success was achieved with stimulation experiments 
performed immediately after isolation of the cells. For my study, therefore, I chose to follow more 
closely the rheumatoid/atherosclerosis model and restrict efforts to establishing short-term 
cultures. Similarities between the responses of tumour-derived cultures and those of Caco-2 cells 
would serve to validate the cell-line data obtained using the same experimental hypoxia model, as 
presented in Chapter 3. Furthermore, evaluation of the angiogenesis response to hypoxia of TDCs 
might give an insight into the angiogenic phenotype of the individual donor tumour. In view of 
the paucity of predictive markers for CRC, particularly with regard to response to angiogenic 
therapy, this model might provide data to address this.  
It is important to note that the aim of the technique is to investigate the ability of the 
cultures to respond to hypoxia, rather than to assess the hypoxic status of the original tumour. The 
latter objective would require immediate fixation once the sample is obtained, and would result in 
an analysis that provided a “snapshot” of the level of hypoxic activation at the time of fixation. A 
significant limitation of this approach is that tumour oxygen levels are highly dynamic in vivo. 
While the integrity of the blood supply to the tumour determines the maximum oxygen delivery 
Chapter 5 
161 
that can be achieved, the actual oxygen tension at any given timepoint is dependent on local blood 
flow and arterial oxygen saturation. Hypotension and hypoxaemia are not uncommon during 
surgery (Bijker et al. 2007; Ehrenfeld et al. 2010). Furthermore, the surgical technique requires 
ligation of the blood supply to the tumour-bearing segment of colon prior to its resection. 
Depending on the technical difficulty of the operation, there may be up to 30 minutes (or more) 
between interruption of the blood supply and removal of the specimen. Even at the earliest time 
that the sample could be taken from the excised specimen and fixed, the oxygen tension bears 
little relation to “normal” levels, and the significant variation in resection time confounds 
comparisons between samples obtained from different operations. More biologically relevant is 
the way the cancer cells respond to hypoxic episodes. The manner in which the extracted cells 
respond to hypoxia (or other stimuli), provided they remain viable, is likely to remain unchanged 
within the lifespan of these short-term cultures.  It is this capacity that this model aims to 
evaluate. 
Previous experience with establishing mixed cultures from rheumatoid and atherosclerotic 
tissue has demonstrated that a delay of up to 72 hours from surgery to enzymatic digestion does 
not significantly affect the yield of viable cells. For colonic tissue, however, I observed a drop-off 
in yields if digestion was delayed for more than 48 hours, with bacterial overgrowth being 
common beyond 72 hours. Therefore enzymatic digestion was commenced within 24 hours of 
surgery wherever possible. Once established, although there were still some viable cells after 7 
days, cell viability was observed to decrease significantly after 48 hours of incubation in 
normoxia. In addition to observations from rheumatoid and atherosclerotic cultures that cytokine 
expression peaks between 24 and 48 hours (Brennan et al. 1989b; Monaco et al. 2004), this 
prompted the decision to perform experiments immediately after isolation of the TDCs for a 
period 24 hours. As well as minimising loss of cell viability, and investigating the cells when they 
are at their most active, 24 hour stimulation also allowed direct comparison with the Caco-2 data. 
Attempts were made to establish TDCs using tissue from 34 patients. Comparison of 
demographic and pathological data with national statistics showed that this cohort was 
representative of the general UK population of CRC patients and tumours. Despite the restriction 
of the technique to establishing short-term (as opposed to long-term) cultures, significant 
technical challenges were encountered, particularly with the earliest samples. This may be 
attributable in part to an initial learning curve. One of the main problems encountered, particularly 
with earlier samples, was that of insufficient cell yields. A number of factors were observed to 
influence this. The first was insufficient tissue, and there was, as might be anticipated, a 
correlation between sample mass and cell yield. In addition, tissue taken from the leading edge of 
the tumour yielded more cells than that taken from the centre, which tended to be necrotic. 
Another observation was that samples with a firm texture, which was evident when dicing the 
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sample with a scalpel and possibly indicated fibrosis and/or necrosis, yielded fewer cells. A high 
proportion of fatty tissue, manifested as a layer of stringy, yellow material which persisted after 
filtration to remove acellular debris following collagenase treatment, also tended to lower cell 
yields. Factors affecting cell yield also influenced RNA yield, but the correlation was less clear-
cut. Some small samples, for example, yielded higher RNA concentrations than much larger ones. 
There was, however, a linear correlation between cell yield and RNA yield (data not shown).  
Density-gradient separation was introduced into the protocol in a previous study in our 
laboratory in which the aim was to establish long-term CRC cultures. The effect of RBC 
“contamination” was thought to have potential adverse effects on the propagation of these 
cultures. Nevertheless, the depletion of otherwise large numbers of RBCs appeared to enrich the 
epithelial cell fraction. Certainly, my observation was that omission of density-gradient separation 
resulted in very large numbers of anuclear RBCs, which when plated at the target cell density led 
to much lower RNA yields. A drawback of gradient separation is that it increases the time 
required to complete the cell dissociation process by almost an hour. Attempts were made to 
achieve RBC depletion using a RBC lysis buffer, but this proved a far less efficient method and 
was not pursued further. 
Of the total 34 patients, the evaluation of angiogenesis response to hypoxia was possible 
in 13 (38%). The major limitation was the lack of sufficient RNA for cDNA synthesis. None of 
the first 9 TDCs yielded sufficient RNA. If one assumes that this is was due to a learning-curve 
effect, excluding these 9 patients gives an improved rate of 52%. This compares favourably to 
success rates for the establishment of long-term cultures from primary tissue, which range from 
10% to 45% (Leibovitz et al. 1976; McBain et al. 1984; Kirkland and Bailey 1986).  
Initial characterisation of the TDCs was performed by observing cell morphology. 
Microscopy revealed significant morphological heterogeneity, which became more apparent when 
the cultures were maintained for several days. Some cells with similar morphology to Caco-2 
cells were seen. Despite density-gradient separation it was observed that the cultures contained 
some RBC-like cells. In addition to colonic tumour cells that are exclusively of epithelial origin, 
the methodology employed to establish these cultures would be anticipated to generate a variety 
of other cell types, such as fibroblasts, tumour-associated macrophages and other immune cells. 
Further characterisation experiments therefore aimed to identify epithelial cell markers. Q-PCR 
was used to evaluate the expression of the epithelial cell markers Ep-CAM and VE-Cadherin. The 
former is exclusively expressed by epithelial cells, and expression of the latter, although 
predominantly found in vascular endothelium, has also been reported in tumours of epithelial 
origin (Labelle et al. 2008). VE-Cadherin expression in Caco-2 cells was demonstrated in my 
earlier experiments (Figure 3.8). Both markers were expressed in TDCs, indicating the presence 
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of epithelial cells. Mean Ep-Cam expression was similar in TDCs and Caco-2 cells, while mean 
VE-Cadherin was much lower in TDCs. There was significant variation between donors, which 
may reflect variation in epithelial cell fraction.  
Expression of carcinoembryonic antigen (CEA), a tumour marker used in the follow-up of 
post-surgical CRC patients, was also evaluated. CEA expression has been reported in normal 
epithelial cells outside of the GI tract at low levels (e.g. uterine cervix and sweat glands), and can 
be elevated in tumours arising from these tissues (Metze et al. 1996; Ikeda et al. 2012). In the 
colon CEA is exclusively found in columnar epithelial and goblet cells (Hammarström 1999), and 
expression has been reported in Caco-2 cell, in which it was found to be hypoxia regulated and 
HIF-1α dependent (Kokkonen et al. 2007). CEA was readily detected in TDC supernatants at high 
concentrations, indicating the presence of tumour cells. Expression was unaffected by hypoxia. In 
addition CEA was not detected in Caco-2 cell supernatants. While this is contrary to Kokkonen et 
al., that study detected CEA by Western Blot using whole cell lysates and did not investigate 
secreted CEA in supernatants.  
These characterisation experiments indicated the presence of cells of epithelial origin in 
the TDCs. Accurate cell-type identification was not performed, and this is an important next step 
in the development of this model.  
Angiogenic responses of the TDCs were then investigated. Due to the limited RNA 
yields, it was not possible to evaluate responses to both hypoxia and DMOG. The Caco-2 array 
data indicated that hypoxia stimulated more pronounced responses than DMOG, both in terms of 
fold-changes and number of altered genes, and the decision was taken to use hypoxia for the TDC 
experiments. Before utilising the array, preliminary experiments used Q-PCR to evaluate 
hypoxia-induced expression of four genes (VEGF, ANGPTL-4, EFNA-3 and TGF-β1) in two 
donors. Results were similar, but not identical, to the Caco-2 data. A significant benefit of the 
PCR array is the ability to rapidly generate large amounts of data. However, its utility is 
somewhat limited by high costs (over £1000 per donor assayed), and the complexity of the data 
generated can be difficult to interpret. It was therefore used to evaluate angiogenic gene responses 
in a limited number of patients. Of the 13 TDCs from which sufficient RNA was obtained, 6 
consecutive samples were assayed. Within the limitations of the small sample size, statistical 
analysis indicated that these 6 were representative of the whole cohort of 34 in terms of 
demographics and pathology. In order to validate the array results, Q-PCR was used to analyse 
expression of VEGF, ANGPTL-4, EFNA-3 and TGF-β1. Pooled analysis of Q-PCR data for the 6 
donors reflected the array results, with greater than 2-fold upregulation seen for ANGPTL-4 only  
(Figure 5.13 and Figure 5.15).  
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Overall it was clear that there was marked heterogeneity in the pattern of hypoxia-induced 
angiogenic gene expression between donors. A simple illustration of this can be seen in the 
number of genes detected, and of genes altered greater than ±2-fold for each donor (Table 5.8). 
Genes detected varied from 83 (99%) to 50 (60%), and the number of genes altered ranged from 
63 (75%) to 24 (29%). When altered genes were considered alone, upregulation predominated in 
response to hypoxia stimulation some donors (e.g. 28 of 33 genes in donor 2), while in others 
genes were mainly downregulated (14 of 19 genes for donor 5).  
Variability of cell composition between individual TDCs would limit the validity of any 
direct comparisons. If the variations in hypoxia response were entirely due to cell-type 
heterogeneity, one would anticipate little or no consistency in either gene abundance or fold-
changes between the donors. Furthermore, there would be little or no similarity between TDC 
gene expression patterns and that of the CRC monoculture of Caco-2 cells. Array analysis of 
Caco-2 cells identified 9 genes that were consistently upregulated (“Caco-2 signature” genes) 
(Figure 3.11). As illustrated in Figure 5.13, when the data for all 6 donors was pooled, there was 
consistency within the cohort in terms of both abundance (based on 2
- Ct
 values) and fold-changes 
(based on 2
- Ct
 values) for 8 of the 9 CSGs. In addition, gene abundance was comparable to that 
in Caco-2 cells. While further work is necessary to more accurately characterise the TDCs, this 
consistency suggests that the data from Caco-2 cells and TDCs are mutually supportive to a 
degree. 
Since there was significant inter-donor expression of the 84 genes in the array, an attempt 
was made to identify genes for which there were consistent changes. Results for all 6 donors were 
pooled, and only genes that were detected in 3 or more donors were included (Figure 5.14). To 
eliminate genes for which abundance varied greatly between donors, an arbitrary cut-off was set. 
Genes were excluded if the SEM of 2
-ΔCt
 values was greater than half of the mean. This analysis 
resulted in a “TDC signature” of 18 genes which were up- or downregulated by greater than 2-
fold. This was distinct from the Caco-2 signature, although there was some overlap, with 3 genes 
being upregulated in both cell types (Figure 5.17). The Caco-2 signature included only genes 
induced by both hypoxia and DMOG, since these are most likely to be HIF-dependent (8 genes 
that were exclusively hypoxia-regulated were excluded). Only hypoxia-stimulation was used for 
the TDC array, and it may be that several of the 18 genes identified are not induced by DMOG, 
and hence likely to be HIF-independent. (None of the 8 genes that were only hypoxia-regulated in 
Caco-2 cells featured in the TDC signature.) A further distinction between the two cell types was 
that 5 genes were downregulated in TDCs, whereas none were in Caco-2. 
The wide variation in gene expression patterns revealed by the array data may reflect 
heterogeneity in the proportions of mixed cell-types in each TDC. However, as described in the 
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introduction to this chapter, it is clear that CRC is a highly heterogeneous disease, and these 
variations may reflect real differences in the hypoxic response of tumour cells from different 
donors. Clearly, identification of correlations between expression patterns and clinical or 
demographic data would address this question, but a meaningful analysis was not possible due to 
the low number of donors assayed by PCR Array. Due to the prohibitive cost, subsequent TDCs 
were analysed by Q-PCR only, focusing on VEGF, ANGPTL-4, EFNA-3 and TGF-β1 expression. 
These genes were chosen for several reasons. Having been identified as part of the Caco-2 
signature in Chapter 3, their regulation by HIF was shown in Chapter 4. The importance of VEGF 
in CRC is well established. The role of ANGPTL-4 in angiogenesis and cancer has emerged over 
the last decade, and although its expression in CRC has been reported to correlate to poor 
prognosis (Nakayama et al. 2011; Tan et al. 2012), there is some controversy as to whether it 
promotes or enhances angiogenesis and metastasis (Galaup et al. 2006; Kim et al. 2011). TGF-β1 
is known to be upregulated in early cancer, with subsequent downregulation as invasion and 
metastasis develop (Massagué 2008). Recent evidence suggests a role for hypoxic regulation of 
TGF-β1 (Wincewicz et al. 2010; Xian et al. 2011). Hypoxic regulation of ephrin-A3 has recently 
been reported in rheumatoid arthritis in our laboratory, but its role in cancer is not known.  
Q-PCR analysis was performed for a further 7 patients. The expression pattern of 
ANGPTL-4 (upregulated), EFNA-3 and TGF-β1 (unchanged) that was seen in the 6 array donors 
persisted when Q-PCR data for all 13 patients was analysed (Figure 5.16). However, some of the 
additional patients showed much higher VEGF upregulation. No correlation with clinical data was 
seen, but this may be a function of the low sample size. Whether the ability of TDCs to upregulate 
these four genes (or other genes) is related to clinical parameters is an interesting question. 
Clearly greater numbers are necessary, and this is the subject of on-going work in our laboratory. 
Thus, the Caco-2 and TDC signatures included a total of 24 hypoxia-induced 
angiogenesis genes. These fall into 5 broad functional groups, namely transcription factors, 
cytokines, growth factors, vascular remodelling factors and matrix remodelling/adhesion factors 
(Figure 5.18). These genes are discussed below.  
Transcription Factors 
The transcription factors altered in Caco-2 and TDC were HIF-1  and HAND2. The 
function of HIF-1α has been extensively described in earlier chapters. As shown in Chapter 4, 
HIF-1α mRNA levels in Caco-2 are suppressed by hypoxia, due to a negative feedback 
mechanisms including aHIF (Thrash-Bingham and Tartof 1999; Bruning et al. 2011; Xu et al. 
2012). Moderate downregulation was also seen in the array data (Figure 3.10). HIF-1α was 
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upregulated in TDCs, which suggests that this negative feedback loop may be suppressed or 
absent in these cultures.  
HAND2 overexpression in squamous cell carcinoma of the lung has been reported 
(Metodieva et al. 2011). While it has an important role in cardiovascular and sympathetic nervous 
system development, but its role in cancer is poorly understood. Its angiogenic function may be 
mediated via the VEGF signalling pathway (Yamagishi et al. 2000), and it has been reported to 
regulate ECM remodelling (Yin et al. 2010). The significance of hypoxic downregulation of 
HAND2 seen here is unclear, and requires further investigation. 
Cytokines 
A number of cytokines and chemokines relevant to angiogenesis were altered by hypoxia 
in both cell types. CCL11 (eotaxin) stimulates endothelial cell migration, implicating it in 
angiogenesis (Salcedo et al. 2001). In lymphoma and ovarian cancer, it can promote proliferation 
and inhibit apoptosis (Levina et al. 2009; Miyagaki et al. 2011). In CRC, increased eosinophil 
infiltration correlates to better prognosis (Pretlow et al. 1983; Fernández-Aceñero et al. 2000). 
CRC patients have decreased plasma concentrations of CCL11, with lower levels associated with 
later stage, while expression is increased in tumour versus normal tissue (Wågsäter et al. 2007). 
Hypoxic suppression of CCL11 expression by adipocytes has been reported (Famulla et al. 2012), 
in contrast to the upregulation seen in TDCs in my study. 
Upregulation of CXCL-3, CXCL-9 and IL-8 has been reported in CRC tissue (Erreni et 
al. 2009; Doll et al. 2010). CXCL-3 and IL-8 are angiogenic, stimulating endothelial cell 
migration (Vandercappellen et al. 2008). CXCL-3 is also associated with metastasis in several 
cancers, and is upregulated by prolonged hypoxia in myeloid dendritic cells, but little is known 
about hypoxic-induction of CXCL-3 in CRC (Blengio et al. 2012). In the absence of functional 
HIF-1α, IL-8 is upregulated by hypoxia and can mediate VEGF-induced tumour angiogenesis 
(Mizukami et al. 2005). Increased expression of CXCL9 (which is angiostatic unlike CXCL-3 and 
IL-8) has been reported in CRC tissue (Erreni et al. 2009), and exogenous CXCL9 has been 
shown to have tumour-suppressive effects in both in vitro and mouse models of CRC (Ruehlmann 
et al. 2001). Although downregulation of CXCL9 by hypoxia has been reported in glioma 
(Marotta et al. 2011), there are no reports of hypoxia-regulation in CRC. 
The interferons exert their angiostatic effects both directly by inhibiting endothelial cell 
function (Indraccolo 2010), and indirectly, by inhibiting angiogenic factors such as VEGF, IL-8, 
and MMP-9 (von Marschall et al. 2003). IFN-γ is upregulated in CRC tissue and is associated 
with increased CRC risk (Slattery et al. 2011; Nam and Park 2012). IFN-γ-stimulated 
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mesenchymal stem cells (MSCs) promote angiogenesis and tumour growth in a VEGF-mediated, 
HIF-1α-dependent mechanism in a CRC cell-line xenograft model (Liu et al. 2011).  
The importance of TNF-α in systemic inflammation is evidenced by the success of anti-
TNF therapies in rheumatoid arthritis (Brennan et al. 1989a; Feldmann and Maini 2003). Septic 
shock is the clinical end-point of the TNF-α-mediated response to bacterial endotoxins (Tracey et 
al. 1986), in which HIF-1α has been shown to play a role (Peyssonnaux et al. 2007). The link 
between inflammation and cancer is well-established (see Chapter 1). While TNF can have anti-
tumour effects (Kashii et al. 1999) it also promotes the development and progression of cancer 
(Balkwill 2006; Balkwill 2009). Elevated TNF-α levels in CRC is associated with poor prognosis 
(Naylor et al. 1990; Szlosarek and Balkwill 2003). TNF-α can induce cancer cell production of 
IL-8, MMP-9, TGF-β1 and VEGF (Nabors et al. 2003; Balkwill 2004; Kulbe et al. 2005; Stuelten 
et al. 2005). Hypoxia induces TNF-α expression in macrophages (Liu et al. 2008), but reduces 
adipocyte expression of TNF-α-induced cytokines by downregulating the TNF-α receptor TNF-
R1 (Famulla et al. 2012). TNF-α has been reported to upregulate VEGF production by 
mesenchymal stem cells in a HIF-1α-dependent manner, promoting angiogenesis and tumour 
growth in CRC cell xenografts (Liu et al. 2011), but it can also inhibit HIF-1α activity in 
osteoblasts (Mendonça et al. 2011). In view of its complex, context-specific regulation and 
function, it is difficult to interpret the hypoxic downregulation of TNF-α seen in my TDC array 
data. The therapeutic targeting of TNF-α activity in cancer has been the focus of much research 
(Szlosarek and Balkwill 2003). A key question is whether therapies should aim to stimulate or 
inhibit TNF-α (Balkwill 2009). A systematic review of clinical trials found no increased risk of 
malignancy in rheumatoid arthritis patients receiving anti-TNF therapy (Setoguchi et al. 2006). 
Early clinical trials of TNF antagonists in advanced cancer have demonstrated some efficacy in a 
limited proportion of patients (Harrison et al. 2007; Brown et al. 2008). TGF- 1 is discussed in 
the subsequent section, due to its function as both a cytokine and growth factor. 
Growth Factors 
Growth factors stimulate cellular growth, proliferation and cellular differentiation, and a 
total of 6 growth factors/growth factor receptors (TGF- 1, ephrin-A1 and -A3, PDGF-A, VEGF 
and its receptor FLT1) were hypoxia-regulated. Transforming growth factor-β1 (TGF-β1) and its 
interactions with the HIF pathway has been discussed earlier (sections Error! Reference source 
ot found. and 3.4). In CRC, elevated TGF-β1 levels are associated with increased angiogenesis 
and poor prognosis (Gulubova et al. 2010), and correlation of TGF-β1 and HIF-1α expression has 
been reported in CRC (Wincewicz et al. 2010). In a study of a variety of 50 cancer cell-lines 
derived from various primary tissues, a trend towards downregulation of TGF-β1 protein 
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expression in response to hypoxia was seen (Heinzman et al. 2008), which is reflected at the 
mRNA level in my TDC data.  
The ephrins have been discussed in Chapter 1 and Chapter 3. Aberrant Eph/ephrin 
expression is seen in several cancers including CRC, and correlates with stage and prognosis 
(Miyazaki et al. 2003; Fox and Kandpal 2004; Jubb et al. 2005; Herath et al. 2006; Herath et al. 
2009). The precise role of ephrin ligand-receptor interactions in CRC is complex. A oncogenic 
role has been proposed for several Eph receptors which are upregulated in early CRC, and their 
subsequent silencing in more advanced tumours is thought to play a role in invasion and 
metastasis (Herath and Boyd 2010). Marked upregulation of ephrin-A3 is seen in lung tumours, 
but equal expression in normal colon and CRC has been reported (Hafner et al. 2004). 
Upregulation of several Eph receptors and ephrins by hypoxia has been reported in hepatoma and 
prostate cancer cell-lines (Vihanto et al. 2005), but the hypoxic induction of ephrin-A3 seen in 
Caco-2 has not been previously reported in CRC. 
PDGF (platelet-derived growth factor) is a member of the same growth factor family as 
VEGF with diverse functions (Yu et al. 2003). It is a potent mitogen for cells of mesenchymal 
origin, and induces cellular processes including angiogenesis, proliferation, migration and 
apoptosis (Yu et al. 2003). It is critical in embryonic development, and plays an important role in 
inflammation and wound healing. Its tumourigenicity was first discovered almost 30 years ago 
(Deuel et al. 1983), and it has been implicated in several cancers such as gliomas, sarcomas and 
leukaemias (Heldin 2012). PDGF has been detected in CRC tissue, and elevated levels have been 
reported in platelets from CRC patients (Peterson et al. 2012). PDGF can promote tumourigenesis 
through autocrine (Uhrbom et al. 2000) and paracrine mechanisms (Sundberg et al. 1997). 
Hypoxia has been shown to enhance PDGF signalling via a HIF-1α-mediated mechanisms in 
pulmonary arterial smooth muscle cells (ten Freyhaus et al. 2011), and breast cancer (Schito et al. 
2012) leading to enhanced metastasis. Therapeutic targeting of the PDGF pathway has shown 
promise in cancers such as chronic myeloid leukaemia and gastro-intestinal stromal tumours. 
Imatinib (Gleevec ©) a potent PDGF receptor inhibitor, has FDA approval for the treatment of 
both cancers (Cohen et al. 2005; Cohen et al. 2012), and in CRC has been shown to inhibit CRC 
cell growth and stromal fibroblast activity in vitro (Stahtea et al. 2007).   
Vascular Remodelling Factors 
The angiopoietins (ANGPT) and angiopoietin-like (ANGPTL) proteins have been 
discussed in Chapter 1 and Chapter 3. Overexpression of ANGPT-1 has been reported to suppress 
angiogenesis and tumour growth in CRC, while ANGPT-2 has the opposite effect (Ahmad et al. 
2001b; Stoeltzing et al. 2003). ANGPT-1 was induced by both hypoxia and DMOG in Caco-2 
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cells, suggesting HIF-independence. It was only detected in 1 of the 6 donors (in which it was 
strongly upregulated), supporting reports that it is rarely expressed in primary CRC tissue (Ahmad 
et al. 2001a). Hypoxic induction of pro-angiogenic ANGPT-2 has been reported in CRC cell-lines 
(Gu et al. 2006), but in my data this was only seen in one of 6 donors. In Caco-2 cells it was 
upregulated by hypoxia but not DMOG, suggesting HIF-independence. ANGPT-1 and -2 both 
signal via the Tie-2 (TEK) receptor. Hypoxia regulation of the Tie-2/TEK receptor has not been 
previously investigated in CRC cells, although induction has been reported in monocytes 
(Murdoch et al. 2007). In the present study, Tie-2 expression in TDCs was reduced by hypoxia, 
the significance of which warrants further investigation.  
The structural complexity of ANGPTL-4 underlies its remarkably diverse roles (Zhu et al. 
2012), and it can have both pro- and anti-tumourigenic roles (Tan et al. 2012). Elevated 
expression levels have been detected in cancers including CRC, and correlate with venous 
invasion and metastasis (Nakayama et al. 2011). ANGPTL-4 is upregulated by hypoxia via HIF-
1α (Kim et al. 2011), supporting my data, and by TGF-β1 (Padua et al. 2008). It was upregulated 
in both TDCs (hypoxia) and Caco-2 cells (hypoxia and DMOG). In the latter, data suggested a 
reciprocal relationship between HIF-1α and HIF-2α regulation of ANGPTL-4. ANGPTL-3, which 
differs from ANGPTL-4 in expression patterns, regulation and function (Li 2006), has been 
reported to have similar angiogenic potency to VEGF in stimulating endothelial cell adhesion and 
migration via integrin-mediated signalling (Camenisch et al. 2002). To my knowledge, hypoxic 
induction of ANGPTL-3 as seen in TDCs has not been reported previously. 
Adhesion Factors/Molecules And Matrix Remodelling Factors 
As discussed in Chapter 3, upregulation of MMP-2 and MMP-9 and downregulation of 
TIMP3 are associated with angiogenesis, advanced tumour stage, increased metastasis and poorer 
survival in CRC (Grigioni et al. 1994; Zeng and Guillem 1996; Zeng et al. 1996; Kim and Kim 
1999; Kikuchi et al. 2000; Bai et al. 2007). Hypoxia induction of both MMP-2 and -9 has been 
previously reported in the CRC cell-line LoVo (Wu et al. 2008), supporting my Caco-2 (MMP-9) 
and TDC (MMP-2) data. The hypoxic downregulation of TIMP shown here in TDCs has been 
reported in breast cancer cell-lines (Fu et al. 2009), although the isoforms differed (TIMP-3 in my 
study versus TIMP-4 in breast). Interestingly, IL-8, which was also hypoxia-induced in TDCs, has 
been shown to upregulate both MMP-2 and -9 in endothelial cells (Li et al. 2003a).  
ANPEP which has similar enzymatic activity to MMPs, promotes human umbilical vein 
endothelial cell (HUVEC) proliferation, migration and capillary tube formation in vitro 
(Fukasawa et al. 2006). ANPEP expression has been reported in Caco-2 cells (Howell et al. 
1992), and tissue expression correlates with increased tumour size and poor prognosis in several 
Chapter 5 
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cancers including CRC (Hashida et al. 2002; Wickström et al. 2011). In endothelial cells it is 
induced by hypoxia, VEGF and TNF-α (Bhagwat et al. 2001). Hypoxia induction, as seen in 
TDCs, has not been previously reported.  
Urokinase-type plasminogen activator (uPA/PLAU) is a component of the urokinase 
plasminogen activating system (uPAS). As well as being implicated in angiogenesis, uPAS 
function can influence tumour cell proliferation, adhesion and migration, intravasation and 
metastasis (Blasi and Carmeliet 2002; Choong and Nadesapillai 2003). Increased expression of 
uPAS components has been reported to correlate to poor outcomes in numerous tumours 
including CRC. In CRC, uPA and its receptor (uPAR) accumulate at the invading tumour edge, 
and expression levels correlate with advanced Dukes’ stage and poor prognosis (Buo et al. 1995; 
Tatsuta et al. 1997). A link between hypoxia and the uPAS system is suggested by the fact that 
uPAR and HIF-1α co-localise of at the tumour edge in CRC (Pyke et al. 1991), and supported by 
the finding that hypoxia-induced invasion in the HCT116 CRC cell-line is attenuated by anti-
uPAR antibodies (Krishnamachary et al. 2003). The hypoxia-induction of uPA in TDCs in my 
study is in line with these findings. 
A necessary step in the initiation of invasion of epithelial tumours is disruption of the 
basement membrane (BM), the major structural component of  which is Collagen type IV alpha 3 
(α-3(IV), encoded by the COL4A3 gene)  (Tanjore and Kalluri 2006). Downregulation of α-3(IV) 
has been reported in CRC (Polette et al. 1997) and lung cancer (Nakano et al. 2001). Recombinant 
α-3(IV) potently inhibits angiogenesis and tumour growth in an in vivo melanoma model 
(Petitclerc et al. 2000), via mechanisms involving cleavage of α-3(IV) by MMP-9, or suppression 
by α-3(IV) of MMP-2 activation (Martinella-Catusse et al. 2001; Hamano et al. 2003). The 
hypoxic downregulation of α-3(IV) seen in TDCs has not been previously described. The α-3(IV) 
detected in the TDCs may derive from tumour or stromal cells. Nevertheless, the suppressive 
effect of hypoxia on α-3(IV) might be anticipated to be tumourigenic, either through a reduction 
of its potent angiostatic effects, or through disruption of its structural role in the BM. 
  
Chapter 5 
171 
Summary 
Analysis of the array data revealed a putative TDC Signature, comprising of a set of 18 
angiogenic genes that are regulated by hypoxia in TDCs. As discussed above, these genes are 
implicated in numerous signalling pathways and cellular processes, often interacting with each 
other in complex networks, which enhance the ability of tumour cells to proliferate, invade local 
tissue, and metastasise.  
The methodology employed in this chapter represents a novel model for the investigation 
of hypoxia-induced angiogenesis in CRC. The use of cells derived directly from donor tumours 
avoids some of the problems associated with cell-lines that limit the strength of conclusions that 
can be drawn from their use. The TDCs established displayed similar characteristics to the Caco-2 
cell-line such as expression of epithelial and CRC markers. Furthermore, the angiogenic 
responses to hypoxia of both cell-types showed some similarity, which provides a degree of 
validation of the Caco-2 data in Chapters 3 and 4. There was significant variation in the responses 
of different donors. This may be partly due to the mixed cell-types in the TDCs, but may also 
reveal true biological differences between the tumours of each donor, and further work is 
necessary to elucidate this (see Further Work). In addition, there were significantly more hypoxia-
responsive genes in the TDCs than in the Caco-2 cells. This discrepancy further underlines the 
inability of the cell-lines to truly represent the behaviour of tumour cells in vivo. 
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6 CONCLUDING REMARKS 
 
The aims of this study were firstly to investigate the relative contribution of HIF-1α and 
HIF-2α in the hypoxia regulation of CRC (objectives 1 and 2), and secondly to compare the 
hypoxia-induced angiogenesis response of an established CRC cell-line (Caco-2) with primary 
cultures (TDCs) (objective 3).  
Caco-2 hypoxia-responses were characterised (Chapter 3), and 3 novel hypoxia-induced 
angiogenesis genes (ANGPTL-4, EFNA-3 and TGF-β1) were identified using a PCR 
angiogenesis array. The effect of selective silencing of the two HIF isoforms was investigated 
(Chapter 4), and the roles of HIF-1α and HIF-2α in the regulation of Caco-2 hypoxia-responses 
were found to be different, thus disproving the first null hypothesis.  
In the second part of the study, similarities in the hypoxia response of Caco-2 cells and 
TDCs in terms of angiogenesis genes were identified (Chapter 5), thus disproving the second null 
hypothesis. Of particular note was the heterogeneity of hypoxia-induced angiogenesis responses 
from patient to patient. 
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6.1 General Discussion 
As discussed in Section 1.3, evidence for the divergent roles of HIF-1α and HIF-2α in 
mediating gene expression in response to changes in oxygen tension has accumulated in recent 
years (Hu et al. 2003). It has been shown in several cell-lines and tissue types that they have 
different target genes (Wang et al. 2005; Carroll and Ashcroft 2006), albeit with some overlap. In 
addition, isoform-specific regulatory mechanisms have been described (Thrash-Bingham and 
Tartof 1999; Koh et al. 2011). Evidence from experiments in renal cancer suggests that HIF 
regulation can switch from HIF-1α to HIF-2α dominance, with upregulation of the latter 
suppressing expression of the former, resulting in a more aggressive phenotype (Koh et al. 2011). 
In CRC, there is controversy as to which isoform, if any, is dominant (Yoshimura et al. 2004; 
Franovic et al. 2009; Imamura et al. 2009; Rasheed et al. 2009), and as to whether this is 
functionally significant. 
My data described in this thesis has demonstrated that both HIF-α isoforms are involved 
in hypoxia-regulated angiogenesis gene expression in Caco-2 CRC cells. Each of four genes 
(ANGPTL-4, EFNA-3, TGF-β1 and VEGF) was induced by HIF-1α. TGF-β1 was also induced 
by HIF-2α, and there was a trend (not statistically significant) towards HIF-2α induction for 
VEGF and EFNA-3. Interestingly, expression of ANGPTL-4 was suppressed by HIF-2α, and 
there was a trend towards the same for VEGF and TGF-β1. This supports evidence from breast 
and renal cancer cell-lines of a reciprocal relationship between the two isoforms (Raval et al. 
2005; Carroll and Ashcroft 2006), which has not been previously described in CRC. The 
functional significance of these HIF-isoform specific changes in gene expression requires further 
investigation. Preliminary experiments conducted in normoxia suggested an effect of HIF-2α 
Caco-2 proliferation, but technical difficulties were encountered with a functional assay of 
angiogenesis.  
Hypoxia-induction of BNIP-3 was exclusively HIF-1α-regulated in Caco-2 cells, as has 
been shown in numerous cell-types. Of 4 other apoptosis genes investigated, 2 were 
downregulated by hypoxia (survivin, BAX), while 2 were unchanged (XIAP, Bcl-2). The 
functional relevance of these conflicting changes in apoptosis gene expression requires further 
examination (see section 0). Three cell-adhesion molecules were investigated, of which two (CD-
151 and VE-Cadherin) were unaffected by hypoxia or DMOG. However, hypoxia-regulation of 
STAB-1 was seen. STAB-1 has a variety of functions in several cell-types, and its role in cancer 
is poorly understood. Hypoxia has been reported to both up- and downregulate expression in 
different cell-types (Movahedi et al. 2010; Ong et al. 2010). Interestingly, data indicated hypoxic 
suppression when confluence was below 50%, and induction above 50%. Modulation of hypoxic 
responses by cell-cell contacts is supported in data from bladder cancer cell-lines, in which 
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hypoxic VEGF induction in sub-confluent cells was abolished upon reaching confluence (Jones et 
al. 2001). However this reversal of regulation has not been previously described. Repeat 
experiments are necessary to confirm this finding, which would be interesting to explore further.  
The differences in HIF isoform specificity between my data and the literature may reflect 
cell-line specificity. Confirmation of this could be achieved by repeating the Caco-2 experiments 
in different cell-lines, selected according to factors known to influence hypoxia responses, using 
criteria such as mutation status of common oncogenes/tumour suppressors (e.g. p53, K-ras and 
BRAF). This may help to tease apart the mechanisms that drive this variability in cell-line 
responses, and build up a more accurate picture of the behaviour of cancers in vivo.  
The question still remains: how accurately can cell-lines model “real” CRC cells? The 
considerable heterogeneity of CRC makes translation of this kind of data to individual patients 
problematic. Drawing from considerable previous experience in our laboratory of using short-
term primary cultures, I sought to examine angiogenic responses to hypoxia of cells derived 
directly from patients’ tumours. I was able to establish cultures of mixed cells that responded to 
hypoxia by altering their expression of angiogenesis genes. Angiogenesis array data showed some 
similarity between the responses of these TDCs and Caco-2 cells, with notable differences. For 
example, the TDCs expressed more genes overall (70 were detected on average, compared to 53 
in Caco-2). In addition, whereas only upregulation was seen following hypoxia-stimulation in 
Caco-2 cells, downregulation of some genes was also seen in TDCs. This may be a reflection of 
the mixed cell-types in the TDCs, and further work to characterise the composition of TDCs is 
required. 
An interesting finding was the significant inter-donor variation in the pattern of 
angiogenic responses in TDCs. This is best appreciated from the scatter plots of the array data 
(Figure 5.7 to Figure 5.12). For example, Donors 1 and 2 showed both strong induction and 
suppression of several genes, Donor 3 showed mainly upregulation, and Donor 4 showed mainly 
downregulation. This inter-donor variation persisted when analysis was limited to four genes, 
namely EFNA-3, ANGPTL-4, TGF-β1 and VEGF. While no clear correlation with 
clinicopathological parameters was seen, the small sample-size was a significant limitation, and 
this is being addressed in an on-going project in our laboratory. The continued use of PCR array 
analysis is precluded by prohibitive costs. Therefore, the study is increasing patient numbers and 
analysing hypoxia-induced expression of a group of 14 genes including EFNA-3, ANGPTL-4, 
TGF-β1 and VEGF by Q-PCR. It is hypothesised that correlations will emerge between patterns 
of hypoxia-induction and clinicopathological parameters. 
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Should this be the confirmed, a number of possibilities follow. Firstly, it would provide 
proof-of-concept of this “live sampling” technique. This could be developed in a numerous ways. 
Firstly, modification of the protocol may improve success rates for establishing TDCs and 
increase RNA (and protein) yields. This could potentially be applied to any solid cancer tissue. 
Refinement of the angiogenesis hypoxia-response signature may be achieved by increasing the 
sample size (n number) and expanding the PCR array data, allowing data analysis utilising robust 
statistical/bioinformatic techniques. Examination of protein expression (e.g. cytokine arrays) may 
improve this further. Numerous commercially available PCR and protein arrays could be used to 
examine tumourigenic processes other than angiogenesis, such as apoptosis, cell-motility and 
EMT. The use of stimuli other than hypoxia, such as cytokines and growth factors, would expand 
this further, allowing the investigation of specific signalling pathways.  
6.1.1 Limitations 
My Caco-2 work focussed primarily on gene expression, and due to time constraints, 
protein expression and functional studies were limited. Novel hypoxia-regulated genes were 
identified, but whether these findings are reflected at the protein level, and whether there are any 
functional consequences, is unclear. Similarly, although differences in HIF-isoform regulation of 
several genes involved in CRC pathogenesis was seen, the effect at the protein and functional 
levels was not investigated (see section 6.2.1). Furthermore, translation of results from a single 
immortalised cell-line is problematic. 
The aim of the TDC work was to reliably establish viable short-term cultures whose 
hypoxia responses could be investigated in a manner comparable to Caco-2 cells. The small size 
of tissue samples resulted in low cell yield, which in turn meant that limited protein/RNA material 
would be available for analysis. Therefore the initial focus was on using the available material to 
establish that hypoxia responses could be consistently analysed, before turning attention to 
accurate characterisation of culture composition. As a result, while the presence of CRC cells in 
the TDCs is supported by the expression of CEA, Ep-CAM and VE-Cadherin, the precise 
composition of these cultures is unclear. It may therefore be that the differences in hypoxia-
response between donors are due to different TDC composition, rather than the characteristics of 
the originating lesion. A larger data set may reveal correlations between TDC response patterns 
and tumour biology, but the numbers in this study are insufficient (see section 6.2.2).  
As discussed in section 5.1, the inability of immortalised cell-lines to accurately represent 
the behaviour of cancers in situ is a major weakness of their use. My study sought to address this 
by comparing a cell-line with freshly-derived CRC cultures. However, HIF-isoform roles were 
only investigated in Caco-2 (see section 6.2.1). There were similarities between Caco-2 and TDC 
hypoxia-responses, which provides a degree of mutual validation of the data. However, the 
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strength of this validation depends absolutely on two conditions. Firstly, the TDC data may 
provide support for Caco-2 cells as a model of CRC providing the TDCs are (predominantly) 
composed of CRC cells. This has not been shown definitively (see section 6.2.2). Secondly, as it is 
a well-established CRC cell-line, the Caco-2 data may provide support for the TDC model 
providing the Caco-2 cells are representative of the original CRC tumour from which it was 
derived. This has also not been shown (see section 6.2.1). 
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6.2 Future Work 
6.2.1 Caco-2 
RNA and Protein 
Further characterisation of Caco-2 hypoxia responses, and the effects of HIF-α 
knockdown, should examine protein expression, particularly of the three novel genes EFNA-3 
(ELISA Kit, Antibodies-online Inc.; Atlanta, USA), ANGPTL-4 (Duoset © ELISA Kit, R&D 
Systems) and TGF-β1 (ELISA Kit, Abcam). Antibodies are also available for Western Blotting of 
whole cellular extracts (Invitrogen, Paisley, UK; Santa Cruz Biotechnology; Abcam). 
Confirmation of the HIF specificity data should include further knockdown experiments 
using different siHIF-1α and siHIF-2α sequences, and by overexpression studies using a plasmid 
or viral vector. To further investigate the possible reciprocal effects of the HIF-α isoforms, and to 
examine possible HIF-independent effects, double-knockdown experiments, or knockdown of the 
common HIF-β-subunit, should be performed. Cell-viability at the end of transfection should be 
confirmed using trypan blue stain. 
It would be interesting to investigate the roles of the three novel genes, particularly for 
EFNA-3, since induction of this gene by hypoxia has not previously been described in CRC, and 
very little is known about its function. As well as examining protein expression, siRNA 
knockdown followed by functional studies (see below) should be performed. 
The downregulation of HIF-1α and HIF-2α mRNA by hypoxia highlighted the 
complexity of HIF regulation. The role of the PHDs and FIH could be further investigated by 
selective knockdown (and overexpression) of the respective genes followed by examination of the 
effects on HIF mRNA and protein, and on cell function (see below). HIF activity should also be 
assessed using the TransAM™ HIF-α binding assay (Active Motif, Rixensart, Belgium), which 
measures binding to HRE. 
Functional Studies 
Functional studies are required to investigate the relevance of the Caco-2 HIF-α 
knockdown data. Preliminary experiments were performed using a BrdU assay (section 7.1), 
which require optimisation and replication. Apoptosis assays should include a cell-death assay 
(e.g. MTT Assay, Roche, Burgess Hill, UK) and fluorescence-activated cell sorting (FACS) with 
Annexin V-labelling.  
Angiogenesis requires induction of endothelial cell function. Human Umbilical Vein 
Endothelial Cells (HUVEC) are primary endothelial cells regularly used in our laboratory to 
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investigate angiogenesis. A co-culture technique has previously been applied in our laboratory to 
assess the angiogenic potential of CRC cell-lines (T. Khong, unpublished data). HUVEC and 
Caco-2 cells are co-cultured in a double chamber which allows angiogenic cytokines released by 
Caco-2 cells in the bottom chamber to cross a semi-permeable membrane into the HUVEC 
chamber (Figure 6.1). The HUVEC migrate towards the Caco-2 along a chemotactic gradient. The 
number of HUVEC that migrate in a given time period is proportional to the potency of the 
angiogenic stimulus from the Caco-2 cells. Initial attempts used conditioned medium from 
hypoxia-stimulated transfected Caco-2 cells (avoiding direct exposure of HUVEC to hypoxia). 
This was unfortunately unsuccessful, in part due to inconsistent HUVEC responses to positive 
controls. Substitution of HUVECs with human microvascular endothelial cells (HMEC) showed 
some promise. This requires further optimisation. 
Further techniques for assaying angiogenic function include the Matrigel (BD 
Biosciences) and Angiokit (TCS Cell Works, UK) Assays which allow quantitative measurement 
of tubule development in HUVECs. Finally, Caco-2 have been shown to be tumorigenic in mouse 
xenografts. Should these assays indicate functionally diverse roles of the HIF isoforms, 
transplantation of HIF-isoform deficient or overexpressing Caco-2 cells into immunodeficient 
mice would serve to confirm this. HIF silencing would require more stable transfection than 
siRNA achieves, for example with shRNA. 
 
Figure 6.1 HUVEC Migration Assay 
Caco-2 cells, adherent to the lower chamber, are exposed to various experimental conditions (e.g. 
transfection, hypoxia) prior to the introduction of HUVECs, which are cultured independently within cell 
inserts. HUVECs migrate in response to a chemical gradient of angiogenic mediators released by the CRC 
cells. Following removal of unmigrated cells from the inner surface of cell inserts, the number of migrated 
cells on the undersurface of the cell insert membrane will be counted, and a mean calculated. (Courtesy T. 
L. Khong). 
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Cell-lines 
The Caco-2 cell-line is derived from a primary tumour with relatively low 
tumourigenicity. It would be interesting to compare hypoxia-expression profiles and HIF-isoform 
roles with cell-lines of metastatic origin (e.g. SW620), or with a more aggressive phenotype such 
as HT-29 (intermediate) and HCT116 (high) (Yeung et al. 2010). Caco-2 cells were obtained 
directly from ATCC. A study investigating cell-line contamination and mis-identification did not 
identify this cell-line as being prone to these issues (O'Brien 2001), but for completeness, testing 
could be performed using short tandem repeat profiling (Masters et al. 2001). Passage number 
should be carefully recorded for all experiments to address any possible confounding effects. 
6.2.2 TDCs 
Enlarge Data Set 
Data from the 13 patients for whom TDCs analysed by PCR (array and/or Q-PCR) 
suggests variation in hypoxia-induced angiogenesis gene expression, which is hypothesised to be 
related to the biological behaviour of the originating tumours. Correlation of expression patterns 
with clinico-pathological parameters would support this, but the numbers in this study are 
insufficient to confirm this. Increasing the sample size forms a significant part of an on-going 
follow-up project. Expression patterns of genes including VEGF, EFNA-3, ANGPTL-4 and TGF-
β1 are being evaluated by Q-PCR. Demographic and pathological data is being collected from 
medical notes and routine histopathology reports, including tumour site, stage, differentiation 
grade, vascular invasion, use of neoadjuvant chemo-radiotherapy, morbidity and mortality. As the 
numbers increase, it is hoped that factors will emerge that influence the success of the TDC 
establishment method, so that data yields may be increased. 
Characterisation 
In order for strengthen the validity of comparisons of hypoxia responses between donors, 
it is important to confirm whether the composition of TDCs is consistent. Fuller characterisation 
of the TDCs should be carried out using FACS to identify the constituent cell-types. This may 
also assist with interpretation of gene expression patterns. Inconsistency in TDC composition 
would not automatically invalidate inter-donor comparisons, since the composition may itself be 
influenced by clinically relevant biological characteristics of the tumour. In addition, lack of any 
correlation between clinical variables and expression of the selected genes may simply indicate a 
weakness in the “signature” identified, rather that invalidating the hypothesis entirely. Further 
work to refine the signature may include investigation of protein expression using ELISA and 
Western Blotting (and/or protein/cytokine arrays to identify novel proteins). Functional assays to 
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investigate the ability of TDCs to induce endothelial cell function (section 6.2.1) should also be 
used. 
Controls 
Since the aim of this study was to investigate differences in hypoxia-induced angiogenic 
responses between TDCs from different donors, the controls used were unstimulated (normoxic) 
cells from the same TDC. In order to fully characterise the TDCs, a further control would be to 
use cells derived from normal colon tissue from the same patient. In order that sufficient tissue 
was obtained, this would be taken from the resection margins of the same specimen, since 
obtaining a sample of adequate size from the remaining colon would increase the risk of post-
operative leak. Further controls could include cells derived from non-cancer operations, such as 
bowel resections for diverticular disease or IBD. Such samples would control for any 
inflammatory component to the behaviour of TDCs. In addition, tissue could be obtained from 
benign colonic lesions (e.g. adenomas) and/or biopsies of normal mucosa, obtained via 
colonoscopy. However, these would likely yield small amounts of tissue, and in the case of 
normal mucosal biopsies would increase the risk to the patient (bleeding, perforation). Finally, it 
would be interesting to establish TDCs from metastatic deposits, particularly where comparison to 
the primary lesion were possible. 
Inhibitors 
It would be interesting to investigate the role of HIF in the TDC hypoxia responses, by 
treating the cultures with HIF inhibitors prior to hypoxia experiments. These are commercially 
available (e.g. Biomol, Exeter, UK). Further possibilities include the use of angiogenesis 
inhibitors, or other commonly-used therapeutic agents, which may give some insight into their 
therapeutic utility in specific patients. In addition, pathways other than hypoxia-induced 
angiogenesis could be investigated using different stimuli and the appropriate readouts (e.g. 
doxorubicin or 5-FU to induce apoptosis followed by evaluation of apoptosis gene and protein 
expression (Q-PCR or PCR Array), MTT assay, FACS). 
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6.3 Clinical Implications 
The potential for HIF inhibition as a therapeutic strategy in CRC has been recognised for 
some time (Semenza 2002b). Evidence suggests that HIF-induction enhances resistance to 
chemotherapy (Rohwer et al. 2010) and radiotherapy (Moeller et al. 2007), and it may be involved 
in the development of resistance to novel biological therapies such as imatinib (Zhao et al. 2010). 
HIF induction may be a feature of response to antiangiogenic therapy, since effective disruption 
of tumour blood supply would result in hypoxia. It has been suggested that HIF inhibition may 
improve the efficacy of antiangiogenic drugs, particularly in patients with documented HIF 
overexpression in biopsy or resection specimens (Semenza 2012). Many anti-cancer drugs 
designed to target non-HIF mechanisms have been shown to inhibit HIF-1α mRNA and/or protein 
(e.g. mTOR inhibitors such as temsirolimus; topoisomerase inhibitors such as topotecan) 
(Semenza 2007). Some of these drugs are known to be HIF-1α specific (Semenza 2012), while for 
others (including some used in CRC) the effect on HIF-2α is unknown. The involvement of both 
HIF-α isoforms in the regulation of Caco-2 angiogenesis responses seen in my experiments 
supports data indicating that simultaneous inhibition of both isoforms may be desirable (Burkitt et 
al. 2009). In view of the possibility of compensatory mechanisms, as in the case of ANGPTL-4 
mRNA regulation in Caco-2 seen in my data for example, the inhibition of HIF-1α alone may in 
fact be undesirable (Carroll and Ashcroft 2006). Although some publications discussing HIF 
inhibition continue to consider anti-HIF-1α activity alone (Wang et al. 2011a; Xia et al. 2012), 
drugs that inhibit both isoforms are under development (Bohonowych et al. 2011; Chen and Sang 
2011). Thus, mounting evidence underlines the importance of considering both HIF isoforms. 
Conventional biomedical research techniques typically begin with assessment of tumour 
specimens for surrogate markers of tumourigenicity, such as distorted anatomy/morphology (e.g. 
differentiation, invasion, MVD), and altered patterns of gene and protein expression. The rapid 
and continued development of new molecular biology techniques (e.g. DNA sequencing, gene 
and protein (micro-)arrays), has greatly enhanced the degree and sophistication with which this 
type of sampling can be performed. In combination with powerful statistical techniques (and an 
exponential increase in the computational power of the micro-chip), correlations can be identified 
between such biomarkers and clinical outcomes that have prognostic and predictive value. 
However robust such statistical associations may be, the relation of these markers to tumour cell 
function can generally only be inferred. An understanding of function is crucial for the 
development of interventions that will improve outcomes. In vitro experimental techniques, for 
example using cell-line models, provide powerful tools for the investigation of the function of 
specific genes, proteins and signalling pathways. This experimental data can then be used to 
validate the observed clinico-pathological correlations (as well as identifying new hypothetical 
markers).  
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Significant advances in our understanding of cancer biology, and the attendant 
improvements in clinical outcomes, are testament to the success of this paradigm. However, a 
weakness of this approach is the remove between in vitro models and the in vivo milieu. Deep 
insights into the huge complexity and heterogeneity of cancer cell biology have accrued from in 
vitro research. When one considers that in vitro model systems are simplified by necessity, in 
order that a limited number of variables can be investigated, it can be assumed that this 
complexity is even greater in vivo. A further layer of heterogeneity is introduced by the stromal 
cells with which cancer cells interact in vivo (Hanahan and Weinberg 2011; De Palma and 
Hanahan 2012), increasing the complexity by orders of magnitude. This can limit the validity 
applying experimental results to the clinical setting, and may contribute to issues such as side-
effects and variable responses to novel therapies (Kerbel and Ebos 2010; Nikolinakos et al. 2010), 
and to the long delays that intervene between basic research findings and clinical applications. 
The short-term TDC model may address some of these problems by virtue of retaining some of 
the inter-cellular interactions that are lost with cell-lines. 
This gap between the bench and the clinic has been the driving force behind the 
development over the past 20 years of the field of Translational Research, which has seen a shift 
in emphasis from “basic” research (which may be characterised purely theoretical) to research that 
can be more directly related the patient. A critical component of translational research is the 
concept of Personalised Medicine, an important goal of which is the identification of biomarkers 
which when applied to an individual patient will aid accurate prognostication, and selection of 
appropriate therapeutic strategies. This is an extension of traditional staging of tumours (e.g. 
TNM), whereby tumours can be stratified into categories which, although having useful 
prognostic/predictive power, are often too broad to accurately reflect the heterogeneity of tumour 
behaviour. Personalised medicine aims to achieve classification with much finer resolution, 
increasing predictive accuracy, and avoiding the unnecessary use of often expensive, potentially 
toxic drugs.   
Perhaps the most exciting possibility arising from the short-term TDC model is its 
potential for use in personalised medicine. It may be possible to treat TDCs from an individual 
patient with antiangiogenic agents, and measure the attenuation, if any, of the gene response to 
hypoxia. Such a “chemosensitivity and resistance assay” (CSRA) technique, analogous to 
antibiotic sensitivity testing for bacterial infections, has been utilised with some success in 
ovarian and bladder cancer (Havaleshko et al. 2007; Ferriss and Rice 2010). CSRAs measure cell-
death/apoptosis of tumour-derived cells treated with specific chemotherapy regimes. Tests of this 
nature, combining therapeutic and diagnostic elements, have been referred to as “Theranostics”, 
and form an important part of the personalised medicine approach. In a retrospective study, 
Gallion et al. reported that in patients receiving a treatment regime to which a CSRA had 
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classified their tumour as “resistant”, a 3-fold increased risk of progression was predicted (Gallion 
et al. 2006). A small RCT reported a trend towards better outcomes in patients receiving a CSRA-
selected chemotherapy regime, compared to those for whom treatment was selected according to 
“physician’s choice” (Cree et al. 2007). The TDC short-term model investigated in my study 
would aim to use hypoxia-induced alterations in angiogenic function as a readout, rather than cell-
death, and as such may prove to be a more sensitive method of predicting angiogenic drug 
response.  
The short-term TDC model offers the prospect of direct measurement of the angiogenic 
capacity of a tumour. It has the potential to be applied to other tumourigenic processes and 
different cancers, and may have both diagnostic and therapeutic applications.  
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7 APPENDIX 
7.1 Supplementary Caco-2 Data 
Angiogenesis Array 
Table 7.1 Genes not detected by PCR Array in Caco-2 Cells 
A total of 31 genes were not detected by PCR Array (Ct values > 30). 
BAI1 CXCL9 IFNB1 PGF 
CCL11 TYMP IFNG PLG 
CDH5 FGF1 IL6 PTGS1 
CXCL1 FGF2 LECT1 TEK 
CXCL10 FIGF LEP TIMP3 
CXCL3 HAND2 MDK TNF 
CXCL5 HGF NOTCH4 TNFAIP2 
CXCL6 IFNA1 PF4 
 
 
Preliminary Functional Assays 
 
Figure 7.1 Caco-2 cell growth in normoxia following HIF knockdown 
Caco-2 cells transfected with siHIF-1α or siHIF-2α and incubated in normoxia for 5 days, and 
photographed daily. At the end of the experiment, cells were trypsinised and counted (Figure 7.2).  
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Figure 7.2 Caco-2 cell counts after 5 days of normoxia following HIF knockdown 
Caco-2 cells transfected with siHIF-1α or siHIF-2α and incubated in normoxia for 5 days (see Figure 7.1). 
At the end of the experiment, cells were trypsinised and counted by the trypan blue exclusion method. 
Graph shows cell counts (x106/ml). Data are mean±SEM from a single experiment. (* p<0.05, ** p<0.01, 
ns = not significant, 1-way ANOVA versus siControl unless otherwise stated. 
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Figure 7.3 Caco-2 proliferation following HIF knockdown  
Caco-2 cells transfected in 6-well plates with siControl siHIF-1α or siHIF-2α. 100µl BrdU (Roche, Burgess 
Hill, UK) was added to each well at the end of transfection and the cells incubated in normoxia for 24 or 48 
hours. At each time-point, cells were trypsinised and transferred to a 96-well ELISA plate. The plate was 
centrifuged at 1500rpm for 20 mins, supernatants were discarded, and the plate allowed to air dry. 
Peroxidase-labelled anti-BrdU antibody was added, followed by TMB substrate, resulting in a colourimetric 
reaction which was measured using a microplate reader at 450nm wavelength (Thermo Labsystems). 
Graphs show optical density at 24 hours (left) and 48 hours (right). Data are mean±SEM from a single 
experiment. (* p<0.05, ** p<0.01, ns = not significant, 1-way ANOVA versus siControl unless otherwise 
stated.) 
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7.2 Supplementary Information CRC Patients 
Table 7.2 Demographic and pathology characteristics of donors analysed by Q-PCR 
Table shows age, gender, site (proximal or distal colon, or rectum) and differentiation grade for the 13 
donors analysed by Q-PCR. 
Donor Age (yrs) Gender Site 
Dukes’ 
Stage 
Differentiation 
1 66 F Rectum A moderate 
2 73 M Proximal B moderate 
3 68 M Distal A moderate 
4 64 M Rectum C moderate 
5 59 M Distal C moderate 
6 55 F Distal C moderate 
7 70 F Distal A moderate 
8 85 M Distal B moderate 
9 81 F Distal B poor 
10 76 M Rectum D  poor 
11 51 F Distal C poor 
12 80 M Proximal C moderate 
13 77 M Proximal D poor 
 
Table 7.3 Q-PCR patients pathology statistics 
Table shows pathology statistics for donors analysed by array. 
Parameter n % 
Full Cohort 
(n=34) % 
Site   
Proximal colon 3 23.1 50.0 
Distal colon 7 53.8 23.5 
Rectum 3 23.1 26.5 
Dukes’ Stage   
A 3 23.1 12.1 
B 3 23.1 36.4 
C 5 38.5 39.4 
D 2 15.4 12.1 
Differentiation   
moderate 9 69.2 63.6 
poor 4 30.8 33.3 
undifferentiated 0 0 3.0 
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The section on bevacizumab therapy in the Introduction (section 1.2.4.1) is based on the 
following review paper: 
Angiogenesis as a Therapeutic Target in Rheumatoid Arthritis: Learning the Lessons of the 
Colorectal Cancer Experience. 
Thairu N., Kiriakidis S., Dawson P., Paleolog, E.  
Angiogenesis, 2011 Sep; 14(3):223-34 
 
